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ABSTRACT 
Over 600,000 bone-grafting operations are performed each year in the 
United States. The majority of the bone used for these surgeries comes from 
autografts that are limited in quantity or allografts with high failure rates. Current 
synthetic bone grafting materials have poor mechanical properties, handling 
characteristics, and bioactivity. The goal of this dissertation was to develop a 
clinically translatable bone tissue engineering scaffold with improved handling 
characteristics, bioactivity, and smart delivery modalities. We hypothesized that 
this could be achieved through the rational selection of Food and Drug 
Administration (FDA) approved materials that blend favorably with hydroxyapatite 
(HA), the principle mineral component in bone. This dissertation describes the 
development of smart bone tissue engineering scaffolds composed of the 
biodegradable amphiphilic polymer poly(D,L-lactic acid-co-ethylene glycol-co-
D,L-lactic acid) (PELA) and HA. Electrospun nanofibrous HA-PELA scaffolds 
exhibited improved handling characteristics and bioactivity over conventional HA-
poly(D,L-lactic acid) composites. Electrospun HA-PELA was hydrophilic, elastic, 
stiffened upon hydration, and supported the attachment and osteogenic 
differentiation of rat bone marrow stromal cells (MSCs). These in vitro properties 
translated into robust bone formation in vivo using a critical-size femoral defect 
model in rats. Spiral-wrapped HA-PELA scaffolds, loaded with MSCs or a low-
dose of recombinant human bone morphogenetic protein-2, templated bone 
formation along the defect. As an alternate approach, PELA and HA-PELA were 
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rapid prototyped into three-dimensional (3-D) macroporous scaffolds using a 
consumer-grade 3-D printer. These 3-D scaffolds have differential cell adhesion 
characteristics, swell and stiffen upon hydration, and exhibit hydration-induced 
self-fixation in a simulated confined defect. HA-PELA also exhibits thermal shape 
memory behavior, enabling the minimally invasive delivery and rapid (>3 sec) 
shape recovery of 3-D scaffolds at physiologically safe temperatures (~ 50ºC). 
Overall, this dissertation demonstrates how the rational selection of FDA-
approved materials with synergistic interactions results in smart biomaterials with 
high potential for clinical translation. 
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CHAPTER I: INTRODUCTION 
  
  
2 
1. Introduction 
While bone has remarkable healing capacity, large fractures or defects 
cannot heal without intervention. This results in over 600,000 bone-grafting 
operations each year in the United States alone, and this number is expected to 
increase with the aging population.[1] The first autologous bone graft was 
performed by Dr. Fred Albee in 1915.[2] Since then, autograft bone has become 
the gold standard because it does not illicit an adverse immune response, 
maintains mechanical integrity, allows for cell binding, supplies mesenchymal 
stem cells, and contains endogenous growth factors.[3] Autologous bone is 
usually harvested from the patient’s iliac crest, resulting in long-term functional 
impairment and pain which persists for at least two years in 15-39% of 
patients.[4,5] Since a second operation for bone harvest is necessary, 
complications arise such as risk of infection, limited bone quantity, and 
compromised bone quality. Furthermore, rigid allograft bone is difficult to shape 
and fit into defects, particularly cranio-maxillofacial defects with complex 
geometries.[6,7] Autografting procedures are also associated with increased 
operating time, length of hospital stay, and blood transfusions.[8] Even with these 
drawbacks, autograft bone is used in 60% of grafting procedures.[9]  
When an autograft is not possible, the most common alternative is to use 
donor bone, referred to as an allograft. This bone is heavily processed to prevent 
disease transmission and rejection. However this processing removes progenitor 
cells [10] and disrupts mechanical properties [11], osteoblast-graft interactions 
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[12], and growth factor stability.[13] As a consequence, allografts often fail to 
integrate with host bone and remodel, resulting in 10-year failure rates as high as 
60%.[14]  
The discovery of osteoinductive factors in bone matrix by Marshall Urist in 
1965 [15] and the subsequent cloning of bone morphogenetic proteins (BMPs) by 
Wozney et al. in 1988 [16] has led to the widespread use of recombinant human 
bone morphogenetic protein-2 (rhBMP-2) and rhBMP-7 in bone grafting 
procedures. These readily available but costly synthetic bone grafts are typically 
composed of a collagen sponge carrier and the growth factor (rhBMP-2 or 
rhBMP-7). While these growth factor loaded synthetic bone graft substitutes are 
as effective as autografts for some indications, particularly non-weight bearing 
ones,[17] they require loading doses of rhBMP-2 as high as 4.9 mg or 12.7 mg 
per graft,[18] compared to ~5 µg/kilogram BMP-2 in natural bone.[19] 
Documented complications from such supra-physiologic doses rhBMP-2 include 
ectopic bone formation, inflammation, sexual dysfunction, and potentially 
cancer.[20,21] The need for such a high dose is a result of the burst release 
profile of rhBMP from the collagen carrier (e.g. 100% released in vitro after 2 
days [22]). By contrast, although endogenous BMP-2 is expressed most highly 
early during fracture healing in mice (~1 day), it’s expression is sustained during 
the 21-day healing cascade.[23] Furthermore, the poor handling and mechanical 
properties of the collagen sponge results in difficulty in inserting and retaining the 
graft at the defect site.[24] Other attempts to improve the handling characteristics 
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and bioactivity of synthetic carriers include mixing collagen with calcium 
phosphate minerals and forming simple gels, foams, pastes, or granules.[25] 
These materials tend to soften upon hydration and some composites are too 
brittle due to poor structural integration between components, making their stable 
fixation with the defect site difficult to achieve. Taken together, current synthetic 
bone grafts fail to recapitulate the biology of native bone and their physical 
properties do not support convenient clinical uses. Thus there remains a critical 
need for translatable bone grafting materials with improved handling 
characteristics and safer, more effective clinical outcomes. 
The field of tissue engineering combines cell biology, materials science, 
and engineering to develop strategies to regenerate damaged tissues and 
organs. This is often accomplished by using biodegradable scaffolds that deliver 
cells/therapeutics, template tissue formation, and ultimately regenerate the tissue 
of interest [26,27]. An ideal scaffold should be one that can recapitulate the key 
mechanical and biological features of the tissue of interest while possessing 
handling characteristics that facilitate cell and/or therapeutic loading and surgical 
delivery. With regards to bone repair, tissue engineering approaches have the 
potential to overcome the limitations of autograft and allograft bone.[28–31] This 
dissertation will describe the development of a biodegradable amphiphilic 
organic-inorganic composite biomaterial for bone tissue engineering applications. 
Overall, I will demonstrate how rational selection and integration of FDA-
approved components with synergistic interactions results in the development of 
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“smart” tissue engineering scaffolds with novel handling characteristics and 
effective biological performance. 
2. Overview of scaffold-based tissue engineering 
The history of tissue engineering has been previously reviewed [32,33] 
and will be highlighted briefly. The remainder of this section will discuss the 
common fabrication strategies and biodegradable polymers used to construct 
tissue engineering scaffolds.  
2.1. Historical perspective 
As described by Charles A. Vacanti, M.D.,[32] one of the pioneers in the 
field of tissue engineering, the idea of de novo construction of new tissues and 
organs can be traced as far back as Genesis I:1 “So the Lord, cast a deep sleep 
on the man, and while he was asleep, he took out one of his ribs and closed up 
its place with flesh. The Lord then built the rib that he had taken from the man 
into a woman.”[34] However, from ancient Egyptians constructing the first 
wooden toe replacement[35] to the 1980’s, materials for medical applications 
were limited to prosthetics that could provide mechanical or structural support 
and bioinert implants intended to resist significant adverse immune responses. 
The first attempt at what is now described as “tissue engineering” was credited to 
W.T. Green, M.D., who in 1977 cultured rabbit chondrocytes on a decalcified 
bone scaffold in an attempt to repair articular cartilage.[36] Dr. Green implanted 
the constructs into full-thickness rabbit articular cartilage defects in the knee and 
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observed some cartilage-like tissue formation after 10 days. Even in this early 
experiment, the importance of appropriate materials selection was apparent 
because Dr. Green reported that chondrocytes cultured on collagen sponges 
rather than on decalcified bone failed to induce cartilage repair. In 1981, John 
Burke, M.D. and colleagues described the application of a porous 
collagen/chondroitin-sulfate sponge covered with a Silastic® (silicone) membrane 
for treating burn wounds.[37] Fibroblasts and blood vessels from the wound bed 
grew into this “artificial skin” scaffold and remodeled the scaffold into a 
neodermis that could be covered with additional skin grafts.  
Joseph P. Vacanti, M.D., first presented the tissue engineering concept as 
it is recognized today during the 1988 meeting of the New England Surgical 
Society.[38] In his lecture, Dr. Vacanti described his work with Robert Langer, 
Sc.D., where they combined cell suspensions isolated from various organs with 
fibrous synthetic polymeric scaffolds and implanted the constructs into animals. 
They originally termed this approach as “chimeric morphogenesis”.[39] A 
subsequent review of the emerging field now called Tissue Engineering, 
published in Science in 1993 by Langer & Vacanti, has been widely cited as a 
pioneering article that galvanized the field.[27] Dr. Charles A. Vacanti garnered 
widespread media attention by growing a human ear-shaped cartilage-like tissue 
on the back of a nude mouse dubbed the “Vacanti mouse”.[40] While this 
experiment demonstrated the potential of tissue engineering, true restoration of 
functional tissue and clinical translation to widespread use remains a challenge. 
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Just a few of the issues that remain include cell sourcing, immunogenicity, 
scalability, the vascularization of large constructs, and regulatory and business 
considerations. The development of appropriate scaffolds to template the tissue 
formation is one approach to overcome some of these challenges and advance 
of the field of tissue engineering. 
The simplest definition of a tissue engineering scaffold is a structure that 
provides temporary mechanical support and shape to a growing or regenerating 
tissue in vitro or in vivo.[41] These scaffolds can be composed of synthetic or 
natural materials, or their combinations, and fabricated through a variety of 
techniques, some of which will be described in this thesis. While early tissue 
engineering scaffolds relied on simple single-component materials as 
structural/mechanical support, next-generation “smart” scaffolds aim to guide cell 
fate, respond to cell signals by degrading or releasing growth factors, and enable 
novel delivery modalities such as shape-memory, self-fixation, or change form 
(liquid to gel) at the implantation site.[41,42]  
2.2. Polymers for tissue engineering scaffolds 
Both natural and synthetic polymers have been used as tissue 
engineering scaffolds. Natural polymers such as collagen, gelatin (denatured 
collagen) and fibrin are part of the natural extracellular matrix (ECM) or secreted 
during the wound healing process. While natural materials such as collagen and 
fibrin are in clinical use, their batch-to-batch variability in isolation/purification, 
weak mechanical properties, poorly controlled degradation, cost, processing 
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difficulties, and immunogenicity present challenges.[43] Synthetic polymers, if 
properly designed, can be fabricated reproducibly in large scales, exhibit 
improved mechanical properties and predictable degradation behaviors, and are 
amenable to a variety of chemical functionalization or physical modifications to 
introduce bioactivity. The Food and Drug Administration (FDA) has approved 
many products comprised of synthetic polymers with acceptable biocompatibility. 
Chemical structures of the building blocks of FDA-approved degradable synthetic 
polymers described in this thesis are shown in Figure 1.1. 
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Figure 1.1. Chemical structures of commonly used synthetic polymers in tissue 
engineering. 
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Figure 1.1 
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2.3.1 Biodegradable polymers 
The most widely used FDA-approved degradable polymers are the 
hydrophobic polyesters poly(lactic acid) (PLA), poly(glycolic acid) (PGA), 
poly(lactic-co-glycol acid) (PLGA), or poly(ε-caprolactone) (PCL). These 
materials are most commonly found in surgical products such as resorbable 
sutures, meshes, or orthopedic fixation devices.[44] 
PLA is composed of chiral lactide building blocks that can be polymerized 
in an enantiomerically pure L form (PLLA) or a racemic D/L form (PDLLA).[45] 
PLLA is semi-crystalline and PDLLA is amorphous, resulting in vastly different 
mechanical properties and degradation rates. PLLA is a rigid polymer with a 
glass transition temperature (Tg) of 60-65 ºC, melting point (Tm) of ~175 ºC, and a 
tensile modulus of 2.7 GPa. [46] PDLLA is a weaker material (1.9 GPa tensile 
modulus) and has a Tg of 55-60 ºC.[47] PLLA and PDLLA are thermoplastics that 
can be fabricated into scaffolds with a variety of architectures including dense 
and nanoporous films by solvent-casting and electrospinning, respectively, as 
well as dense filaments and macroporous 3-D scaffolds by extrusion and fused 
deposition modeling techniques. However, relatively high temperatures are 
required to melt and process PLLA (> 175 ºC) and PDLLA (~>130 ºC).  
PLA degrades by hydrolysis of the ester bonds into lactic acid, which is a 
natural metabolic byproduct and may be cleared by the body as carbon dioxide 
and water.[44] The accumulation of lactic acid released from degrading PLA and 
the resulting pH drop in the vicinity of the implant can cause an inflammatory 
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immune response and bone resorption.[48,49] PLLA takes over 2 years to 
degrade, and full degradation of PLLA crystallites can take over 5 years,[49] 
while PDLLA degrades in ~1 yr.[44]  
PGA is a highly crystalline polymer, resulting in its insolubility in most 
organic solvents and high stiffness (12.8 GPa tensile modulus).[47] It has a high 
melting point (225 ºC) and is typically processed by injection molding/extrusion. 
PGA degrades by hydrolysis in 6-12 months, depending on its molecular weight, 
into glycolic acid which can be cleared by the body.[44] The degradation 
behavior and high-strength fiber forming ability of PGA led to its use as the first 
biodegradable synthetic suture material (Dexon®).[44] However its use has been 
relatively limited in tissue engineering due to its low solubility, limited high-
temperature processing options, and high stiffness. Co-polymers of PLA and 
PGA, called PLGA, overcome the processing difficulties (solubility) and 
excessive stiffness of PGA. By varying the ratio of PLA to PGA, the degradation 
rate can vary from 1-2 months (50/50 ratio) to 6 months (85/15 ratio).[44] The 
tunable degradation rates, ease of processing, and established medical uses of 
PLA and PLGA have led to their wide incorporation in tissue engineering 
scaffolds.  
The use of PCL has generally been restricted to slow degrading drug 
delivery devices and sutures, but more recently its application has been 
extended to tissue engineering applications, as reviewed by Woodruff and 
Hutmacher.[50] PCL is a semi-crystalline polymer that is generally weaker than 
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PLA (400 MPa tensile modulus)[46] and degrades by hydrolysis into caproic acid. 
It has a Tg of ~ -60 ºC and a Tm of ~60 ºC. The thermoplastic nature and relatively 
low melting point of PCL enables its facile processing into a variety of scaffold 
architectures by techniques such as electrospinning and rapid prototyping. PCL 
can be degraded by bacterial enzymes but its in vivo degradation modality in 
humans and animals is limited to hydrolysis.[50] Since PCL is more hydrophobic 
than PLA,[51] it has a slower degradation rate, with minimal degradation reported 
even after 2 years in vivo (initial Mw = 66,000 Da).[50,52]  
2.3.2 Poly(ethylene glycol) 
Poly(ethylene glycol) (PEG) is a hydrophilic polyether that is clinically used 
in formulating pharmaceuticals, such as for increasing the circulation time of 
protein therapeutics.[53] This increased circulation time is a result of the low-
fouling nature of PEG as it is known to resist protein adhesion through the 
entropic penalty of releasing bound water from the hydrophilic PEG surface by 
approaching proteins.[54] While PEG is non-degradable, PEG chains shorter 
than 30-50 kDa are readily cleared through the kidneys.[53,55] Unmodified PEG 
is not suitable for tissue engineering applications requiring tissue integration 
because it is non-cell adhesive, non-degradable, and water-soluble. With the 
addition of bioactive molecules or fillers, however, cross-linked PEG hydrogels 
have been widely studied for tissue engineering.[56] PEG can also be 
copolymerized with water-stable and degradable hydrophobic blocks, such as 
PLA or PCL. Low molecular weight amphiphilic polymers composed of 
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biodegradable hydrophobic blocks and PEG can form nanoparticles that have 
been used to encapsulate hydrophobic drugs or proteins with extended 
circulation time.[57–59] High molecular weight (>100 kD) amphiphilic PEG-based 
polymers can form membranes or gels that are stable in aqueous environments 
and have been used as degradable anti-adhesion tissue barriers for surgery.[60–
64] PEG-based copolymers have also been used for tissue engineering scaffolds 
as reviewed by Tessmar & Göpferich.[65]  
2.3. Fabrication techniques for tissue engineering scaffolds 
Interconnected porous structures are desired for tissue engineering 
because they enable cellular/tissue ingrowth, nutrient transport, and waste 
diffusion. For example, pore sizes of ~100 µm are required for bone and capillary 
ingrowth in vivo, with pore sizes of 300-400 µm resulting in the most bone 
ingrowth.[66] The high surface area of porous scaffolds also increases the 
capacity for the binding and release of growth factors and other therapeutics that 
could be used to replicate the biochemical environment of the tissue of interest. A 
variety of manufacturing approaches are available for tuning the architecture and 
porosity of scaffolds including solvent casting/particulate leeching,[67,68] gas 
foaming,[69] thermally induced phase separation,[70] self-assembly,[71] 
electrospinning,[72] and rapid prototyping.[73] Each of these approaches has its 
unique advantages and disadvantages, as has been reviewed previously.[74,75] 
Here I will describe the two manufacturing approaches used in this dissertation 
work, electrospinning and rapid prototyping. 
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2.3.1 Electrospinning 
Electrospinning is a method to form nanoscale polymer fibers by ejecting a 
polymer melt or polymer dissolved in solvent though a syringe under high 
voltage. Electrostatic forces cause the polymer at the tip of the syringe to form a 
conical structure called a Taylor cone. As the charge buildup overcomes the 
surface tension of the polymer solution, the solution forms a thin jet emanating 
from the Taylor cone. Whipping and bending of the jet under the electric field 
stretches it into a nano-sized fiber while the solvent is evaporated. The resulting 
charged fiber is collected onto a grounded surface.[76] The size and morphology 
of the fibers can be tuned by varying the electrospinning parameters such as 
solvent, voltage, and collector distance. While the first patent for electrospinning 
polymeric solutions dates back to 1930,[77] it did not garner widespread attention 
until the 1990s, principally driven by research from the Reneker group that 
described the electrospinning of over 20 types of polymers including DNA.[78] 
Facile modification of the electrospinning apparatus has been employed to create 
specialized structures such as aligned fibers,[79] core-shell fibers,[80] and 
tubular constructs [81]. A schematic of the electrospinning process is shown in 
Figure 1.2. 
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Figure 1.2. Schematic of an electrospinning process. 
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Figure 1.2 
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The native ECM that cells create, grow on, and remodel is composed of 
hierarchically organized structures of which nanofibrous proteins are the basic 
building blocks. The ECM provides structure to the tissue and guides cell fate 
and function through a combination of physical and soluble signals.[82] 
Electrospinning is a scaffold fabrication technique well suited for creating ECM-
mimetic nanofibrous materials. The research groups of Frank Ko [83] and Gary 
Bowlin [84,85] performed the early work adopting electrospinning to tissue 
engineering in 2001-2002. The high surface area of electrospun nanofibrous 
materials has been shown to adhere greater numbers of cells than flat 
counterparts.[86] Electrospun materials also effectively retain and release growth 
factors, such as the sustained release of BMP-2 with >80% retention after 7 days 
[87]. Modification of the fiber size and alignment can direct stem cell growth and 
differentiation in vitro.[86] When tested in vivo, Cao et al. found that nanofibrous 
PCL scaffolds resulted in a less fibrous encapsulation than flat PCL films, with a 
37 µm thick fibrous capsule over the film versus an 8 µm thick capsule over 
electrospun fibers.[88] The nanofibrous scaffold morphology may also result in 
improved bone healing. Woo et al. demonstrated that nanofibrous PLLA scaffolds 
supported more bone formation in rat calvarial defects than solvent-cast PLLA 
scaffolds.[89] Cai et al. found that nanofibrous PLLA membranes resulted in 
greater bone formation than collagen membranes in rabbit tibial defects.[90]  
Electrospinning typically produces thin two-dimensional (2-D) fiber mats 
with high bulk porosity but pore sizes (1 – 10 µm) that are too small for the 
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infiltration of cells.[91] This results in difficulty in applying electrospun scaffolds to 
large 3-D defects and poor cellular/tissue ingrowth across the depth of 
electrospun materials. One approach to create 3-D constructs from electrospun 
membranes is to wrap [92,93] or stack [94] the membranes into 3-D 
configurations, however, this alone does not solve the porosity issue. The 
electrospinning setup can be modified to create porous 3-D constructs. Blakeney 
et al. used a grounded spherical dish with an array of metal rods as the 
collector.[95] This produced 3-D “cotton ball-like” scaffolds that improved cell 
infiltration. Yokoyama et al. formed 3-D sponge-like nanofibrous scaffolds by 
electrospinning into tertiary-butyl alcohol.[96] Kim et al. used a femtosecond laser 
to introduce pores into similar electrospun sponges, increasing the pore size from 
5-10 µm to 190-380 µm.[97] Baker et al. increased the porosity of electrospun 
scaffolds by co-electrospinning sacrificial water-soluble fibers.[98] Using this 
method, they were able to increase cell infiltration, where cells grew mainly on 
the surface of the scaffolds without sacrificial fibers but fully colonized the 
thickness of the scaffolds bearing 60% sacrificial fibers.  
2.3.2 Rapid prototyping 
Rapid prototyping or solid freeform fabrication refers to a variety of 
techniques that produce solid structures based on computer aided design (CAD) 
models. Initially, rapid prototyping was used in the medical field to make custom 
titanium bone implants and anatomical models for guiding surgical 
procedures.[99] For tissue engineering applications, rapid prototyping has a 
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distinct advantage over indirect scaffold fabrication techniques such as solvent 
casting-particulate leeching and freeze-drying because it allows for the ability to 
precisely and reproducibly control porosity and macroscopic shape.[73,99] 
Advanced rapid prototyping approaches can also incorporate multiple materials, 
cells/biologics, and a combination of nano, micro, and macro-scale features in a 
single scaffold. 
Rapid prototyping techniques begin with a 3-D CAD model that has either 
been designed de novo or based on anatomical data from computed tomography 
(CT) scans. The CAD model is processed by software that converts the model 
into a collection of surface triangular patches and saves the model as an STL 
file.[75] In order to generate instructions for the rapid prototyping apparatus, the 
STL file is sliced into stacked 2-D cross-sections. The apparatus fabricates these 
cross-sections layer-by-layer, reproducing the final 3-D structure. Common rapid 
prototyping methods include stereolithography, selective laser sintering, 3-D 
printing, and fused deposition modeling. A schematic of the rapid prototyping 
process using fused deposition modeling is shown in Figure 1.3. 
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Figure 1.3. Schematic of rapid prototyping a femoral head with fused deposition 
modeling. 
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Figure 1.3 
 
  
  
23 
Stereolithography 
Stereolithography was the first commercially available rapid prototyping 
technique, developed by 3D Systems in 1986.[100] Stereolithography is based 
on polymerizing photocurable liquid resins. The stereolithography apparatus uses 
an ultraviolet laser or projects an ultraviolet pixel pattern to harden the resin in 
areas defined by the STL file, and then the platform moves down to allow 
polymerization of the following layer. Stereolithography allows for the fabrication 
of complex structures with a resolution in the sub-micron scale.[101] This precise 
geometric control enables the fabrication of scaffolds with high surface areas and 
interconnected porosity by using mathematical modeling techniques such as 
triply periodic minimal surfaces.[102] Stereolithography is amenable to both 
synthetic biodegradable polymers[103] and natural materials[104], but only if they 
can be modified with photoreactive groups for photo-curing. Since 
stereolithography is a low-temperature process performed in solution, live cells 
can be added, enabling the direct encapsulation of cells within the scaffold.[105] 
However, technical challenges with such a cell encapsulation approach include 
inhomogeneous cell distribution due to settling, cytotoxicity imposed by the 
photoinitiators, and potential cellular damage by the ultraviolet light.[100] Other 
disadvantages of stereolithography include the expensive machinery required, 
the inability to print overhanging features without a support, additional post-
processing to complete crosslinking, and the limited number of biocompatible 
stereolithography resins.[100] 
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Selective laser sintering 
Selective laser sintering is similar in principle to stereolithography but the 
resin bath is replaced with a polymer powder. A high-energy laser melts the 
polymer powder to form a solid structure layer-by-layer. Selective laser sintering 
has been used for the fabrication of high-strength polymer and polymer/ceramic 
composite scaffolds.[75] Because the un-melted powder provides a support 
structure to the printed construct, complex shapes with overhangs can be 
produced without a support material. However, the resolution of this technique is 
governed by the powder morphology and heat transfer characteristics, resulting 
in lower dimensional accuracy (45 – 100 µm) than selective laser sintering.[106] 
It can also be difficult to remove trapped powder from the pores of the final 
scaffold.[106] The expensive machinery, high temperatures required, and the 
limited selection of suitable powderized polymers further limit the applications of 
selective laser sintering in tissue engineering.[50] 
3-D printing 
The term “3-D printing” is commonly used to refer to rapid prototyping in 
general, however the specific technique of 3-D printing involves rapid prototyping 
with an ink-jet based system. 3-D printing was first described by Sachs, Cima, 
and Cornie in 1990.[107] Their design involved depositing a stream of binder 
(colloidal silica) droplets from a piezoelectric inkjet nozzle onto a powder bed 
(aluminum oxide). As with other rapid prototyping methods, the 3-D part is built 
by binding the powder layer-by-layer. The powder bed allows for the printing of 
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overhangs without support material. This approach is more cost effective than 
the laser-based approaches, although it typically requires customized 
instrumentation. 3-D printing has been applied to tissue engineering because it 
does not require elevated temperatures and is amenable to a wide selection of 
binder and powder materials. 3-D printing has been used to fabricate scaffolds 
composed of natural polymers including collagen,[108] biodegradable synthetic 
polymers, and polymer/mineral composites.[106] However, the resolution of 3-D 
printing is limited by binder and powder interactions, particularly wettability and 
solvent evaporation, which result in a resolution of 350 µm – 500 µm.[106] The 
number of suitable powderized polymers and binders and the difficulty in 
removing unbound powder are additional limitations of 3-D printing. Rather than 
binding powder, ink-jet-based 3-D printers have been loaded with live cells mixed 
in hydrogels and used to directly print cell-laden constructs.[109] This is a 
promising technique for manufacturing whole engineered tissues and organs but 
complications such as low cell viability, inadequate cell densities, and poor 
nutrient diffusion within such 3-D printed cell-laden scaffolds remain.   
Fused deposition modeling 
Fused deposition modeling (FDM) is a simple and inexpensive rapid 
prototyping approach that has been widely used in the hobbyist community 
(RepRap) and commercialized into consumer-grade “3-D printers” by companies 
such as MakerBot®. Akin to a hot glue gun, a polymer filament is extruded 
through a heated nozzle and deposited onto a build platform. The platform 
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moves to allow construction of the model layer-by-layer, with the heated plastic 
from the layer being deposited fusing at its contact points with the previous layer. 
Advantages of FDM are its accessibility, the ability to print small overhangs 
without support material, and the lack of post-processing steps (no need for 
powder removal/cross-linking). The resolution is most limited by the size of the 
printing nozzle and extrusion characteristics of the polymer, resulting in a line 
width typically approaching 250 µm.[110]  
Disadvantages of FDM include the requirement for thermoplastic polymers 
and the high temperature processing that is unsuitable for the direct deposition of 
growth factors or cells along with the polymer. Customized FDM-based methods 
have aimed to overcome these disadvantages. Instead of extruding melted 
polymer, 3-D fiber deposition uses a pneumatic-driven syringe to deposit viscous 
solutions. This technique has been used to fabricate scaffolds composed of 
biodegradable polymers and polymer/bioglass composites with line widths as low 
as 75 µm.[111] Live cells in hydrogel solutions can also be loaded into the 
syringe barrel and extruded into 3-D scaffolds using this method.[112]  
2.3.3 Combinations of electrospinning and rapid prototyping 
As described previously, electrospinning results in nanofibrous scaffolds 
with high surface areas but limited porosity and thickness. Rapid prototyping 
techniques create 3-D scaffolds with high macroporosity and unlimited thickness 
but the line resolution is unsuitable for fabricating nanoscale features. As recently 
reviewed by Dalton et al., electrospinning and rapid prototyping are converging to 
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incorporate the advantages of each technique into one scaffold.[113] For 
example, nanofibers can be electrospun between layers of a rapid prototyped 
macroporous scaffold. This results in increased cell retention upon cell seeding 
onto the scaffold.[114] Alternatively, electrospinning apparatus have been 
modified to allow direct deposition of electrospun fibers in defined configurations. 
One solution is to electrospin a polymer solution into a moving grounded bath 
collector. This results in 3-D scaffolds with high surface roughness.[115] In 
another modification, melt electrospun fibers were directly deposited in controlled 
configurations, forming rapid prototyped materials with 20 µm fiber 
resolution.[116] However, these techniques are still in the proof-of-concept phase 
and have not yet entered widespread use in the tissue engineering community.  
3. Rational design of organic-inorganic composite scaffolds for  
bone tissue engineering  
3.1. Requirements for a bone scaffold 
The requirements for an ideal bone tissue engineering scaffold vary 
depending on the application but there are some common clinical translation and 
biological factors. From a translational standpoint, the biomaterial should be 
simple to produce, ideally made of building blocks used in FDA-approved 
products, scalable, versatile in its processing, simple to store and transport, cost 
effective, easy to use (i.e. drug/cell loading, molding, delivery, and fixation), and 
ideally cell-free.[25] From a biological standpoint the material should be 
  
28 
biocompatible, support bone ingrowth (osteoconductive), recruit and guide the 
osteogenic differentiation of progenitor cells (osteoinductive), and bio-resorbable 
in a time-scale coincident with healing (3-6 months for bone[117]).[24] To 
facilitate FDA-approval, it is beneficial if these bioactivity characteristics derive 
from the intrinsic properties of the material (hydrophobicity/hydrophilicity, 
stiffness, morphology) rather than from exogenous additives.[118] These 
requirements could potentially be met by designing synthetic materials that mimic 
the key structural components of natural bone while imparting novel “smart” 
functionalities. 
3.2. The structure and cellular composition of native bone 
Bone is a complex tissue that is hierarchically organized from macroscopic 
into micro and nanoscopic scales.[119–121] A simplified schematic of bone’s 
hierarchical structure is shown in Figure 1.4. Macroscopically, bone is composed 
of compact cortical bone and spongy trabecular bone. Most bones are covered in 
periosteum, a thin highly vascularized fibrous tissue that is a source of progenitor 
cells and blood vessels for bone. The inner cavity of bone contains a similar 
fibrous tissue called the endosteum, which is also a source of progenitor cells 
and more differentiated bone cells. At the microscopic scale, bone is composed 
of sheets called lamellae. In compact bone, these lamellae are further 
cylindrically organized into osteons. The osteons have Haversian canals in the 
center, through which blood vessels provide nutrients. Transverse canals called 
Volkmann’s cannals link the Haversian canals together. Residing in the bone are 
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cells called osteocytes which sense mechanical forces and guide bone 
turnover.[122] They can communicate to each other through a network of 
channels called canaliculi.[121] Osteoblasts, derived from bone marrow stromal 
cells (MSCs) or other progenitors (e.g. periosteal cells) are the cells that secrete 
osteoid and mineralize the osteoid into bone. The osteoblasts secrete signaling 
molecules that stimulate bone-resorbing cells called osteoclasts. Osteoclasts are 
multinucleated cells derived from monocytes. The coordinated remodeling 
activity of osteoblasts and osteoclasts is critical for skeletal injury repair and the 
maintenance of healthy bone tissue.[121] 
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Figure 1.4. The hierarchical structure of bone. From: Stevens MS, George JH. 
Exploring and Engineering the Cell Surface Interfance. Science (310) 
2005;5751:1135-1138. Reprinted with permission from AAAS. 
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Figure 1.4 
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On the nano-scale, bone is a composite predominantly of type-I collagen 
and nanocrystalline hydroxyapatite (Ca10(PO4)6(OH)2; HA) (50-70% dry weight, 
with varying degrees of carbonation and substitution by halides). Collagen 
provides a tough and elastic structure that is reinforced by the HA. The excellent 
structural integration of HA with the collagen template is critical for cortical bone’s 
robust compressive strength (78-151 MPa), young’s modulus (6-13 GPa), and 
fracture toughness (2-12 MPa m1/2).[123] Apart from mechanical reinforcement, 
the HA component of bone is also an important bioactive component of the ECM. 
HA supports bone growth (osteoconductive) and can induce the recruitment and 
differentiation of bone progenitor cells (osteoinductive). This bioactivity is a result 
of a combination of HA’s physical properties including it’s dynamic surface that 
can sequester and release proteins,[124,125] the release of calcium and 
phosphate ions driving osteogenic differentiation of stem cell cells,[126] and 
mechanical cues. While replicating the complex hierarchical structure of bone is 
yet to be achieved, mimicking the nanoscale organic/inorganic composition of 
bone has been a widely used strategy in the design of bone tissue engineering 
scaffolds. One way this can be accomplished is by blending synthetic polymers 
(organic component) with HA or other osteoconductive minerals (inorganic 
component). 
3.3. Synthetic organic-inorganic composites 
Synthetic HA is clinically used in bone cements,[127] hip prosthesis 
coatings,[128] and for middle ear reconstruction.[129] However, the brittle 
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mechanical properties of HA results in poor handling characteristics and make it 
unsuitable for load-bearing applications. A rational strategy to overcome the 
brittleness and poor handling characteristics of HA while exploiting its bioactivity 
has been to blend HA with synthetic biodegradable polymers. These polymer-HA 
composite biomaterials can then be fashioned into tissue engineering scaffolds 
by a variety of approaches including electrospinning and rapid prototyping. The 
addition of HA to biodegradable polymers has been shown to improve cell 
attachment,[130] osteogenic differentiation of stem cells,[131,132] growth 
factor/drug binding and release,[133,134] and expedite bone healing in vivo.[135] 
HA and other calcium phosphates can also buffer the acid byproducts of polymer 
degradation, potentially mitigating adverse immune responses.[136,137] In such 
polymer-HA composites, adequate HA dispersion and interfacial adhesion 
between the HA and polymer is critical.  
Poor dispersion and interfacial adhesion of HA in polymer blends results in 
HA aggregation and mechanical failure sites at the polymer-HA interface. This 
leads to deterioration of the mechanical and handling properties of the resulting 
composite scaffold.[138–140] Most FDA-approved biodegradable polymers, 
including PLA and PCL, are hydrophobic and blend poorly with the hydrophilic 
HA mineral. This hydrophobic-hydrophilic mismatch yields scaffolds with 
compromised mechanical properties and bioactivity, particularly when 
incorporated with high HA contents (>10 wt.%). Poor adhesion between the 
polymer and mineral phase is apparent when casting simple films, as described 
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by Kim et al.[141] Loading 30 wt.% calcium phosphate/PCL films under tension 
results in failure points at the mineral/polymer interface. Poor HA adhesion and 
dispersion results in further compromised performance of porous scaffolds. 
Jeong et al. used electrospinning to produce a nanofibrous composite of PLLA  
and 20 wt.% HA.[142] This combination resulted in a brittle material with an 
ultimate tensile strength of 0.262 MPa and young’s modulus of 4.771 MPa.  Poor 
dispersion of HA can also result in HA aggregates when rapid prototyping 3-D 
scaffolds. Rodriguez et al. fabricated HA-PCL composite scaffolds by fused 
deposition modeling.[143] Micro-computed tomography (µ-CT) reconstruction of 
the scaffolds showed large HA aggregates and a non-uniform distribution 
throughout the scaffold.  
Aggregation of HA can also result in inconsistent biological properties 
because adhered cells are not uniformly exposed to HA.  MC3T3 pre-osteoblast 
cells seeded on the nanofibrous composite of PLLA and 20 wt.% HA maintained 
viability and proliferated for 21 days, with a trend showing improved viability on 
the HA composites albeit with no difference at increasing HA contents.[142]  
D’Angelo et al. electrospun composites of 1-8 wt.% calcium-deficient HA and 
PLLA. [131] They found that the HA promoted a dose-dependent increase in 
osteogenic gene expression in bone marrow stromal cells, induced pluripotent 
stem cells, and embryonic stem cells when cultured in basal medium. However, 
the impact of HA was negated when the cells were cultured in osteogenic 
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medium. Furthermore, even at 8 wt.% HA there was a wide variation in fiber 
diameters and the storage modulus decreased 9-fold. 
The addition of surfactants and the surface modification of HA have been 
used to improve the interfacial adhesion of HA with hydrophobic polymers. These 
approaches have demonstrated some success but also introduced ill-defined 
consequences on in vivo safety and performance. Kim et al. used a surfactant to 
disperse HA and electrospin PDLLA composites with up to 20 wt.% HA.[144] 
This composition increased alkaline phosphatase (ALP) activity over scaffolds 
without HA. However, no mechanical testing was performed. Hydroxyl groups on 
the HA surface are amenable to covalent coupling. Silane coupling reagents 
have been studied to covalently modify the reactive HA surface,[145] however, 
the biocompatibility of these approaches and the toxicity of leaching silane 
coatings is unclear.[146] Qui et al. modified HA with L-lactic acid and then used 
the modified HA as initiators to polymerize PLA.[147] The surface modification 
significantly increased the ultimate stress and elongation at break of PLLA 
composites with 15 wt.% HA. Wang et al. grafted PCL to the surface of HA to 
improve HA blending in porous PCL scaffolds.[148] The grafted HA particles 
resulted in significantly increased compressive modulus and compressive 
strength of the scaffolds, but no biological assessment was performed. 
Designing biomaterials with intrinsic HA bonding capacity is an alternative 
strategy to improve HA dispersion and adhesion in bone tissue engineering 
scaffolds. Using a combinatorial phage display strategy, HA-binding 
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oligopeptides bearing hydroxylated residues every 3 amino acids, mimicking the 
periodic presence of hydroxyproline in type I collagen, was discovered.[149] 
Similarly, hydrophilic poly(hydroxyethyl methacrylate) (pHEMA) hydrogels are 
efficient templates for HA mineralization.[150–152] Cross-linked pHEMA 
hydrogels with 50 wt.% HA withstand compressive strains of >80% and 450 MPa 
compressive loads.[153] Blending HA with PEG has shown similar results.[130] 
This improvement in mechanical properties can be attributed to the favorable 
adhesion of HA, a hydrophilic mineral, with hydrophilic residues in the 
polymers.[138] The pHEMA-HA composites also demonstrated useful handling 
characteristics (press-fitting), sustained release of bioactive proteins and 
antibiotics,[133,154,155] and the ability to expedite healing of critical-size bone 
defects in rats with an exceptionally low dose of osteogenic growth 
factor.[135,154] However, hydrophilic polymers including pHEMA need to be 
crosslinked to achieve aqueous stability and mechanical integrity. Cross-linked 
polymers cannot be dissolved or melted for processing into diverse scaffold 
architectures. Therefore, the pHEMA-HA composites need to be cross-linked in 
specifically designed molds to achieve the desired shape. Such an approach is 
not practical for fabricating tissue engineering scaffolds where the desired shape 
and size often change case by case based on specific patients and defects. 
Additionally, like PEG, pHEMA is not biodegradable, thus the implant would not 
be absorbed. Overcoming these disadvantages of cross-linked hydrophilic 
polymers while maintaining favorable HA interactions could yield bone tissue 
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engineering scaffolds with improved processing/handling properties and 
bioactivity. 
5. Overview of dissertation content 
The overall hypothesis of this dissertation is that clinically translatable and 
smart bone tissue engineering scaffolds bearing useful handling characteristics 
and improved bioactivity can be designed through the rational selection and 
assembly of FDA-approved biocompatible building blocks. Specifically, this 
dissertation describes the development of bone tissue engineering scaffolds 
composed of a thermoplastic amphiphilic tri-block copolymer of PLA-PEG-PLA 
(PELA) and HA. In the HA-PELA composites, hydrophilic PEG blocks bind and 
disperse the bioactive HA, while the PLA blocks provide biodegradability and 
aqueous stability without cross-linking. The amphiphilic nature of PELA enables 
unique handling and surgical delivery characteristics including super-
hydrophilicity for loading therapeutics, hydration-induced stiffening, and shape 
memory. The versatility of the HA-PELA platform has been demonstrated by 
fabricating the composite into scaffolds by electrospinning and rapid prototyping 
approaches. The bioactivity of these scaffolds was examined by evaluating the 
scaffold-bone marrow stromal cell (MSC) interactions in vitro, and by guiding the 
healing of critical-size bone defects in rats.  
Chapter II describes the development and in vitro characterization of 
electrospun HA-PELA scaffolds. This chapter tests the hypothesis that the 
incorporation of a hydrophilic PEG block in PLA will result in a HA-polymer 
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composite with improved processing properties, handling characteristics and 
bioactivity than unmodified HA-PLA. Indeed, HA-PELA composites were 
electrospun with minimal settling of HA, resulting in more uniform scaffolds than 
HA-PLA. HA-PELA demonstrated improved mechanical properties (storage 
modulus, hydration-induced modulus increase, elasticity), hydrophilicity, and 
aqueous stability than HA-PLA. Furthermore, MSCs cultured on the HA-PELA 
composites exhibited higher levels of osteogenic gene expression than MSCs 
cultured on HA-PLA. 
Chapter III describes the performance of spiral-wrapped electrospun HA-
PELA scaffolds in guiding the healing of critical-size femoral segmental defects in 
rats. We show that MSC-seeded HA-PELA can template bone formation in the 
defect and that a low-dose of rhBMP-2 results in almost complete bridging of the 
defects by 12 weeks. Furthermore, we track the survival of transplanted MSCs by 
labeling them with green fluorescent protein (GFP) and show that they survive up 
to 7 days in vivo, albeit at decreased viability over time. This spiral-wrapped 
scaffold strategy can be used to study how combinations of exogenous cells and 
growth factors impact healing and for evaluating the performance of other 
electrospun bone tissue engineering materials in vivo. 
Chapter IV describes the rapid prototyping of HA-PELA into macroporous 
scaffolds using an unmodified consumer-grade 3-D printer. An in vitro pull-out 
test was designed to quantify hydration-induced fixation of the scaffolds in a 
simulated confined defect. We show that PELA and HA-PELA scaffolds swell and 
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stiffen upon equilibration in water, resulting in their self-fixation in the simulated 
defect. This feature could potentially be used for the facile implantation and 
stabilization of bone tissue engineering scaffolds, reducing the reliance on the 
use of fixation devices and preventing bone resorption resulting from inadequate 
graft fixation. To demonstrate the potential utility of this material platform in 
guided bone regeneration applications, we demonstrate the differential cell 
attachment on the low-fouling PELA and more cell-adhesive HA-PELA and 
demonstrated the fabrication of biphasic PELA/HA-PELA scaffolds by rapid-
prototyping. The ability of the 3-D HA-PELA scaffolds to support the attachment 
and osteogenic differentiation of MSCs was also demonstrated. 
Shape memory materials could enable the minimally invasive delivery and 
stable fixation of tissue engineering scaffolds, enabling a complementary delivery 
strategy to the hydration-induced self-fixation behavior described in Chapter IV. 
Chapter V describes the thermal responsive shape memory properties of HA-
PELA as function of HA content around physiological temperatures. HA 
incorporation increases the stiffness of PELA films but does not impact shape 
memory properties below 10 wt.% HA. At 20 wt. % HA, the shape recovery of 
PELA is slowed but overall shape memory behavior is still maintained. 
Furthermore, the thermoplastic nature of HA-PELA enables the re-programming 
of the permanent shape. Finally, we show that the shape memory performance is 
retained in rapid prototyped macroporous HA-PELA scaffolds. 
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Chapter VI will discuss conclusions of this thesis, future directions, and the 
translational potential of this work. 
  
  
41 
CHAPTER II: An amphiphilic degradable polymer/hydroxyapatite composite 
with enhanced handling characteristics promotes osteogenic gene 
expression in bone marrow stromal cells. 
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Preface 
 
This chapter has been adapted from: 
Kutikov AB, Song J. “An amphiphilic degradable polymer/hydroxyapatite 
composite with enhanced handling characteristics promotes osteogenic gene 
expression in bone marrow stromal cells” Acta Biomaterialia 2013; 9(9):8354-
8364. 
 
The experiments in this work were designed by Dr. Jie Song and Artem Kutikov 
and performed by Artem Kutikov. 
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Abstract 
Electrospun polymer/HA composites combining biodegradability with 
osteoconductivity are attractive for skeletal tissue engineering applications. 
However, most biodegradable polymers such as PLA are hydrophobic and do not 
blend with adequate interfacial adhesion with HA, compromising the structural 
homogeneity, mechanical integrity, and biological performance of the composite. 
To overcome this challenge, we combined a hydrophilic PEG block with PDLLA 
to improve the adhesion of the degradable polymer with HA. The amphiphilic 
triblock copolymer PLA-PEG-PLA (PELA) improved the stability of HA 
suspension at 25 wt.% HA content, which was readily electrospun into HA-PELA 
composite scaffolds with uniform fiber dimensions. HA-PELA was highly 
extensible (failure strain >200% vs. <40% for HA-PLA), superhydrophilic (~0º 
water contact angle vs. >100º for HA-PLA), and exhibited an 8-fold storage 
modulus increase upon hydration (unlike deterioration for HA-PLA), owing to the 
favorable interaction between HA and PEG. HA-PELA also better promoted 
osteochondral lineage commitment of bone marrow stromal cells in unstimulated 
culture and supported far more potent osteogenic gene induction than HA-PLA. 
We demonstrate that the chemical incorporation of PEG is an effective strategy 
to improve the performance of degradable polymer/HA composites for bone 
tissue engineering applications. 
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1. Introduction 
Synthetic polymeric, ceramic, or polymer-ceramic composite scaffolds, 
when engineered with proper physical, chemical, and biomechanical cues, can 
play an important role in directing cellular fate / functions in scaffold-assisted 
regeneration of bone, cartilage, tendon, or their respective interfaces.[156–160] 
An ideal scaffold would recapitulate some key structural and biological properties 
of the extracellular matrices of the tissues of interest while exhibiting unique 
features important for its clinical translation such as scalability and ease of 
use.[25,26,82,161] Achieving this delicate balance requires thoughtful selection 
and integration of biomaterial building blocks, which remains a fundamental 
challenge in the design of synthetic tissue scaffolds. 
Bone is a structural composite mainly of type-I collagen and calcium 
phosphate minerals (50-70% dry weight), of which nanocrystalline HA is the main 
component, that is hierarchically organized from nanoscopic to macroscopic 
length scales.[119,162] HA is an osteoconductive bioceramic that has been 
shown to support bone cell attachment, growth factor binding and release, and 
expedite healing of bone defects in vivo.[130,133,135] Due to its high stiffness 
and brittleness, however, HA alone is not well suited for broad orthopedic 
applications beyond use as a non-weight-bearing bone void filler. Consequently, 
HA has been incorporated with synthetic polymers as 2-D or 3-D dense or 
porous composite scaffolds using a wide range of fabrication techniques 
including, but not limited to, electrospinning, phase separation, injection molding, 
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and 3-D prototyping.[140,163–166] The integration of these discrete structural 
components can be accomplished by either direct mixing/blending or by 
subjecting the polymer scaffolds to HA-mineralization,[167,168]  where interfacial 
adhesion/affinity between HA and the polymeric component is the key to 
achieving structural and mechanical integrity of the final composite.[138,141] In 
the case of fabricating HA-polymer composite scaffolds by electrospinning - a 
process that uses electrical charge to form non-woven fibrous meshes with fiber 
dimensions in the nano to micro scale[72,78,87]  - additional considerations for 
the stability and electrospinnability of the polymer-HA solution also need to be 
taken into account. 
PLA is one of the most widely used biodegradable polymers in synthetic 
tissue scaffolds. It is readily electrospinable, and its in vitro and in vivo 
degradation profiles are well established. The intrinsic hydrophobicity of PLA, 
however, results in its poor mixing and adhesion with hydrophilic HA[169], 
making it difficult to electrospin HA-PLA composites with uniform fiber structures 
and adequate mechanical properties.[138,147,148,170] HA-PLA composites 
often exhibit inferior handling properties (e.g. brittleness) and inconsistent 
biological performance. For instance, the addition of even low contents of HA (~ 
6 wt.%) results in the deterioration of the tensile modulus and impact strength of 
poly(L-lactic acid) (PLLA) films.[171] Scanning electron microscopy (SEM) 
examination of composite membranes following tensile loading reveals failure at 
the polymer-ceramic interface.[141] The addition of HA to PLA has led to minor 
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improvements in cell adhesion and proliferation.[142,144,171] The effects of HA-
PLA composites on stem cell differentiation reported in the literature have been 
mixed, with some researchers concluding that HA promotes osteogenesis[131] or 
chondrogenesis[172], and others observing little impact of HA addition on 
differentiation.[173] We hypothesized that strengthening the interfacial adhesion 
between HA and PLA-based polymers could produce composite materials with 
greater consistency in structural, mechanical and biological performance. 
Previous attempts to strengthen the interfacial adhesion between HA and 
PLA include the addition of amphiphilic surfactants, or modifying HA with surface-
grafted polymers to improve interactions with the hydrophobic 
polyesters.[131,144,147,171,174,175] Such approaches, however, often 
introduce additives with ill-defined biological consequences. An alternative 
approach is to chemical integration of non-anionic structural motifs exhibiting 
adequate bonding affinity to HA (into the degradable polymer). Our group and 
others have demonstrated favorable blending of HA with hydrophilic polymers 
such as pHEMA and PEG.[130,151,153] In these hydrophilic composites, HA 
reinforces the mechanical properties of the polymers. A freeze-dried pHEMA-HA 
composite containing 50% HA withstood >80% compressive strains and 450 
MPa loads without exhibiting brittle fractures,[153] while PEG-HA composites 
containing 15% HA withstand strains of ~2000% without breaking.[130] These 
remarkable mechanical properties are a result of strong interfacial adhesion 
between HA and the hydrophilic polymers.[151] In addition, the osteoconductivity 
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of HA has endowed the otherwise bioinert pHEMA hydrogel with the ability to 
enrich endogenous bioactive factors in vivo, promoting the healing of critical-size 
femoral defects in rats.[135] Unfortunately, hydrophilic pHEMA and PEG 
themselves lack biodegradability and are not stable in aqueous environments 
without chemical crosslinking, making underivatized pHEMA or PEG unsuitable 
for fabricating degradable HA-polymer composites by electrospinning.  
Here we report the design and characterization of an electrospun, 
biodegradable amphiphilic polymer/hydroxyapatite composite based on tri-block 
copolymer PDLLA-PEG-PDLLA (PELA). Although PELAs of different molecular 
weights or block compositions (e.g. diblock or triblock copolymer) have been 
previously developed, they were intended for drug delivery applications,[176–
178] modulating the physical properties of PLA blends,[179,180] or reducing non-
specific protein adsorption on PLA-based tissue scaffolds.[62] The rational 
design of PELA to improve the interfacial binding with HA and optimize the 
physical and biological performance of degradable polymer-HA composite 
scaffolds for bone tissue engineering applications has not been previously 
explored. This design combines the degradability and aqueous stability of the 
PLA block with the HA-binding capability of the PEG block and the 
electrospinability of both. We hypothesized that the addition of a hydrophilic PEG 
block to PLA could facilitate HA binding to the polymer, resulting in improved 
handling characteristics and more consistent biological activity. We tested this 
hypothesis by comparing the impact of HA incorporation on the performance of 
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electrospun PELA and PLA with similar molecular weights and polydispersity.  
We examined their structural integration (fiber morphology, HA distribution), 
surface properties (water contact angle), tensile elasticity and storage modulus, 
in vitro degradation, and impact on the attachment, proliferation, lineage 
commitment and differentiation of bone marrow stromal cells.  
2. Materials and Methods 
2.1. Materials 
3,6-Dimethyl-1,4-dioxane-2,5-dione (D,L-lactide) was purchased from 
Sigma-Aldrich (St. Louis, MO) and purified by recrystallization twice in anhydrous 
toluene and dried under vacuum prior to use. PEG (BioUltra, 20,000 Dalton) was 
purchased from Fluka (Switzerland). Polycrystalline HA powder was purchased 
from Alfa Aesar (Ward Hill, MA). All other solvents and reagents were purchased 
from Sigma-Aldrich (St. Louis, MO) and used as received.  
2.2. Polymer synthesis and characterization 
PELA tri-block copolymer was synthesized by melt ring-opening 
polymerization. Briefly, PEG (20,000 Dalton, 4 g, 0.2 mmol) was heated to 100 
ºC in a Schlenk flask and stirred under vacuum for 1 h to remove residual water. 
The melt was cooled to room temperature before Sn(II) 2-ethylhexanoate (~95%, 
24.18 mg, 0.06 mmol) in anhydrous toluene was introduced by syringe. The 
toluene was removed by heating the mixture under vacuum at 100 ºC for 15 min. 
The mixture was cooled to room temperature before D,L-lactide (17.295 g, 0.12 
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mol) was added under argon purge. The melt polymerization proceeded at 130 
ºC for 5 h under argon. PLA was synthesized in the same manner with 
anhydrous ethylene glycol (99.8%, 0.87mg, 0.1407 mol) as the initiator. Briefly, 
D,L-lactide (15 g, 0.1038 mol) was added to the ethylene glycol in a Schlenk 
flask and heated to 130 ºC. Sn(II) 2-ethylhexanoate (21 mg, 0.05 mmol) was 
introduced by syringe and the melt polymerization proceeded for 5 h. The crude 
PELA and PLA were dissolved in chloroform, purified by precipitation in 
methanol, and dried under vacuum. 
The molecular weights and polydispersity of PELA and PLA were 
determined by gel-permeation chromatography on a Varian Prostar HPLC 
system equipped with two 5-mm PLGel MiniMIX-D columns (Agilent, Santa 
Clara, CA) and a PL-ELS2100 evaporative light scattering detector (Polymer 
Laboratories, UK). Tetrahydrofuran was used as an eluent at 0.3 mL h-1 at room 
temperature. Molecular weight and polydispersity calculations were calibrated 
with EasiVial polystyrene standards (Agilent, Santa Clara, CA).  
1H NMR spectra were recorded on a Varian Mercury 400 MHz 
spectrometer at 298K using CDCl3 containing tetramethylsilane as the solvent. 
1H NMR (400 MHz, CDCl3) for PELA: δ 5.19 (m, 1126H), 3.65 (m, 1816H), 1.5 
(m, 3921H) ppm.  
2.3. Electrospinning  
HA-PELA and HA-PLA composite scaffolds with 0 and 25 wt.% HA were 
prepared by electrospinning. HA powder was sonicated in 5 mL 1:4 (v/v) 
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dimethylformamide/chloroform for 30 min to break up aggregates before PELA or 
PLA (1.25g, 25% w/v) was added. The mixture was stirred overnight at room 
temperature and loaded into a 5 mL syringe. A high-voltage power supply 
(Gamma High Voltage Research, Ormond Beach, FL) delivered a voltage of 12 
kV between a 22G ejection needle and an aluminum collection plate set 15 cm 
away. The polymer solution was fed through the needle at rate of 1.7 mL h-1 with 
a syringe pump (Orion Sage M361, Thermo Scientific, Billerica, MA), and the 
fibers were collected on the aluminum collector plate. The electrospinning 
proceeded for 2 h, with the collecting plate rotated by 90° every 15 min to ensure 
the homogeneity of the fibrous scaffold. The scaffolds (0.1 - 0.2 mm final 
thickness) were dried in a vacuum oven for 48 h to remove any residual solvent 
and stored in a desiccator prior to use.  
2.4. Differential scanning calorimetry (DSC) 
Thermal transitions of PELA and PLA were determined by conventional 
DSC and modulated DSC (MDSC) on a Q200 MDSC (TA Instruments, New 
Castle, DE). For DSC experiments, specimens (~6 mg) were scanned twice from 
-90 ºC to 150 ºC (20 ºC min-1). A constant nitrogen flow of 50 mL min-1 was 
applied. Temperature was calibrated with indium, gallium, and tin standards. Tg 
was defined as the midpoint of the inflection tangent from the second heating 
curve. MDSC was used to further analyze endothermic transitions in electrospun 
PELA. Samples (3.6 mg) were held isothermal at -40 ºC for 15 min and then 
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heated at 2 ºC min-1 to 110 ºC with a 60 s temperature modulation period and an 
amplitude of 0.318 ºC, as described elsewhere.[181]  
2.5. Scanning electron microscopy (SEM) 
As-spun and vacuum-dried scaffolds were sputter coated with Au (~4 nm 
thick) and imaged on a Quanta 200 FEG MKII SEM (FEI Inc., Hillsboro, OR) 
under high vacuum at 5 kV. Fiber diameter was quantified from the SEM 
micrographs by measuring 100 random fibers, from micrographs of five different 
areas, with ImageJ software (National Institutes of Health).  
2.6. Thermogravimetric analysis (TGA) 
TGA was used to determine the actual percentage of HA in the as-spun 
and vacuum-dried scaffolds. The samples were heated at a rate of 20 ºC min-1 
from room temperature to 500 ºC and the mass changes were recorded on a 
TGA Q50 (TA Instruments, New Castle, DE). HA powder was used as a control.  
2.7. Ultimate tensile strain and ultimate tensile stress 
HA-PELA and HA-PLA scaffolds were strained to failure in order to 
evaluate the effect of PEG on the extensibility and strength of the HA 
composites. Tensile tests were carried out according to ASTM D882-97. 
Scaffolds (13 mm wide, 75 mm long and 0.1-0.14 mm thick) were ramped to 
failure on a MTS Bionix 370 testing system equipped with a 500 N load cell. A 25 
mm initial grip separation and 250 mm min-1 grip separation rate were applied. 
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Ultimate tensile strain and stress were recorded at the peak of the stress-strain 
curve. 
2.8. Water contact angle measurements 
The wettability of the scaffolds was examined by the sessile drop 
technique. Droplets of deionized water (5 µL) were deposited onto as-spun and 
vacuum-dried scaffolds or scaffolds freeze-dried following 24 h equilibration in 37 
ºC deionized water. The water contact angle was recorded using a CAM 200 
goniometer (KSV Instruments, Finland). The droplet was imaged at 30 s and the 
average contact angle from the left and right side of the drop was recorded. Five 
randomly selected areas per scaffold were used for each water contact angle 
measurement.  
2.9. Dynamic mechanical analysis (DMA) 
The tensile storage moduli of dry and hydrated (deionized water) scaffolds 
(n=3) were determined on a Q800 DMA (TA Instruments, New Castle, DE). 
Specimens (5.3 × 20 mm) were cut with a parallel blade cutter and loaded onto a 
film tension fixture with a grip separation of 10 mm. Dry and hydrated samples 
were preloaded with a 0.001 N and 0.05 N force, respectively. Samples were 
equilibrated at 37 ºC and held isothermally for 10 min prior to initiating 0.02% 
strain at a frequency 1 Hz and the tensile storage moduli were recorded. The 
0.02% strain chosen falls within the linear viscoelastic region of the scaffolds.  
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2.10. In vitro hydrolytic degradation 
In vitro hydrolytic degradation of PELA, HA-PELA and HA-PLA was 
determined by monitoring the mass loss of the scaffolds upon incubation in 
Ca2+/Mg2+-free phosphate-buffered saline (PBS) (pH 7.4) at 37 ºC. As-spun 
scaffolds were cut into 20 mm × 20 mm squares (n=3 for each time point), 
weighed on an analytical balance (XS105, Mettler Toledo, Columbus, OH), and 
placed in conical tubes containing 20 mL of PBS, and incubated at 37 ºC for up 
to 12 weeks. At each time point, three specimens were removed, washed three 
times with deionized water, and lyophilized. The mass of each retrieved and 
dried specimen was recorded.  
2.11. Rat bone marrow stromal cells (rMSCs) isolation 
The rMSCs were isolated from the long bones of a 4 week old male 
Charles River SASCO SD rat according to the procedure approved by the 
University of Massachusetts Medical School Institutional Animal Care and Use 
Committee and described previously.[153] Briefly, whole bone marrow was 
flushed from the marrow canal of a dearticulated rat femur with minimal essential 
medium (αMEM without ascorbic acid, Life Technologies, Grand Island, NY). 
After lysing red blood cells with sterile water, the cells were centrifuged, 
resuspended in αMEM (without ascorbic acid) containing 20% FBS, 1% 
penicillin-streptomycin, and 2% L-glutamine, passed through a sterile strainer, 
and cultured in the same medium. Non-adherent cells were aspirated 4 days 
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after initial plating and the remaining adherent cells were cultured to 70% 
confluence before being trypsinized and seeded onto various scaffolds.  
2.12. Attachment and proliferation of rMSCs on scaffolds 
MTT cell viability assay (Roche, Indianapolis, IN) was performed to 
quantify cell attachment and early proliferation on the electrospun scaffolds. 
Scaffolds (n=3 per time point) were cut into 6.35 mm diameter circles using a 
hole punch, sterilized under UV for 1 h each side, and equilibrated in MSC 
expansion medium (αMEM without ascorbic acid, 20% FBS, 2% L-Glutamine, 1% 
penicillin-streptomycin) at 37 ºC overnight. Passage 1 rMSCs (15,625 cells cm-2) 
were seeded on the scaffolds placed in ultra-low-attachment 96-well plates 
(Corning Inc., Corning, NY) and cultured in expansion medium for 24 or 96 h. 
The MTT assay was performed according to manufacturer’s instructions. 
Absorbance of the MTT product was read on a Multiskan FC microplate 
photometer (Thermo Scientific, Billerica, MA) at 570 nm with a 690 nm 
background correction. 
2.13. Spontaneous lineage commitment of rMSCs on scaffolds 
rMSCs were cultured on the scaffolds in expansion medium to determine 
the effect of scaffold composition on their un-stimulated lineage commitment. 
Scaffolds were sterilized under UV for 1 h each side and equilibrated in MSC 
expansion medium at 37 ºC overnight. The scaffolds were placed in ultra-low-
attachment 24-well plates (Corning Inc., Corning, NY) and seeded with passage 
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1 rMSCs (50,000 cells cm-2). Following 7 and 14 days in culture, total RNA from 
the MSCs adhered on the scaffolds and those from rMSCs prior to seeding on 
scaffolds (time 0 control) was isolated using TRIzol (Invitrogen, Carlsbad, CA) 
and purified by Direct-Zol miniprep (Zymo Research, Irvine, CA). RNA was 
reverse transcribed into cDNA with SuperScript III Reverse Transcriptase 
(Invitrogen, Carlsbad, CA) according to manufacturer’s instructions on a 
GeneAmp 2700 PCR system (Applied Biosystems, Foster City, CA). Quantitative 
polymerase chain reaction (qPCR) was performed on an Applied Biosystems 
7500 fast real-time PCR system with TaqMan Gene Expression Master Mix 
(Applied Biosystems, Foster City, CA) and inventoried TaqMan probes for SOX9, 
osteocalcin, PPARG and housekeeping gene GAPDH. All reactions were 
performed in triplicate and gene expression was quantified using the delta-delta 
Ct method. Expression of each gene of interest at each time point was 
normalized using GAPDH and plotted as expression relative to that of rMSCs at 
time 0. 
2.14. Osteogenic differentiation of rMSCs on scaffolds 
PELA, HA-PELA and HA-PLA scaffolds were sterilized and seeded with 
Passage 1 rMSCs (50,000 cells cm-2) as described above. The rMSCs were 
allowed to attach to the scaffolds for 24 h before the medium was replaced with 
osteogenic medium (MSC expansion medium supplemented with 10 nM 
dexamethasone, 20 mM ß-glycerol phosphate, 50 µM L-ascorbic acid 2-
phosphate). The scaffolds were cultured in the osteogenic medium for 14 days 
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with medium changes every 3-4 days. Total RNA was isolated, purified, and 
reverse transcribed to cDNA as described above. qPCR was performed with 
TaqMan Gene Expression Master Mix (Applied Biosystems, Foster City, CA) and 
inventoried TaqMan probes for Runx2, osteopontin, osteocalcin, and 
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(Applied Biosystems, Foster City, CA). All reactions were performed in triplicate 
and gene expression was quantified using the delta-delta Ct method. Expression 
of each gene of interest at each time point was normalized using GAPDH and 
plotted as expression relative to that of undifferentiated rMSCs at time 0. 
2.15 Statistical analysis 
All data are presented as mean ± standard deviation. Statistical 
significance was determined by one-way ANOVA with Tukey post-hoc testing. 
Differences were considered significant when p < 0.05.   
3. Results 
3.1 Synthesis of PELA and PLA 
PELA and PLA control were synthesized with similar molecular weights 
(116,298  and 126,139 Dalton, respectively) and polydispersity (PDI = 1.44) by 
melt ring-opening polymerization of cyclic D,L-lactide, using PEG and ethylene 
glycol as initiators, respectively, under the catalysis of Sn(II)  2-ethylhexanoate 
(Figure 2.1). DSC analyses revealed glass transitions at 17.73 and 44.77 ºC for 
PELA and PLA, respectively.  
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Figure 2.1. Synthetic schemes for PELA (1) and PLA (2). x= 454, n= 608, m= 
750. 
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3.2 Electrospinning HA-PELA and HA-PLA composites 
The improved bonding affinity of HA with the amphiphilic PELA over PLA 
was manifested by the significantly more stable HA-PELA suspension in 1:4 (v/v) 
dimethylformamide/chloroform. No obvious settling of HA from the HA-PELA 
suspension (at HA content as high as 33 wt.% relative to polymer weight) was 
detected upon storage at ambient conditions for days whereas the HA settled 
from the HA-PLA suspension by 24 h (Fig. 2.2). The HA-PELA suspension could 
be readily electrospun without noticeable blockage of the needle tip by 
aggregated HA as was often observed during the electrospinning of HA-PLA. 
HA-PELA and HA-PLA composite scaffolds (average thickness of 0.1 - 0.2 mm) 
with 0 and 25 wt.% HA were obtained after 2 h electrospinning and dried in a 
vacuum oven.  
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Figure 2.2. Stability of HA suspension in PELA vs. PLA after 1 week. 
(A) HA (33 wt.%) in a 1:4 dimethylformamide/chloroform solution of PELA (25% 
w/v). (B) HA (33 wt.%) in a 1:4 dimethylformamide/chloroform solution of PLA 
(25% w/v). Visible settling/aggregation of HA to the bottom of the HA-PLA 
suspension was observed as early as day 1 (arrows) while the HA remained well-
dispersed in HA-PELA suspension for days. 
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Figure 2.2 
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3.3 Microstructural and compositional analyses of electrospun HA-PELA 
vs. HA-PLA composites 
SEM and subsequent image analysis was used to quantify the fiber 
uniformity of the electrospun scaffolds.  While the mean diameter of the HA-PLA 
fibers more than doubled over that of PLA, there was no significant increase in 
fiber diameter of HA-PELA over that of PELA (Fig. 2.3a and b). The HA-PELA 
composites also exhibited a narrower distribution of fiber dimensions and fewer 
defects than HA-PLA.  
TGA of the electrospun PELA revealed a transition at approximately 83% 
weight loss, which closely correlated with the weight percentage of PLA in the 
PELA scaffolds (Fig. 2.3c). The PLA blocks, with a lower decomposition 
temperature (onset ~297 ºC) than PEG (onset ~340 ºC), were decomposed first. 
This stepwise decomposition feature, however, was not observed in the HA-
PELA composite, suggesting an insulating effect of HA incorporation. The HA 
that remained after complete PELA thermal decomposition (>400 °C) matched 
precisely with the weight percentage of HA in the electrospinning solution (25%). 
By contrast, the actual HA content in the electrospun HA-PLA composite as 
determined by TGA was 28.4%, >3% higher than that of the HA-PLA suspension 
prior to electrospinning. Homogeneous HA distribution within the HA-PELA 
fibrous matrix was further confirmed by von Kossa staining for calcium[182] 
where intense positive von Kossa stain was detected uniformly within all fibers 
(Fig. 2.4).  
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Figure 2.3. Microstructural and compositional properties of electrospun HA-
PELA and HA-PLA composite scaffolds. a) SEM micrographs of electrospun 
scaffolds. Scale bars = 50 µm. b) Fiber diameters (n=100, mean ± standard 
deviation) of electrospun scaffolds as determined from SEM micrographs using 
ImageJ. * p<0.05 (One-way ANOVA with Tukey post-hoc).  c) TGA  plots  of  
electrospun  scaffolds  and  HA  powder  control. 
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Figure 2.3 
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Figure 2.4. von Kossa-stained electrospun HA-PELA composites. Photographs 
(a) and bright-field microscopy images (b; 10× objective, scale bar: 100 µm). 
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Figure 2.4 
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3.4 Tensile compliance of electrospun HA-PELA vs. HA-PLA composites 
Tensile testing was performed to assess the extensibility and in turn the 
interfacial HA-polymer adhesion in the electrospun scaffolds. Electrospun HA-
PELA was highly extensible, achieving ultimate tensile strains of over 200% (Fig. 
2.5). By contrast, the HA-PLA was characterized with failure strains below 40%. 
HA-PELA also exhibited a failure stress of 2.5 MPa, 5-fold that of the HA-PLA.  
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Figure 2.5. Tensile stress-strain curves of HA-PELA and HA-PLA composites. 
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3.5 Hydration-dependent surface properties of HA-PELA vs. HA-PLA 
composites 
The hydrophilic PEG block in PELA significantly reduced the water contact 
angle (increased the wettability) of the scaffolds when compared to PLA. The 
contact angle of HA-PELA dense films decreased by 17º following hydration (Fig. 
2.6a). For electrospun scaffolds, HA incorporation slightly increased the water 
contact angle of the PELA but exerted no significant effect on the wettability of 
PLA (Fig. 2.6b). To capture the polymer chain arrangements at the fully hydrated 
state, scaffolds were equilibrated in water at 37 ºC for 24 h, and then freeze-dried 
before performing water contact angle measurements. The prior hydration 
significantly reduced the water contact angle of PELA from 71º to 54º and that of 
HA-PELA from >85º to 0º, revealing superhydrophilicity of the latter upon water 
equilibration. By contrast, water equilibration only reduced the contact angle on 
the HA-PLA scaffolds by 11º (Fig. 2.6b).  
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Figure 2.6. Hydration-dependent surface property changes of HA-PELA and 
HA-PLA. (a) Water contact angle of dry and lyophilized films following water 
equilibration (n=5). (b) Water contact angle of as-spun and lyophilized 
electrospun scaffolds following water equilibration (n=5). #, water fully absorbed 
(~0º). n.a., no contact angle obtained due to scaffold shrinkage. * p<0.05 (One-
way ANOVA with Tukey post-hoc). 
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Figure 2.6 
 
  
  
73 
3.6 Hydration dependent mechanical properties of HA-PELA vs. HA-PLA 
The differences in surface properties between HA-PELA and HA-PLA 
upon hydration were also accompanied by drastic mechanical property 
alterations. Dynamic mechanical testing was used to assess the tensile storage 
modulus of both dry and hydrated samples at 37 ºC (Fig. 2.7). The storage 
modulus of the dry PELA increased from 1.1 MPa to 2.99 MPa with the 
incorporation of HA. By contrast, addition of HA significantly deteriorated the 
tensile storage modulus of dry PLA scaffolds from 110 MPa to 43 MPa. 
Strikingly, the amphiphilic PELA and HA-PELA scaffolds exhibited 75-fold and 8-
fold increases in storage modulus upon hydration, respectively. As expected, 
hydration of PLA and HA-PLA resulted in significant storage modulus reductions. 
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Figure 2.7. Mechanical property changes of electrospun PELA and PLA 
composite scaffolds upon hydration. Storage modulus (n=3) of dry and hydrated 
scaffolds at 37 ºC determined by dynamic tensile mechanical analysis (0.02% 
strain, 1 Hz). * p<0.05 (One-way ANOVA with Tukey post-hoc). 
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Figure 2.7 
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3.7 DSC and MDSC analysis of the hydration dependent rearrangement in 
PELA  
Conventional and modulated DSC was carried out on scaffolds with and 
without prior hydration history to assess possible hydration-induced thermal 
behavior changes and the underlying structural rearrangements. Conventional 
DSC revealed an endothermic peak around 50 ºC only with previously hydrated 
PELA specimens (Fig. 2.8a). To assess the nature of this transition, whether a 
reversible crystalline melting or an irreversible transition such as polymer aging, 
MDSC was carried out. MDSC confirmed that this sharp transition was present in 
the reversible heat flow, consistent with a typical crystalline melting peak (Fig. 
2.8b). 
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Figure 2.8. Crystallization behavior of PELA scaffolds upon hydration. (a) DSC 
curves of electrospun PELA scaffolds with or without hydration history. Hydrated 
PELA samples were equilibrated in deionized water @ 37 ºC for 24 h and 
lyophilized. (b) MDSC curves of lyophilized electrospun PELA after water 
equilibration depicting reversible heat flow (green) and total heat flow (blue). 
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Figure 2.8 
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 3.8 In vitro hydrolytic degradation of HA-PELA and HA-PLA composites 
The in vitro hydrolytic degradation behavior of the HA-PELA and HA-PLA 
scaffolds (n=3) was examined by monitoring mass loss upon incubation in PBS 
at 37 ºC over a period of 12 weeks. 1H NMR analysis showed a strong PEG peak 
in the PELA degradation solution (Fig. 2.9). The PELA and HA-PELA scaffolds 
lost ~20% of their mass over 12 weeks, whereas HA-PLA only lost ~3% of its 
mass during the same period (Fig. 2.10a). SEM monitoring of structural changes 
of the incubated scaffolds revealed the least change in HA-PELA fiber 
morphology by 3 weeks, while PELA fibers fused at their contact points and HA-
PLA fibers aggregated together (Fig. 2.10b). The addition of HA effectively 
reduced the degree of fusing of the PELA fibers. 
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Figure 2.9. 1H NMR (CDCl3) of PELA and PELA degradation products. 
In order to obtain NMR spectra of the PELA degradation products, electrospun 
PELA was incubated in PBS at 37 ºC. Following 12 weeks of incubation, the PBS 
degradation solution was lyophilized, degradation products were dissolved in 
CDCl3, and salts were filtered out with a .2 µm PTFE filter. The NMR spectrum of 
the degradation products indicates a PEG peak. Lactic acid is not readily 
apparent by NMR, likely due to the poor solubility of lactic acid in CDCl3. 
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Figure 2.9 
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Figure 2.10. Hydrolytic degradation of HA-PELA and HA-PLA scaffolds in PBS. 
(a) Mass loss over 12 weeks. (b) SEM micrographs of PELA, HA-PELA, and HA-
PLA scaffolds following a 3-week incubation in PBS (pH 7.4, Ca2+/Mg2+-free) at 
37 ºC. Scale bar = 50 µm. 
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Figure 2.10 
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3.9 The role of PEG and HA on rMSC proliferation 
rMSCs were seeded onto the PELA and HA-PELA scaffolds (n=3) and the 
viability of adherent cells was quantified by MTT assay at 24 and 96 h and 
compared with those adhered to HA-PLA (Fig. 2.11). More viable cells were 
adhered to HA-PELA than to PELA at 24 h. rMSCs adhered on all substrates 
were able to proliferate to some degree as indicated by MTT cell viability at 96 h. 
However, the increase in MTT absorbance from 24 h to 96 h was only significant 
for HA-PELA. 
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Figure 2.11. rMSC attachment and early proliferation on electrospun PELA, HA-
PELA, and HA-PLA scaffolds (n=3) as determined by MTT cell viability assay at 
24 and 96 h after initial cell seeding. * p < 0.05 (One-way ANOVA with Tukey 
post-hoc). 
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Figure 2.11 
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 3.10 The role of PEG and HA on the lineage commitment and induced 
osteogenic differentiation of rMSCs. 
To examine the effects surface chemistry and HA incorporation on the 
spontaneous lineage commitment of MSCs, we cultured rMSCs on PELA and 
HA-PELA scaffolds along with HA-PLA control in expansion medium without 
differentiation-inducing supplements. Gene expression of typical osteoblast, 
chondrocyte, and adipocyte markers was analyzed by qPCR at 7 and 14 days to 
determine the temporal nature of the rMSC response to the PELA, HA-PELA, 
and HA-PLA scaffolds. Data were normalized to those obtained from the rMSCs 
prior to seeding on the various substrates (time 0). For the PELA scaffolds, HA 
incorporation resulted in significantly increased expression of the chondrogenic 
marker Sox9 and the osteogenic marker Bglap (osteocalcin) mRNA as early as 7 
days (Fig. 2.12a). Expression of Sox9 and osteocalcin was significantly higher for 
MSCs cultured on HA-PELA scaffolds than for those cultured on HA-PLA. 
Although the expression level of osteocalcin by MSCs cultured on HA-PELA 
decreased from day 7 to day 14 (Fig. 2.12b), it was still significantly higher than 
those observed with MSCs cultured on HA-PLA. The differences in the 
expression of Sox9 by MSCs cultured on HA-PELA vs. HA-PLA, on the other 
hand, was even more pronounced by day 14. The adipogenic maker Ppparg was 
significantly higher at day 7 on PELA than on HA-PELA, but the differences were 
not sustained to day 14. 
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Figure 2.12. Effect of scaffold composition (polymer chemistry and HA) on the 
lineage commitment of rMSCs in un-stimulated culture. Expression of Sox9, 
osteocalcin, and Pparg following (a) 7 or (b) 14 days culture in expansion 
medium, as determined by qPCR. Data are normalized with housekeeping gene 
GAPDH and plotted as expression relative to that of rMSCs at time 0 (prior to 
seeding onto scaffolds). * p < 0.05 (One-way ANOVA with Tukey post-hoc). 
 
  
  
89 
Figure 2.12
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Finally, we examined the impact of HA and PEG on the potency of 
induced osteogenic differentiation of rMSCs for potential bone tissue engineering 
applications. PELA, HA-PELA, and HA-PLA scaffolds were cultured with rMSCs 
for 14 days in osteogenic medium and total RNA was isolated. We used qPCR to 
quantify the expression of Runx2, osteopontin, and osteocalcin (Fig. 2.13). 
rMSCs adhered on HA-PELA expressed significantly higher levels of all these 
marker genes than those adhered on PELA or HA-PLA. The expression of 
osteopontin and osteocalcin was over two orders of magnitude higher for MSCs 
adhered on HA-PELA than either PELA or HA-PLA on day 14. 
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Figure 2.13. Effect of scaffold composition (polymer chemistry and HA) on the 
osteogenic differentiation of rMSCs under induced differentiation culture 
conditions. Expression of Runx2, osteopontin, and osteocalcin following a 14-day 
culture in osteogenic medium. Data are normalized with housekeeping gene 
GAPDH and plotted as expression relative to that of rMSCs at time 0 (prior to 
seeding onto scaffolds). * p < 0.05 (One-way ANOVA with Tukey post-hoc). 
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Figure 2.13
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4. Discussion 
PLA is a widely used material in the field of tissue engineering due to 
favorable properties such as biocompatibility, biodegradability, and ease of 
processing into diverse architectures. However, the intrinsic hydrophobicity of 
PLA compromises its aqueous dimensional stability and its ability to support cell 
seeding, growth factor and hydrophilic drug loading, and direct blending with 
hydrophilic materials such as HA.[169] We tested the hypothesis that by 
chemically inserting a hydrophilic PEG block within PLA, the resulting amphiphilic 
triblock co-polymer PELA will favorably interact with HA and be readily 
electrospun into HA-PELA composite scaffolds with improved physical and 
biological properties over HA-PLA composites or PELA alone. 
We chose racemic D,L-lactide over L-lactide due to its accelerated 
degradation profile and a lack of crystalline degradation by-products which can 
elicit adverse tissue responses during potential in vivo applications.[48,121] By 
simply changing the initiator (PEG vs ethylene glycol), we were able to 
synthesize both the PELA and PLA with similar molecular weights and 
polydispersity. This allowed us to investigate the effect of polymer chemistry on 
the HA-composite scaffold properties without additional confounding factors. The 
facile synthesis and purification of PELA is advantageous for subsequent scale-
up for clinical use. 
In order to reproducibly fabricate a uniform HA-polymer composite scaffold 
by electrospinning, the HA needs to be homogenously dispersed in the 
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electrospinning solution. A manifestation of poor adhesion between a polymer 
and HA is that the HA would rapidly settle out of the suspension, as was 
observed with HA-PLA. We demonstrated that with PELA, a stable HA 
suspension could be achieved even at HA contents as high as 33 wt.%, in the 
absence of any surfactants. Such stability is one manifestation of the improved 
interfacial adhesion between PELA and HA. Consequently, electrospinning of the 
stable HA-PELA suspension resulted in a scaffold with more uniform fiber 
morphology and more predictable HA content than electrospun HA-PLA (Fig. 2.3 
b&c).  
The robust blending and interfacial adhesion between HA and PELA was 
further manifested in the storage modulus enhancement of the HA-PELA 
composite over PELA, in contrast to the mechanical strength deterioration of HA-
PLA compared to PLA (Fig. 2.7). In addition, HA-PELA exhibited a 5-fold higher 
ultimate tensile strain and a 10-fold higher ultimate tensile stress than HA-PLA 
(Fig. 2.5). The far more brittle nature of the HA-PLA composite reflects the 
inadequate interfacial adhesion between PLA and HA.[169] The significantly 
enhanced extensibility and ultimate tensile strength of electrospun HA-PELA 
compared to those of HA-PLA is advantageous for potential surgical 
manipulation. 
The amphiphilic nature of PELA is expected to lead to hydration-induced 
structural rearrangement of the polymer chains[183,184] and corresponding 
changes in surface wettability and mechanical properties, which are important for 
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tissue engineering applications. As expected, the chemical incorporation of PEG 
into PLA reduced the water contact angle of the scaffold compared to PLA. A 
striking observation was that prior hydration conferred superhydrophilicity to 
electrospun HA-PELA (Fig. 2.6b), with its water contact angle approaching 0º, 
pointing to a possible hydration-induced structural rearrangement of the 
amphiphilic polymer that exposes the hydrophilic PEG to the surface (Scheme 2). 
The water contact angle of PELA was also reduced upon hydration, although the 
effect was less dramatic than that observed with HA-PELA, suggesting that the 
HA plays a role in stabilizing hydration-induced structural rearrangement of the 
amphiphilic polymer and/or affecting the morphology of the scaffold. We found 
that the nanofibrous morphology of the HA-PELA scaffolds was indeed important 
for acquiring hydration-induced superhydrophilicity as the water contact angle 
drop decrease was far less dramatic on solvent cast HA-PELA films. Contact 
angle measurement of the PLA scaffold after the water equilibration could not be 
obtained because the hydrophobic scaffold shrank dramatically upon hydration. 
Such an observation is consistent with previously reported dimensional instability 
of electrospun poly(D,L-lactic acid) scaffolds in aqueous environments.[185–187] 
The extent of shrinkage of the HA-PLA was milder, likely due to the stabilizing 
effect of the HA within the composite scaffold. The superhydrophilicity combined 
with the dimensional stability of HA-PELA is advantageous for the loading of cells 
and aqueous therapeutics, allowing them to be readily absorbed into the scaffold.  
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We also observed striking storage modulus increases in the PELA and 
HA-PELA scaffolds upon hydration (Fig. 2.7). The storage modulus of the 
electrospun PLA and HA-PLA scaffolds, on the other hand, expectedly reduced 
upon hydration, likely due to a combination of the plasticizing effect of water and 
the amorphous nature of PLA.[188] We hypothesize that the hydration-induced 
structural rearrangement of the amphiphilic polymer chains that exposes the 
hydrophilic PEG blocks to the surface, thereby reducing interfacial energy and 
lowering the water contact angle, also resulted in the reinforcement of the 
storage modulus of the material (Fig. 2.14). Indeed, using conventional DSC, we 
showed that while the as-spun dry PELA specimen only possessed a single 
glass transition, the specimen with prior hydration history had an extra 
endothermic peak in the DSC spectrum around 50 ºC (Fig. 2.8a). This thermal 
transition, also present in the reversible MDSC heat flow (Fig. 2.8b), is consistent 
with a crystalline melting temperature (Tm) of PEG, the only crystalline 
component in the PELA triblock copolymer. It has been previously reported that 
the Tm for PEG in a PEG-PLA diblock polymer was 50 ºC as opposed to 60 ºC for 
pure PEG. [181] This melting peak indicates that the concentration and 
orientation of surface exposed PEG was sufficient to induce crystallization. In 
turn, this hydration-induced structural rearrangement permitted load-transfer in 
the polymer network, as described for other amphiphilic polymer systems.[189] 
The hydration-induced stiffening of the HA-PELA scaffolds is potentially 
advantageous for applications such as scaffold-guided skeletal/dental bone 
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regeneration. The elastic membrane, upon surgical delivery to fill in or cover an 
osseous defect, would stiffen within the physiological environment of the defect 
to prevent soft tissue collapse, thereby maintaining adequate space for bone 
regeneration. 
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Figure 2.14. Depiction of a proposed structural rearrangement of the PELA block 
copolymer chains within HA-PELA composites upon hydration. 
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Figure 2.14 
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As the HA-PELA scaffolds are designed to be biodegradable, we 
evaluated their in vitro degradation in PBS over 12 weeks (Fig. 2.10a). HA-PELA 
exhibited an accelerated degradation compared to HA-PLA, resulting in ~20% 
mass reduction in 3 months. Such a degradation profile is desired for scaffold-
assisted repair of long bone fractures where the maturation/remodeling of bony 
calluses typically takes place 3-4 months following injury in adults.[121] It 
ensures that the scaffold fully exerts its templating role during the early stage of 
scaffold-assisted repair and only degrades at the desired later stage of callus 
remodeling. The accelerated degradation of PELA and HA-PELA compared to 
HA-PLA can be attributed to a combination of the more effective water 
penetration throughout the amphiphilic scaffold enabled by the hydrophilic PEG 
blocks, and the clearance of the cleaved water-soluble PEG segments from the 
polymer, as previously described.[190–192] 1H NMR monitoring of the 
degradation products confirmed clearance of the PEG segments (Fig. 2.9). 
Monitoring of microstructural changes of the scaffolds by SEM upon incubation in 
PBS for 3 weeks revealed that the HA-PLA scaffolds suffered from 
hydrophobicity-driven collapse of the fibers while the HA-PELA fiber morphology 
was maintained (Fig. 2.10b). The PELA scaffold without HA exhibited some 
degree of fiber fusions upon incubation in PBS, although to a much lesser extent 
compared to HA-PLA. The PEG blocks in PELA have likely prevented more 
dramatic hydrophobicity-driven fiber aggregation observed with PLA or HA-PLA, 
while the dynamic rearrangement and crystallization of PEG blocks in aqueous 
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buffer may have resulted in the fusing of the amphiphilic fibers around their 
physical contact points. The maintenance of HA-PELA fiber morphology upon 
PBS incubation further demonstrates the structural stabilizing effect of HA on the 
amphiphilic scaffold. This combination of dimensional stability, 
surperhydrophilicity, and superior mechanical integrity of HA-PELA composites in 
an aqueous environment establish HA-PELA composites as far more 
advantageous scaffolds for tissue engineering applications than the conventional 
HA-PLA composites.  
To further evaluate the applicability of HA-PELA composites for skeletal 
tissue engineering applications, we compared the ability of HA-PELA and HA-
PLA composite scaffolds to support the attachment and guide lineage-specific 
differentiation of mesenchymal stem cells (MSCs) for the regeneration of bone or 
cartilage tissues. MSCs residing in the bone marrow are capable of differentiating 
into a variety of cell types including osteoblasts, chondrocytes, adipocytes, and 
myoblasts.[193] They can be readily isolated and enriched as adherent bone 
marrow stromal cells, and expanded and used as a progenitor cell source for 
musculoskeletal tissue engineering.[194]  
The non-fouling PEG block and the osteoconductive HA component of the 
HA-PELA composites are expected to exhibit opposite effects on protein and cell 
adhesion. For instance, un-mineralized di-block or tri-block PELA have been 
used as anti-adhesion membranes,[62] with their low protein adsorption 
characteristics attributed to the PEG exposed on the surface in the aqueous 
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environment.[195,196] Meanwhile, HA is known for its ability to absorb a wide 
range of proteins due to its dynamic surface properties (e.g. pH-dependent zeta 
potential) and large surface area (for HA nanocrystals), promoting cell 
attachment.[125,197,198] We hypothesized that the incorporation of HA could 
improve rMSC attachment on PELA. We showed by MTT assay that the addition 
of HA to PELA indeed increased the attachment of rMSCs (Fig. 2.11). HA also 
supported the rMSC proliferation with a significant increase in cell viability from 
24 h to 96 h on HA-PELA. It has been reported previously that rMSC proliferation 
is reduced on PEG-PLA materials.[195] In our study, this effect was offset by the 
incorporation of HA. It is also worth noting that high standard deviation was 
observed for the cell viability at 96 h in the HA-PLA group, reflecting the poor HA 
dispersion within the inhomogeneous HA-PLA scaffold. 
The addition of HA to synthetic scaffolds has been shown to promote 
osteochondral lineage commitment of MSCs in un-stimulated 
culture[131,132,172] or more potent chondrogenesis/osteogenesis of MSCs in 
response to chondrogenic/osteogenic inductions in culture and skeletal tissue 
repair in vivo.[135,199–202] However, such an effect has not been consistently 
established, potentially due to the inhomogeneous distribution of HA within many 
of the hydrophobic degradable polymer scaffolds utilized for such investigations. 
Further, how amphiphilic polymer-HA scaffolds impact the gene expression of 
MSCs under un-stimulated culture conditions is largely unknown.  
 
  
103 
We cultured rMSCs in expansion medium on the PELA, HA-PELA, and 
HA-PLA scaffolds and used qPCR to quantify changes early (7 d) and later (14 d) 
gene expression changes in osteogenesis, chondrogenesis and adipogenesis 
markers. By using expansion medium free of differentiation inductive agents, we 
can examine the effect of scaffold composition on guiding rMSC differentiation 
towards a particular lineage. We showed that MSCs cultured on HA-PELA 
scaffolds expressed consistently higher expression of the chondrocyte maker 
SOX9 and the osteoblast maker osteocalcin throughout the 14-day culture (Fig. 
2.12). However the difference was not statistically significant at day 14, possibly 
due to the unstimulated culture conditions being insufficient to sustain the 
spontaneous osteogenic differentiation over time. The increased osteochondral 
gene expression at day 7 with the addition of HA to PELA is in contrast with prior 
reports using materials such as electrospun HA-PCL or poly(ethylene oxide 
terephthalate)–poly(butylene terephthalate)-HA, where the addition of HA had 
little or no effect on MSC gene expression.[132,203] Another observation is that 
the expression of adipogenic marker PPARG significantly decreased upon the 
addition of HA to PELA at 7 days. Furthermore, the expression of PPARG trends 
higher at 7 days for rMSCs cultured on HA-PLA than those cultured on the HA-
PELA. These results suggest that the osteochondral-inductive properties of HA 
are more effectively manifested on HA-PELA where polymer-HA interfacial 
adhesion and dispersion is improved over HA-PLA.  
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To examine the role of polymer chemistry and HA incorporation in 
promoting osteogenesis of MSCs upon culture induction, we quantified the 
osteogenic gene expression of rMSCs cultured on PELA, HA-PELA and HA-PLA 
in osteogenic medium. The expression of early (RUNX2), middle (osteopontin), 
and late stage (osteocalcin) osteogenesis markers were all significantly up-
regulated on HA-PELA compared to PELA or HA-PLA scaffolds (Fig. 
2.13).[204,205] In particular, the expression of osteopontin and osteocalcin was 
increased over two orders of magnitude on HA-PELA. Prior work on MSCs 
attached to electrospun HA-PLLA (calcium deficient) scaffolds showed increased 
osteogenic gene expression with increasing HA content in expansion medium 
while the effects were abrogated in osteogenic medium.[131] By contrast, here 
we show that the HA-PELA scaffolds promoted osteogenic gene expression in 
MSCs in both stimulated and unstimulated cultures. More homogenous HA 
distribution within the amphiphilic HA-PELA scaffold as opposed to the uneven 
distribution of aggregated HA within the HA-PLA scaffold may translate into a 
higher surface area of the osteoconductive HA interacting with adherent MSCs. 
Furthermore, prior work has shown that PEG/PLA diblock co-polymers or 
PEG/PLA blends promote the osteogenic differentiation of MSCs.[196,206] Here 
we show that the synergy between HA and PEG supported an even more potent 
osteogenic MSC response. By sensitizing the response of MSCs to osteogenic 
induction,[204] it may be possible to deliver exogenous osteogenic inductive 
agents such as bone morphogenetic protein (rhBMP-2) via HA-PELA with 
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reduced loading doses for enhanced safety and reduced cost. Taken together, 
HA-PELA composites exhibit unique handling properties (elasticity, 
superhydrophilicity, hydration-induced stiffening) and bioactivity (rMSC 
attachment, osteochondral gene expression) ideal for osteochondral tissue 
engineering and in vivo application.  
5. Conclusions 
A biodegradable electrospun HA-PELA composite was designed for 
skeletal tissue engineering applications. We showed that favorable interactions 
between HA and the PEG component of the amphiphilic block copolymer 
dictated the physical and biological performance of the composites. The 
hydrophilic PEG block improved HA blending and adhesion to the polymer, 
facilitating the preparation of composite fibrous scaffolds with uniform fiber 
dimensions and HA distribution by electrospinning. The incorporation of well 
integrated HA with PELA improved the dimensional stability and reinforced the 
tensile storage moduli of the electrospun composites while maintaining tensile 
elasticity. The hydrophilicity and mechanical integrity of HA-PELA further 
improved in an aqueous environment, likely resulting from hydration-induced 
structural rearrangement of the PEG domains that may have been more 
effectively stabilized by HA. The combination of dimensional stability, mechanical 
integrity, superhydrophilicity, and tensile elasticity exhibited by HA-PELA can be 
exploited to facilitate cell seeding, drug delivery and convenient surgical 
manipulations of the composite scaffold. Finally, HA incorporation improved cell 
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attachment to the relatively low-fouling PELA, and the HA-PELA composite, 
unlike HA-PLA, promoted osteochondral lineage commitment of MSCs and 
supported more potent osteogenic gene expression upon induction. The 
combination of improved handling characteristics and biological performance 
positions HA-PELA as a more suitable bone tissue engineering scaffold than HA-
PLA. Indeed, the facile synthesis of PELA, the consistent properties of 
electrospun HA-PELA, and the established safety profile of the constituents of 
the composite scaffold are appealing characteristics for successful clinical 
translation. Overall, this study demonstrates the importance of rational selection 
and assembly of key structural components with synergistic interactions in the 
design of effective tissue engineering scaffolds. 
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CHAPTER III: Spiral-wrapped electrospun amphiphilic polymer-
hydroxyapatite scaffold for templated repair of long bone defects in rats 
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Abstract 
Effective repair of critical size long bone defects presents a significant 
clinical challenge. Electrospun scaffolds with adequate hydrophilicity, high 
surface area, and osteoconductivity can be exploited to deliver protein 
therapeutics and stem/progenitor cells, but their standalone application for long 
bone repair is hampered by limited thickness. The electrospun composite of 
amphiphilic PELA and HA supports cell/therapeutics loading and osteogenic 
differentiation of MSCs. Here we explore the strategy of spiral-wrapping 
electrospun HA-PELA to fit in 5-mm rat femoral segmental defects and compare 
the effectiveness of delivering exogenous MSCs versus a low dose of rhBMP-2 
for guiding new bone formation. HA-PELA with pre-seeded MSCs resulted in 
laminated endochondral ossification directly templated by the spiral-wrapped 
scaffold layers across the longitudinal span of the defect. Using GFP-labeling, we 
confirmed that the exogenous MSCs survived 7 days post-implantation. When 
loaded with 500-ng rhBMP-2, HA-PELA spirals led to more robust but less 
templated bone formation than MSCs, with bone bridging over the defect by 12 
weeks. The biodegradable scaffold did not elicit allergic reactions or chronic 
inflammation. These outcomes support spiral-wrapped electrospun HA-PELA as 
a promising strategy for therapeutics delivery and templated long bone repair. 
 
  
110 
1. Introduction 
There remains a significant clinical need for better strategies to repair 
critical-size bone defects resulting from congenital conditions, trauma, or tumor 
resection. Autografting procedures are considered the gold standard but they can 
lead to significant donor site morbidity and are limited by autograft supply.[24] 
Allografts, obtained from human donors, are alternatives to autografts but carry 
an inherent risk for disease transition and suffer from long-term failure rates as 
high as 60% over 10 years.[14] Current commercially available bone graft 
substitutes are typically weak and brittle gels or foams[25] that possess poor 
handling characteristics (e.g. inconvenient surgical insertion and inadequate graft 
fixation). Adequate bone healing facilitated by these materials typically will 
require high doses of exogenous growth factors such as recombinant human 
rhBMP-2. The performance of bone graft substitutes can potentially be improved 
by integrating biomaterials exhibiting desired physical and biological properties 
with appropriate scaffold configurations and a safe loading dose of biological 
factors and/or skeletal progenitor cells.  
Electrospinning is a widely used technique to manufacture tissue 
engineering scaffolds with nanofibrous morphology similar to that of native 
extracellular matrices.[83] Such scaffolds provide a high surface area for cell 
attachment and proliferation,[83] and when properly engineered, can also 
support stem cell differentiation.[207–209] As growth factor delivery vehicles, the 
high surface area of electrospun scaffolds is also desired for protein adsorption 
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and improved sustained release.[87] Another advantage of electrospinning is the 
versatility of fabricating scaffolds from a variety of polymers and composite 
materials. For bone tissue engineering, electrospun composites combining 
degradable polymers with osteoconductive minerals such as HA have long been 
sought after, with recent attention focused on achieving improved polymer-
mineral blending and interfacial adhesion.[131,141,209] The incorporation of HA 
has been shown to promote cell attachment, proliferation, and osteogenic 
differentiation on electrospun polymer scaffolds, especially when they are well-
integrated with the polymer matrix.[131,209–211] Such electrospun materials 
have been used for containing soft hydrogels,[212,213] delivering platelet rich 
plasma,[214] or guiding regeneration of non-weight bearing cranial/mandibular 
defects.[215–218] However, their standalone uses for long bone regeneration, a 
challenging clinical problem in orthopedic trauma care,[219] have been lacking 
due to the limited thickness and inadequate mechanical properties of electrospun 
materials. 
We hypothesized that spiral-wrapping electrospun scaffolds may be a 
promising approach for taking advantage of both the high surface area of 
electrospun materials to deliver therapeutics / support cellular adhesion and the 
defined 3-D configuration of the spiral to guide the regeneration of critical long 
bone defects. Furthermore, the relatively low quantity of polymer used to 
fabricate electrospun materials may also mitigate potential adverse immune 
responses to the degradation products of degradable polymer scaffolds.[220] 
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Spiral-wrapped scaffolds in combination with other materials have been studied 
for potential tissue engineering applications in vitro.[93,221–224] Zhang et al. 
and Wang & Xu have described spiral-wrapped electrospun PCL/salt-leached 
PCL film composites and electrospun PCL/sintered PLGA scaffolds, 
respectively,[222–224] although neither design was tested in vivo. Jiang et al. 
employed an electrostatic assembly strategy to fabricate a spiral-wrapped 
membrane composed of chitosan/cellulose/HA and tested their performance in 
augmenting the repair of rabbit radius defects.[93] However, the non-critical 
defect size they employed makes the efficacy of the scaffold difficult to interpret 
as the no-scaffold defect control also healed. Piskin et al. used spiral-wrapped 
electrospun PCL scaffolds containing simvastatin to aid the healing calvarial 
defects in rats, however, defect closure was not achieved by 6 months post-
op.[221] Overall, in vivo studies that examine the efficacy of standalone 3-D 
electrospun scaffolds in a clinically relevant critical long bone defect model are 
lacking.  
We recently prepared a well-integrated electrospun composite of HA and 
biodegradable amphiphilic tri-block copolymer PELA.[209] The hydrophilic PEG 
segment was chosen to enable the dispersion and binding with the hydrophilic 
HA mineral while the hydrophobic PDLA blocks provided biodegradability and 
aqueous stability. These electrospun HA-PELA composites supported far more 
potent osteogenic differentiation of rMSCs in vitro than conventional electrospun 
HA-PLA composites. Meanwhile, we also observed super-hydrophilicity (water 
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contact angle ~0º), high elasticity (>200% ultimate strain), and hydration-induced 
stiffening of the HA-PELA composite [209]. These physical properties could 
facilitate absorption of aqueous suspensions of cells and growth factors, and 
enable easy surgical handling and stable fixation (e.g. wrapping around a defect, 
fitting within a confined defect,[225] etc.). This combination of bioactivity and 
handling characteristics makes electrospun HA-PELA a promising material for 
bone repair.   
Here we exploit the unique handling characteristics (super-hydrophilicity, 
elasticity, hydration-induced stiffening) and in vitro bioactivity of electrospun HA-
PELA [209] in the form of 3-D spirals for augmenting the repair of critical-size 
long bone defects. We test the hypothesis that electrospun spiral-wrapped 
scaffolds can be readily fit within critical long bone defects and guide bone 
formation throughout the spiral template. Furthermore, we compare the 
robustness of bone formation templated by progenitor cell-seeded scaffolds 
versus osteogenic growth factor-loaded scaffolds. We hypothesized that whereas 
the local sustained release of rhBMP-2 from the HA-PELA scaffold may result in 
more potent osteogenesis throughout the defect, the delivery of exogenous 
MSCs via the scaffold may lead to more organized new bone formation intimately 
templated by the cell-seeded spiral template. We tested these hypotheses by 
comparing the performance of spiral-wrapped HA-PELA scaffolds with or without 
pre-seeded rMSCs to scaffolds loaded with a low dose of rhBMP-2 (500 ng) in 
healing 5-mm critical-size femoral segmental defects in rats (Figure 3.1). 
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Figure 3.1. Schematic of the spiral-wrapping of HA-PELA scaffolds with or 
without pre-seeded cells or absorbed rhBMP-2 for implantation into a 5-mm rat 
femoral segmental defect stabilized by a PEEK fixation plate. 
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Figure 3.1 
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2. Materials and Methods 
2.1 Scaffold fabrication 
PELA was synthesized and electrospun with HA as previously 
described.[209] Briefly, PELA was synthesized by ring opening polymerization of 
3,4-Dimethyl-1,4-dioxane-2,5 dione (D,L-Lactide; Sigma Aldrich, St. Louis, MO) 
initiated by PEG (20,000 Dalton; Fluka BioUltra, Switzerland) and catalyzed by 
Sn(II) 2-ethylhexanoate (500ppm; Sigma Aldrich, St. Louis, MO). The resulting 
polymer (MW: 131,800 Da, PDI: 1.43) was dissolved in chloroform, purified by 
precipitation in methanol, and dried in a vacuum oven. HA-PELA composite 
scaffolds were fabricated by electrospinning a homogenous suspension of 10 
wt%HA in PELA using 1:4 (v/v) dimethylformamide/chloroform as a solvent.[209] 
The suspension was electrospun through a 22 G needle at 12 kV onto a 
grounded aluminum collector positioned 15 cm away. After 2 h of 
electrospinning, the scaffolds were dried in a vacuum oven for 48 h to remove 
any residual solvent and stored in a desiccator at 4 ºC. 
2.2 Rat bone marrow stromal cell (rMSC) isolation 
rMSCs were isolated from the long bones of 4 week old male Charles 
River SASCO SD rats according to the protocol approved by the University of 
Massachusetts Medical School Institutional Animal Care and Use committee, as 
previously described.[153] Bone marrow was flushed with cold minimal essential 
medium (αMEM; Life Technologies, Carlsbad, CA). Prior to plating, red blood 
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cells were lysed with sterile water, cells were re-suspended in MSC expansion 
medium (αMEM without ascorbic acid, supplemented with 20% fetal bovine 
serum, 2% L-glutamine, and 1% penicillin-streptomycin), and passed through a 
sterile strainer. Non-adherent cells were removed after 4 days of culture and the 
remaining adherent cells were expanded until 70% confluent prior to use. 
2.3 Scaffold preparation 
Scaffolds were sterilized by exposure to UV light (254 nm) for 30 min on 
each side and equilibrated overnight in MSC expansion medium prior to use. For 
rMSC loaded scaffolds, 100,000 rMSCs/cm2 in 50 µL expansion medium were 
seeded onto scaffolds (5.3 mm × 40 mm × 0.10 – 0.12 mm) which were placed in 
6-well ultra-low cell attachment plates (Corning Inc., Corning, NY). Following 30 
min of incubation (37 ºC, 5% CO2), 2 mL of expansion medium was added to the 
wells and the scaffolds were incubated for an additional 24 h. Scaffolds were 
washed 3 times with PBS prior to implantation. Cell-free and rhBMP-2 loaded 
scaffolds were processed in the same manner but without rMSCs. Loading of 
rhBMP-2 (CHO-derived; R&D Systems, Minneapolis, MN; 500 ng in 50 µL PBS) 
was performed 15 min prior to implantation. 
2.4 rMSC attachment and viability on spiral-wrapped HA-PELA 
rMSCs were seeded onto electrospun HA-PELA scaffolds as described 
above. After 24 h, scaffolds were spiral-wrapped into 3-D cylinders or cultured on 
unperturbed electrospun meshes in the ultra-low attachment 6-well plates. At 
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each time point, fresh medium containing 9% (v/v) Cell Counting Kit-8 reagent 
(CCK-8; Dojindo Molecular Technologies Inc., Japan) was added to the wells. 
After 4-h incubation, 100 µL of medium was removed for measurement of 
absorbance at 450 nm with 650-nm background correction on a Multiskan FC 
microplate photometer (Thermo Scientific, Billerica, MA). The remainder of the 
medium was aspirated, the scaffolds were washed with PBS, and medium was 
replaced for continued culture up to 14 days. The CCK-8 assay was carried out 
at day 1, 7 and 14. Following the 14-day culture, the spiral-wrapped scaffolds 
were unwrapped and the adherent cells were labeled with Alexa Fluor 488 
Phalloidin and DAPI (Life Technologies, Carlsbad, CA), and imaged on an 
inverted epifluorescence microscope (Ziess Axiovert 40 CFL; Carl Ziess, 
Germany). 
2.5 In vitro rhBMP-2 release from HA-PELA  
Electrospun HA-PELA scaffolds (n=3) were punched into 0.32 cm2 circles, 
sterilized 30 min/side with UV, and equilibrated overnight in deionized water at 37 
ºC.  They were then air dried in a biosafety cabinet, placed in ultra-low 
attachment 24-well plates (Corning Inc., Corning, NY), and loaded with 75 ng 
rhBMP-2 in 5 µL of PBS. One milliliter of PBS was then added to each well and 
the plate was incubated at 37 ºC. For each time point, the release buffer (1 mL) 
was collected and replenished with fresh PBS. The release buffer was frozen and 
stored at -80 ºC prior to rhBMP-2 measurement. At the end of the release 
experiment, all collected release buffers were thawed and the rhBMP-2 
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concentration was determined using a rhBMP-2 ELISA kit (R&D Systems, 
Minneapolis, MN).  
2.6 In vitro bioactivity of rhBMP-2 retained on HA-PELA following 7-day 
incubation in PBS 
The HA-PELA scaffolds, retrieved after 7-day PBS incubation from the 
BMP-2 release study, were then assessed for their ability to support C2C12 
transdifferentiation in order to confirm the osteogenic bioactivity of the rhBMP-2 
retained on the scaffolds. C2C12 cells were seeded directly onto the scaffolds 
(20,000 cells/cm2) that were placed in ultra-low attachment 96-well plates 
(Corning Inc., Corning, NY), and cultured in DMEM containing 5% fetal bovine 
serum and 1% penicillin-streptomycin for 72 h. The scaffolds were fixed in 
periodate-lysine-paraformaldehyde (PLP) fixative[226] and alkaline phosphate 
(ALP) activity was stained using a Leukocyte Alkaline Phosphatase Kit (Sigma-
Aldrich, St. Louis, MO). Following staining, the scaffolds where imaged on an 
inverted microscope (Ziess Axiovert 40). 
2.7 In vivo study design and surgical procedure 
Electrospun HA-PELA alone (n=12), pre-seeded with rMSCs (n=11), or 
loaded with rhBMP-2 (n=11) were rolled into 5.3-mm long and 3-mm wide spirals 
and press-fit into 5-mm segmental femoral defects in rats. Bone healing was 
monitored over time with a Scanco VivaCT75 in vivo microCT scanner every 4 
weeks and also radiographed every 2 weeks. Animals were sacrificed at 4 or 12 
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weeks for histology (n=2 per treatment group / time point). A subset of animals 
was sacrificed at 12 weeks for torsion testing (n=4 for HA-PELA with pre-seeded 
MSCs; n=7 for HA-PELA with rhBMP-2). In order to track the fate of transplanted 
rMSCs, a subset of animals received scaffolds seeded with GFP-transduced 
rMSCs and were sacrificed at 2 days, 7 days, or 4 weeks post-op for histology 
(n=2).  
All animal procedures were approved by the University of Massachusetts 
Medical School Institutional Animal Care and Use Committee. Male Charles 
River SASCO SD rats (290-300 g) were sedated with 5% isoflurane-oxygen and 
maintained at 2% isoflurane-oxygen during surgery. A 5-mm critical sized femoral 
defect was created and stabilized with a polyetheretherketone (PEEK) fixation 
plate as previously described.[135] Briefly, the femur was exposed by a 
combination of sharp and blunt dissection. The periosteum was circumferentially 
removed in order to emulate a challenging healing environment. A PEEK fixation 
plate was secured with 2 stainless steel bicortical screws flanking each side of 
the defect and with the two immediately adjacent to the defect further stabilized 
with hex nuts. The 5-mm defect was created with an oscillating Hall saw and 
bone debris was removed by copious irrigation with sterile saline. The empty, 
MSC-loaded, or rhBMP-2 loaded spiral wrapped scaffolds were then fit into the 
defect. The wounds were closed with sutures and the rats were given cefazolin 
(20 mg/kg, once per day) and buprenorphine (0.08 mg/kg, every 8 h) 
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subcutaneously for 2 days. Rats were radiographed immediately following 
surgery to confirm proper PEEK plate fixation. 
2.8 Micro-computed tomography (µ-CT) 
Every 4-weeks following surgery, animals were sedated and maintained 
with 2% isoflurane-oxygen for scanning of the femurs on a Scanco vivaCT 75 µ-
CT system (Scanco Medical, Switzerland) at a voxel size of 30 x 30 x 30 µm3. 
Scans were also performed on 12-week explants with the same scanning 
resolution. A total of 167 30-µm slices within the defect site, totaling 5.01 mm, 
were used to construct the region of interest (ROI) for analysis. A global 
threshold was applied to remove soft tissue and scaffold background for 
quantification and reconstructing 3-D images. Bone volume and bone mineral 
density within the ROI were calculated using Scanco Medical’s 3D analysis 
software.  
2.9 Histology 
Explants were fixed in PLP fixative[226] at 4 ºC for 2 days and 
subsequently decalcified in 18% aqueous ethlenediaminetetraacetic acid (EDTA) 
(pH 8.0) for 4 weeks with exchanges of fresh EDTA solution twice a week. 
Following removal of the PEEK fixation plates, the explants were subjected to 
serial dehydration, paraffin embedding and sectioning. Six-micrometer thick 
sections were stained by hematoxalyin and eosin (H&E) or toluidine blue. 
  
122 
To identify any potential negative systemic effects of HA-PELA and its 
degradation products, heart, kidney, liver, lung, spleen, and pancreas tissues 
were retrieved from the sacrificed rats at 12 weeks and 24 weeks after receiving 
the implants. The organs were fixed in periodate-lysine-paraformaldehyde 
fixative at 4 ºC for 2 days then paraffin embedded, sectioned, and stained with 
hematoxylin and eosin for pathological evaluation. 
2.10 Biomechanical testing 
Using a Dremel drill, the center of the PEEK plates fixating the explants 
were thinned to minimal attachment to facilitate the handling of those explants 
that were not fully bridged with calcified callus during potting. The explants were 
then potted in zinc-coated aluminum hex nuts with bone cement following 
literature protocol.[227] After both ends were potted, the thinned center of the 
PEEK plate was carefully trimmed with scissors without damaging the underlying 
graft/callus.  Using a mini-torsion tester equipped with an eP2 controller (Admet), 
the explants were torqued to failure at 1°/s. Maximum torque recorded was 
reported as the failure torque, torsional stiffness was determined from the linear 
region of the torque/displacement curve, and torsional energy was determined 
form the area under the torque/displacement curve.  
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2.11 Lentiviral GFP transduction of rMSCs and tracking of implanted GFP-
rMSCs 
rMSCs were transduced with lentiviral vectors (Cellomics Technology) 
expressing enhanced green fluorescent protein (GFP) driven by cytomegalovirus 
(CMV), elongation factor-1 alpha (EF1α), or ubiquitin C (UBC) promoters. Cells 
were transduced with the virus at a multiplicity of infection of 5, 25, or 50. 
Passage 1 rMSCs were seeded at a density of ~10,000 cells/cm2 in transduction 
medium (αMEM, 20% heat-inactivated FBS, 1% L-Glutamine) and cultured for 24 
h before the respective lentiviral vectors were added. The culture plates were 
spun for 30 min in a centrifuge (1200×g, 32 ºC) to increase transduction 
efficiency before subjected to continued culture for 24 h in transduction medium. 
The medium were then changed to MSC expansion medium and the cells were 
cultured for an additional 24 h prior to use. Transduction efficiency (% of cells 
transfected as revealed by green fluorescence) was examined by 
epifluorescence microscopy (Zeiss Axiovert 40 CFL) in 3 randomly selected 
fields of view at 100X magnification.  
MTT cell viability assay (Roche, Indianapolis, IN) was performed to 
quantify cell viability 24 h after lentiviral transduction. Percent cell viability was 
normalized to untreated rMSC controls. Cell proliferation over 72 h was 
quantified by MTT (n=3) and presented as fold-change from initial cell viability 
(24 h following lentiviral transduction).   
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In order to track the viability of MSCs seeded on the scaffold and 
implanted in the rat femoral segmental defect, GFP-rMSCs were seeded on HA-
PELA as described above. One of the GFP-rMSC seeded scaffolds, prepared at 
the same time as the scaffolds to be implanted, was rinsed with PBS and imaged 
on a fluorescent microscope (Zeiss Axiovert 40 CFL) to obtain pre-implantation 
GFP signal control. Remaining scaffolds were rolled into 3-D cylinders and 
implanted into the rat critical size femoral defects as described above. At 2 days, 
7 days and 4 weeks post-op, animals were sacrificed and the scaffolds were 
excised from the defects, carefully unrolled, and mounted on a microscope slide 
for GFP imaging. 
Immunohistochemical staining was used to track GFP-rMSCs at 4 weeks 
post-op. Explants were fixed, decalcified, and processed for histology as 
described above. The sections were deparaffinized, unmasked in 10 mM sodium 
citrate buffer (pH 6.0) and treated with rabbit polyclonal GFP antibody (#2555; 
Cell Signaling Technology) in SignalStain Antibody Diluent (Cell Signaling 
Technology). SignalStain Boost (Cell Signaling Technology) was used for 
detection of the rabbit antibodies. SignalSlide GFP IHC controls (Cell Signaling 
Technology) were used as positive controls. 
2.11 Statistical analysis 
All statistical analysis was performed with Prism 6.0 (GraphPad Software 
Inc., La Jolla, CA). Grubbs’ testing (alpha = 0.05) identified one outlier in the µ-
CT quantification of the HA-PELA group, which was removed from subsequent 
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analyses. Shapiro-Wilk testing confirmed that the data in all groups followed a 
normal distribution. One-way analysis of variance (ANOVA) with Tukey post-hoc 
testing was thus used for all statistical comparisons.  
3. Results 
3.1 MSC attachment and viability  
MSCs readily adhered to the HA-PELA scaffolds. Although cell viability 
was significantly reduced (by 30%) at 24-h post spiral-wrapping, comparable 
numbers of viable cells were present on flat and spiral-wrapped scaffolds by 7 
and 14 days in culture (Fig. 3.2A). MSCs adhered on scaffolds after 14 days in 
culture were visualized by staining F-actin (fluorescent phalloidin) and nuclei 
(DAPI) (Fig. 3.2B). Substantial non-specific absorption of DAPI onto the 
electrospun scaffold was observed.  
  
  
126 
Figure 3.2. Viability of rMSCs adhered to flat and spiral-wrapped HA-PELA 
scaffolds over time. (A) CCK-8 cell viability over 14 days (n=3). Day 0 cell viability 
was determined prior to spiral-wrapping the scaffolds. * p < 0.05, ** p < 0.01 
(ANOVA with Tukey post-hoc) (B) Actin staining of adhered rMSCs on the spiral-
wrapped scaffold after 14 days in culture. Scale bar = 250 µm. 
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Figure 3.2 
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3.2 Retention and release of rhBMP-2 from HA-PELA 
A slow yet sustained release of rhBMP-2 from the HA-PELA scaffold was 
detected by ELISA over 72 h (Fig. 3.3A). Only ~10% of the rhBMP-2 stably 
absorbed to the scaffold was released within the first 24 h and a cumulative 12% 
was released by 72 h. The rhBMP-2 retained on the scaffolds remained bioactive 
and was able to induce the osteogenic transdifferentiation of C2C12 myoblasts, 
as evidenced by the positive staining for the osteogenic marker ALP on the cells 
cultured on the scaffold pre-loaded with rhBMP-2 and subjected to 7-day prior 
incubation in PBS (Fig. 3.3B). ALP staining was not detected with the cells 
cultured on the scaffold without rhBMP-2 loading. 
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Figure 3.3. rhBMP-2 release and bioactivity. (A) Cumulative percentage of 
rhBMP-2 (75 ng loading dose) released from HA-PELA (n=3) in PBS at 37 ºC. 
(B) Alkaline phosphatase staining of the C2C12 myoblasts cultured on HA-PELA 
with or without pre-absorbed rhBMP-2- for 3 days. The scaffolds bearing 75 ng 
rhBMP-2 were incubated in PBS for 7 days before being retrieved and seeded 
with C2C12 cells.  
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Figure 3.3 
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3.3 Radiographic follow-up of implanted spiral-wrapped HA-PELA 
with/without pre-seeded MSCs or rhBMP-2 
HA-PELA scaffolds, with or without pre-seeded MSCs or absorbed 
rhBMP-2, were manually wrapped into cylindrical spirals (Fig. 3.4A) and 
implanted into 5-mm rat femoral defects (Fig. 3.4B). The implanted scaffolds 
could not be readily visualized by post-op x-ray radiographs due to the relatively 
low density of the HA (10 wt%) within the HA-PELA scaffold (Fig. 3.4C). New 
bone formation was visible by radiography in all treatment groups by 12 weeks 
post-op (Fig. 3.4C). The greatest amount of bridging bony callus was detected in 
the groups treated with HA-PELA and 500 ng of rhBMP-2. Of note, for the group 
treated with HA-PELA and MSCs, the new bone formation appeared to have 
occurred within, instead of surrounding the outer surface of, the spiral-wrapped 
scaffold. 
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Figure 3.4. Spiral-wrapping and surgical implantation of HA-PELA scaffolds and 
post-op radiographical follow-ups of the site of implantation. (A) Wrapping HA-
PELA scaffolds into cylindrical spirals prior to surgery. (B) Implantation of spiral-
wrapped HA-PELA scaffolds into 5-mm rat femoral segmental defects. (C) 
Radiographs of the scaffold-filled defects immediately post-op and after 12 
weeks. 
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Figure 3.4 
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3.4 Histological evaluation of the cellularity and new bone formation within 
and surrounding the HA-PELA scaffold with/without MSCs or rhBMP-2 
Histological sections were cut longitudinally, revealing the new 
bone/scaffold morphology across the length of the 5-mm defect (Fig. 3.5A). HA-
PELA scaffolds remained visible at the defect site in all treatment groups by 12 
weeks (Fig. 3.5B). Immune cells infiltrated within these HA-PELA scaffolds 
consisted primarily of macrophages and foreign body giant cells (*, Fig. 3.5B). No 
lymphocytes, neutrophils, eosinophils or mast cells were detected. Consistent 
with this mild local immune response, the implantation of HA-PELA also did not 
lead to gross changes to vital/scavenger organs by up to 24 weeks post-
implantation (Fig. 3.6). 
Substantial new bone formation at the scaffold/cortical bone interface, 
accompanied with neovessel formation (arrowheads, Fig. 3.5B) was readily 
detected in all treatment groups by 12 weeks (visible as early as 4 weeks) as 
revealed by H&E and polarized light microscopy. The new bone formed within 
the HA-PELA scaffolds, however, differed significantly in both morphology and 
maturity among the 3 treatment groups. The new bone formed within the HA-
PELA scaffold was randomly aligned and remained immature by 12 weeks as 
reflected by the lack of strong birefringence under polarized light. By contrast, the 
new bone formed at the center of the scaffold pre-seeded with MSCs was well-
aligned with and encapsulated between adjacent scaffold layers. The new bone 
formation templated by MSC-seeded HA-PELA, however, was still characterized 
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with a weak birefringent signal at 12 weeks. New bone formation was also visible 
within the HA-PELA scaffold absorbed with rhBMP-2, although they did not 
appear to be clearly templated by the spiral wrapped scaffold morphology. With 
the delivery of rhBMP-2, strong birefringence at both the cortical-scaffold junction 
and along the outer periphery of the scaffold indicative of aligned collagen fibers 
and more mature bone was observed under polarized light. Finally, purple 
toluidine blue staining for cartilaginous matrix was detectable in all areas of new 
bone formation, most notably at the cortical bone-scaffold junctions in all 
treatment groups.  
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Figure 3.5. Histological analysis of cellular infiltration and bone formation 
within/around the scaffold-filled defect at 12 weeks post-op. (A) Schematic of the 
histological sectioning along the longitudinal direction to enable examination of 
new bone formation across the full length of the defect; (B) Bright field and 
polarized light (PL) micrographs of hematoxlyn & eosin (H&E) and toluidine blue 
(Tol Blue) stained sections. For each treatment group (HA-PELA, HA-PELA + 
rMSCs, and HA-PELA + rhBMP2), images were taken both at the cortical bone-
scaffold junction and within the center of the scaffold. Arrowheads indicate blood 
vessels and * indicates macrophages/foreign body giant cells. Scale bar = 500 
µm for micrographs taken at 50X magnification and 150 µm for those taken at 
200X magnification. Inset images show a representative blood vessel in the HA-
PELA group and a representative foreign body giant cell in the HA-PELA + 
rMSCs group. Inset scale bars = 20 µm. 
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Figure 3.5 
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Figure 3.6. Hematoxylin and eosin staining of vital/scavenger organs (heart, 
liver, kidney, lung, spleen and pancreas) collected at (A) 12 weeks and (B) 24 
weeks after implantation of HA-PELA. No abnormality was detected compared to 
un-operated healthy controls [135]. 
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Figure 3.6 
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3.5 µ-CT analyses 
Bone mineral density mapping of the longitudinal and axial center slices of 
the reconstructed ROI at 4 and 12 weeks post-op was used to visualize the 
morphology and maturity the new bone formed around/within the scaffold-filled 
defects over time (Fig. 3.7). The color mapping revealed that new bone formed at 
the scaffold/cortical bone interface and within the scaffold-filled defect in all 
treatment groups after 4 weeks. Most robust and mature bone formation was 
observed with the group absorbed with rhBMP-2, with the recanalization of the 
new bone clearly visible at 12 weeks. More robust new bone appeared to be 
localized on the side opposite the PEEK fixation plate. In the absence of rhBMP-
2, bone formation was more clearly templated by the spiral scaffolds for both the 
HA-PELA alone and HA-PELA + MSCs groups. The templated spiral new bone 
growth in these treatment groups can be visualized by the vertical lines and 
concentric lines in the longitudinal and axial color maps, respectively. Maturation 
of the new bone from 4 to 12 weeks was observed for all groups, as evidenced 
by the increased red color in the mineral density color mapping.  
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Figure 3.7. Two-dimensional bone mineral density color maps of the scaffold-
filled defect over time (red representing higher mineral density). Longitudinal 
(top) and axial (bottom) mid-slices of the defect treated with HA-PELA, HA-PELA 
+ rMSCs, and HA-PELA + 500 ng rhBMP-2 at 4 weeks and 12 week post-op are 
shown. Scale bars = 1 mm. 
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Figure 3.7
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Reconstructed 3-D µ-CT images confirmed the bony callus formation at 
the graft-cortical bone interface and some degrees of scaffold-templated growth 
toward the center of the defect in the HA-PELA group (Fig. 3.8A). Greater 
amounts of scaffold-templated new bone formation were visible at the center of 
the defect by 12 weeks with pre-seeded MSCs, consistent with X-ray radiograph 
observations (Fig. 3.4C). The most robust bony callus formation bridging over the 
defect was observed with the HA-PELA + rhBMP-2 treatment group. Bone 
volume and bone mineral density in all treatment groups increased over the 12-
week post-op monitoring period (Fig. 3.8B & C). The HA-PELA + rhBMP-2 group 
resulted in significantly greater bone volume than HA-PELA alone or HA-PELA + 
MSCs at both 4 and 12 weeks post-op (Fig. 3.8B). There was no significant 
difference in bone mineral density among the three treatment groups at a given 
time point examined (Fig. 3.8C). 
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Figure 3.8. In vivo µ-CT monitoring of the scaffold-filled defects over time. (A)  µ-
CT 3-D reconstructions of the ROI immediately post-op and those containing HA-
PELA, HA-PELA + rMSCs, or HA-PELA + rhBMP-2 at 12 weeks post-op. Extra 
slices from the adjacent cortical bone were included for the reconstruction of the 
post-op ROI for convenient visual reference. For all treatment groups at 12 
weeks, only the 5-mm defect site is shown. Global thresholding was applied to 
exclude the HA-PELA scaffold within the defect. (B-C) µ-CT quantification of new 
bone volume (mm3) and bone mineral density (BMD; mg HA/cm3) in the ROI at 4 
and 12 weeks post-op (n=11). Data are graphed as Tukey box and whisker plots 
where whiskers represent the lower and upper 1.5 interquartile ranges (IQR). 
Data points outside the 1.5 IQR are plotted as individual points. * p < 0.05. ** p < 
0.01. *** p < .001. 
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Figure 3.8
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3.6 Torsional testing of treated femurs 
Explants from all three treatments groups were potted in bone cement and 
ramped to failure under torsion. There was no significant difference in maximum 
torque, stiffness, or energy to failure between groups (Fig. 3.9). 
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Figure 3.9. Torsional testing of 12-week explants as a function of treatment (HA-
PELA alone, MSCs, 500-ng rhBMP-2). Data are presented as scatter plots with 
mean ± standard deviation.  
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Figure 3.9
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3.7 Tracking GFP-labeled MSCs in vivo 
We compared the labeling efficacy of GFP driven by cytomegalovirus 
(CMV), elongation factor 1-alpha (EF1α), and ubiquitin C (UBC) promoters at 
three multiplicities of infection (MOI; 5, 25, 50) to optimize lentiviral GFP 
transduction of MSCs. CMV and EF1α promoters resulted in the highest levels of 
GFP signal with high labeling efficiency (>90%) (Fig. 3.10A). EF1α-GFP at an 
MOI of 25 was chosen for all subsequent MSC labeling due to the uniform GFP 
signal, low cytotoxicity (Fig. 3.10B), and minimal effects on cell proliferation (Fig. 
3.10C). There was no significant compromise in the potency of induced 
osteogenic or adipogenic differentiations of the MSCs upon GFP-labeling (Fig. 
3.10D-G).  
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Figure 3.10. Lentiviral GFP labeling of rMSCs. (A) Fluorescence microscopy of 
rMSCs transduced with lentiviral vectors driving GFP expression by CMV, UBC, 
or EF1α promoters with increasing MOI’s. Scale bar = 150 µm. (B) Viability of 
rMSCs upon 24-h exposure to various MOI’s of EF1α -GFP lentivirus relative to 
untreated controls. (C) Fold change in cell viability  of GFP-rMSCs (transduced 
with LV-EF1α-GFP at MOI = 25) vs. untreated rMSCs over 72 h. (D) Alizarin red 
S staining of untreated rMSCs and GFP-labeled rMSCs following 14-day culture 
in osteogenic medium; Scale bar = 250 µm. (E) Oil red O staining of untreated 
rMSCs and GFP-labeled rMSCs following 14-day culture in adipogenic medium; 
Scale bar = 250 µm. (F) Quantification of alizarin red stains in the rMSC and 
GFP-rMSCs cultures after 14 days in expansion (negative control) and 
osteogenic medium. The stains were released by acid treatment for 
spectroscopic quantifications. (G) Quantification of Oil red stains in the rMSC and 
GFP-rMSCs cultures after 14 days in expansion (negative control) and 
adipogenic medium. The stains were released by isopropanol for spectroscopic 
quantifications.  
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Figure 3.10
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GFP-labeled cells were seeded on HA-PELA and implanted in the 5-mm 
femoral segmental defect and their fate was tracked over 4 weeks post-
implantation. GFP-MSCs remained detectable on the scaffold at 2 and 7 days 
after implantation (Fig. 3.11) as shown by fluorescent microscopy, although the 
number of GFP-positive cells decreased over time. Morphology of the GFP-
labeled cells attached to the scaffolds changed from a rounded shape pre-
implantation to a more extended/spindle shape, supporting their ready adhesion 
and spreading on the osteoconductive scaffolds. No labeled cells were detected 
at 4 weeks post-op by immunohistochemistry with anti-GFP antibodies (data not 
shown).  
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Figure 3.11. Fluorescence microscopy of GFP-labeled rMSCs adhered to HA-
PELA scaffolds before and after implantation. Scale bars = 300 µm. 
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Figure 3.11 
 
  
  
155 
4. Discussion 
We hypothesized that a spiral-wrapped electrospun scaffold would support 
templated bone formation to augment the repair of long bone defects. To test this 
hypothesis, we used a 5-mm rat femoral segmental defect which has been 
validated as a critical long bone defect model to test the performance of bone 
tissue engineering scaffolds by our group and others [22,135,166,228]. The 
critical size of the defect, coupled with the removal of the surrounding 
periosteum, serves to emulate a challenging clinical scenario [229] precluding 
healing without proper intervention [230]. In our prior work we demonstrated that 
the handling properties (aqueous wettability and stability, tensile elasticity) and 
bioactivity (osteoconductivity and osteoinductivity) of electrospun degradable 
polymer/HA composites can be significantly improved by using an amphiphilic 
PELA block co-polymer instead of the conventional PLA [209]. Here we 
demonstrated that these handling and bioactivity characteristics made 
electrospun HA-PELA uniquely suited for the spiral-wrapped bone repair 
strategy.  
Specifically, the hydrophilic surface and osteoconductive nature of HA-
PELA allowed for easy loading of the MSC suspension and supported cellular 
adhesion and spreading (Fig. 3.2B & Fig. 3.11). The elastic properties of HA-
PELA facilitated the spiral-wrapping of HA-PELA without brittle fracture. Manual 
rolling of the scaffold did not compromise the viability of the cells seeded on the 
scaffolds as revealed by in vitro monitoring of cell viability and proliferation over 
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the course of 14 days after the spiral-wrapping (Fig. 3.2). Furthermore, the 
aqueous wettability of HA-PELA and high surface area of the well-integrated 
nanocrystalline HA (known for affinity for a wide range of proteins)[135] and 
amphiphilic polymer also enabled facile loading and stable retention of aqueous 
rhBMP-2. The HA-PELA exhibited a slow yet sustained in vitro release of 10-15% 
of the loaded rhBMP-2 (235.8 ng/cm2, same as the in vivo loading dose applied) 
over the first 3 days (Fig. 3.3A). Such an early release profile was in stark 
contrast to the burst release profile of conventional scaffolds (e.g. 100% release 
from clinically used collagen sponge after 2 days in vitro)[22] that are known to 
cause significant local and systemic side effects including ectopic bone 
formation.[20,231–233] Importantly, we also showed that the rhBMP-2 retained 
on the scaffold after 7-day incubation in PBS remained bioactive as evidenced by 
their ability to induce osteogenic transdifferentiation of adhered C2C12 myoblasts 
(Fig. 3.3B).[234] Uncompromised rMSC viability and sustained release of 
bioactive rhBMP-2 supported by HA-PELA allowed us to effectively compare how 
these therapeutic modalities could augment the healing of HA-PELA spiral-filled 
rat femoral segmental defects. 
The spiral-wrapped scaffold, with a structure closely matching with that of 
the removed femoral shaft, could be press-fit within the 5-mm segmental defect 
and remained stably fixed throughout the course of the 12-week study. The 
implanted scaffolds were still visible by histology at 12 weeks post-op (Fig. 3.5), 
consistent with prior in vitro findings of only >20% mass loss after 12-week 
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incubation in PBS.[209] Macrophages and foreign body giant cells but no 
neutrophils or eosinophils were detected from the cells infiltrated to the scaffolds, 
consistent with mild foreign body and immunogenic responses to HA-PELA and 
its degradation products and the lack of severe chronic inflammation or allergic 
reactions.[48] Degradation-induced immune response to PLA-based materials is 
well documented.[48,235] It has been hypothesized that calcium phosphate 
minerals including HA can buffer the acidic degradation products of PLA thereby 
mitigating their immunogenicity.[236] It is unclear whether the mild local immune 
responses observed could be partially attributed to the buffering effect of the 10 
wt% HA incorporated into the amphiphilic scaffold or if it was merely a result of 
incomplete degradation of the scaffold by 12 weeks.   
All treatment groups, including the HA-PELA scaffold alone, facilitated 
new bone formation via an endochondral ossification mechanism within the 
defect site, as revealed by histology (Fig. 3.5) and µ-CT analyses (Fig. 3.7, Fig. 
3.8). The new bone formation resulting from the treatment with HA-PELA alone, 
particularly beyond the scaffold-cortical bone junction, supports the 
osteoconductivity of the scaffold.[135] The delivery of MSCs via the HA-PELA 
spiral resulted in substantial increase of new bone formation away from the 
cortical/implant junctions. In agreement with our hypothesis, the new bone 
appeared to be directly templated by the spiral-wrapped scaffold as confirmed by 
histology (Fig. 3.5B) and µ-CT 2-D bone mineral density mapping (Fig. 3.7). Such 
uniform distribution of new bone across the longitudinal span of the defect, 
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concentrically separated by the spiral-wrapped electrospun scaffold and 
apparently promoted by the pre-seeded MSCs, has not been reported previously. 
Despite the unique morphology of the new bone, the delivery of rMSCs alone did 
not result in significantly higher bone volume or bone mineral density or the 
complete bridging of the defect by 12 weeks (Fig. 3.86B & C). The not-yet 
degraded spiral-wrapped scaffold could have prevented the concentrically 
formed new bone from continuously growing across the axial space and fusing 
together.   
It is widely accepted that exogenous MSCs can improve bone formation in 
critical-size defects,[237–239] although some fail to show statistically significant 
improvement in bone formation with cell-seeded constructs over cell-free 
constructs.[240] It is still under intense debate as to whether exogenous MSCs 
locally delivered to the defect site contribute to healing via paracrine effect (e.g. 
secreted factors) or by direct participation in osteo/chondral differentiation, with 
the former receiving more recent attention.[241–243] Whereas literature reports 
on the fate of transplanted MSCs vary, they generally show that implanted 
exogenous cells have a limited lifetime within the defect site and do not 
substantially differentiate into osteoblast-like cells.[238,244,245] Here, by 
tracking GFP-labeled MSCs delivered by the same method into the 5-mm 
femoral segmental defect, we showed that viable exogenous cells could still be 
detected up to 7 days post-implantation, although their number decreased over 
time. These cells also changed from a rounded shape immediately after cell 
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seeding on HA-PELA to a spindle shape over time, and such improved cell 
spreading is likely due to the absorption of endogenous cell-adhesive proteins 
from the tissue microenvironment onto the scaffolds. Agreeing with literature 
reports that exogenous cells seeded on a mineral-based carrier cannot be 
detected 14 days post- subcutaneous implantation,[244] we also did not observe 
GFP-labeled rMSCs at later time points by IHC. It is unclear whether the failure 
of the new bone templated by HA-PELA + MSCs to completely bridge over the 
entire defect by 12 weeks was due to the poor survival of the transplanted cells, 
the relatively low numbers of MSCs seeded (<240,000 / scaffold), and/or the 
insufficient duration of paracrine effect exerted by the viable transplanted cells.  
With an exceptionally low dose of rhBMP-2 delivered by HA-PELA (~10 
fold lower than those used clinically with collagen sponges in humans, after 
scaling by defect dimensions)[18], we observed robust new bone formation 
across nearly the entire defect site. Our earlier study showed that HA-PELA 
could effectively sensitize the response of MSCs to osteogenic inductions by 
orders of magnitude compared to conventional degradable scaffolds in vitro.[209] 
It is conceivable that the HA-PELA spiral may have also sensitized the response 
of the endogenous progenitor cells that migrated and adhered onto the scaffold 
to the osteogenic induction by the locally released rhBMP-2 in vivo. The new 
bone formed with rhBMP-2 induction was not only significantly higher in volume 
than those templated by HA-PELA alone or HA-PELA + MSC (Fig. 3.8B), but 
also appeared more mature as revealed by polarized light microscopy (Fig. 3.5B) 
  
160 
and the substantial recanalization of new bone by 12 weeks (Fig. 3.7). However, 
in agreement with our hypothesis, the new bone formed by rhBMP-2 induction 
appeared less templated by the spiral configuration than the bone formed in the 
MSC group. This may be due to the released rhBMP-2 being less confined to the 
immediate vicinity of the spiral template, resulting in greater bone formation on 
the scaffold periphery. By contrast, the possible direct participation of exogenous 
MSCs may explain why the new bone formation was confined to the spiral 
template where these MSCs are adhered and confined. 
It is worth noting that restoration of torsional strength of the defect was not 
achieved by 12 weeks in any of the treatment groups (Fig. 3.9). The 12-week 
timeframe in the current study was not sufficient to examine whether the spiral-
templated new bone growth in-between adjacent scaffold layers would eventually 
merge into more mature and congruent bone as the scaffold fully degrades. 
Fusion of the concentrically distributed new bone layers could potentially be 
accelerated by introducing macropores in the spiral-wrapped electrospun 
scaffold, similar to the design proposed by Jiang et al.[93] Meanwhile, doubling 
the loading dose of rhBMP-2 from the exceptionally low 500-ng/defect applied in 
the current study, but still lower than the 2 µg to 11 µg per 5-mm segmental 
defect utilized with most literature scaffolds,[22,213,237,246–248] may expedite 
the functional healing of the defect. Finally, applying a combination of exogenous 
cells, therapeutic agents, or both to the spiral-wrapped scaffold to synergistically 
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stimulate the osteogenesis and angiogenesis may also present an opportunity to 
further improve the functional outcome of bone repair.  
5. Conclusions 
We explored the use of spiral-wrapped electrospun composite HA-PELA 
scaffolds for templating bone formation and promoting the repair of critical-size 
long bone defects. The HA-PELA scaffold was readily seeded with MSCs or 
loaded with rhBMP-2 and stably implanted into 5-mm mid-shaft femoral 
segmental defects in rats. We show that HA-PELA alone, pre-seeded with MSCs, 
or with a low dose of rhBMP-2 (500 ng) all supported varying degrees of bone 
formation within the defect. Bone formation was effectively templated by the 
scaffolds when combined with MSCs, resulting in the formation of laminated new 
bone sandwiched in-between adjacent electrospun scaffold layers. The most 
robust bone formation was obtained with the use of a single low dose of 500-ng 
rhBMP-2. These encouraging in vivo outcomes, coupled with the advantageous 
handling characteristics of HA-PELA (elasticity, hydrophilicity, hydration-induced 
stiffening), support spiral-wrapped electrospun HA-PELA scaffolds as promising 
materials for the repair of long bone defects.  
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CHAPTER IV: Rapid Prototyping Amphiphilic Polymer/Hydroxyapatite 
Composite Scaffolds with Hydration-Induced Self-Fixation Behavior 
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Abstract 
Two major factors hampering the broad use of rapid prototyped 
biomaterials for tissue engineering applications are the requirement for custom-
designed or expensive research-grade three-dimensional (3-D) printers and the 
limited selection of suitable thermoplastic biomaterials exhibiting physical 
characteristics desired for facile surgical handling and biological properties 
encouraging tissue integration. Properly designed thermoplastic biodegradable 
amphiphilic polymers can exhibit hydration-dependent hydrophilicity changes and 
stiffening behavior, which may be exploited to facilitate the surgical delivery/self-
fixation of the scaffold within a physiological tissue environment. Compared to 
conventional hydrophobic polyesters, they also present significant advantages in 
blending with hydrophilic osteoconductive minerals with improved interfacial 
adhesion for bone tissue engineering applications. Here we demonstrated the 
excellent blending of biodegradable, amphiphilic PELA triblock co-polymer with 
HA and the fabrication of high-quality rapid prototyped 3-D macroporous 
composite scaffolds using an unmodified consumer-grade 3-D printer. The rapid 
prototyped HA-PELA composite scaffolds and the PELA control (without HA) 
swelled (66% and 44% volume increases, respectively) and stiffened (1.38-fold 
and 4-fold increases in compressive modulus, respectively) in water. To test the 
hypothesis that the hydration-induced physical changes can translate into self-
fixation properties of the scaffolds within a confined defect, a straightforward in 
vitro pull-out test was designed to quantify the peak force required to dislodge 
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these scaffolds from a simulated cylindrical defect at dry vs. wet states. 
Consistent with our hypothesis, the peak fixation force measured for the PELA 
and HA-PELA scaffolds increased 6-fold and 15-fold upon hydration, 
respectively. Furthermore, we showed that the low-fouling 3-D PELA inhibited the 
attachment of NIH3T3 fibroblasts or MSCs while the HA-PELA readily supported 
cellular attachment and osteogenic differentiation. Finally, we demonstrated the 
feasibility of rapid prototyping biphasic PELA/HA-PELA scaffolds for potential 
guided bone regeneration where an osteoconductive scaffold interior 
encouraging osteointegration and a non-adhesive surface discouraging fibrous 
tissue encapsulation is desired. This work demonstrated that by combining facile 
and readily translatable rapid prototyping approaches with unique biomaterial 
designs, biodegradable composite scaffolds with well-controlled macroporosities, 
spatially defined biological microenvironment, and useful handling characteristics 
can be developed. 
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1. Introduction 
Bone tissue engineering approaches aim to overcome the limitations of 
autografts (donor site morbidity, limited quantity) and allografts (high failure rate, 
risk for infections) for the repair of critical-size bone defects.[24] Tissue 
engineering typically employs degradable biomaterial scaffolds to support the 
delivery of cells/therapeutics to the defect site to guide/promote tissue 
regeneration and eventually be replaced by the regenerated tissue of 
interest.[27] The performance of such scaffolds is dependent not only on the 
chemical and structural properties of the biomaterial (e.g. chemical composition, 
network structure, and interfacial adhesion in the case of composites), but also 
the physical design (e.g. scaffold architecture, porosity), biological performance 
(e.g. osteoconductivity) and handling characteristics of the scaffold. Rational 
design that takes into consideration all of these factors is more likely to produce 
scaffolds that could meet clinical needs and are readily translatable (scalable, off-
the-shelf). 
The bioactivity of synthetic polymeric materials for orthopedic applications 
can be improved by structurally incorporating calcium apatite minerals such as 
HA, the principle mineral component in bone. Besides the intrinsic 
osteoconductivity of HA[249] that encourages osteoblast/progenitor cell 
recruitment and growth,[132] the unique pH-dependent surface potential of HA 
also translates into the ability to enrich a wide range of endogenous protein 
factors and deliver exogenous protein therapeutics including osteogenic growth 
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factors.[135,250] For polymer/HA composite materials, adequate interfacial 
adhesion between the polymer and mineral components is essential for 
achieving robust handling characteristics and mechanical 
properties.[138,151,169] However, most biodegradable polymers used to 
fabricate resorbable scaffolds are hydrophobic. This hydrophobicity/hydrophilicity 
mismatch results in poor interfacial adhesion and brittle composites with poor 
handling characteristics (i.e. difficulty to be press-fit into defects, prone to brittle 
fractures). Furthermore, hydrophobic materials cause difficulty in loading 
aqueous solutions (cells and/or growth factors) into the scaffold and may 
potentially change protein conformations via hydrophobic interactions, resulting 
in compromised bioactivity of the absorbed protein therapeutics.[251,252] 
With the aim of developing an improved biodegradable polymer/HA 
composite, we recently reported the a biodegradable amphiphilic block co-
polymer, PELA-based HA composite.[209] By blending PELA with HA and 
electrospinning the stable suspension, we produced non-woven fibrous meshes 
with more uniform morphologies, increased elasticity, and enhanced 
osteoconductivity and osteoinductivity when compared to electrospun HA-
poly(D,L-lactic acid) composites.  Interestingly, we also discovered that the 
amphiphilic nature of the electrospun scaffolds translated into super-
hydrophilicity (water contact angle ~ 0º) and an increased elastic modulus upon 
hydration. While electrospun HA-PELA would find unique orthopedic applications 
(e.g. as synthetic periosteal membrane wrapped around structural allografts), 
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their limited thickness and porosity[66,95,253] make them less suited for treating  
large defects where sufficient nutrient transport and cellular ingrowth throughout 
a 3-D macroporous scaffold is desired.  
Rapid prototyping techniques such as selective laser sintering (SLS),[254] 
powder-based three-dimensional printing (3DP),[106] and fused deposition 
modeling (FDM) have been employed in the fabrication of large 3-D scaffolds for 
bone tissue engineering. These rapid prototyping approaches have typically 
required custom-designed or expensive (>$100,000) research-grade printers, 
limiting their widespread uses by the research community. Nevertheless, such 
techniques enable the formation of HA or HA/polymer composite scaffolds with 
defined geometries and controlled interconnected pore architecture. This scaffold 
design enables more homogenous cell distribution and ensures consistent 
mechanical properties that are not attainable by less-controlled fabrication 
techniques such as salt leaching or gas foaming.[255,256] While rapid 
prototyping technology has become increasingly refined, the selection of 
biomaterials suitable for prototyping has remained limited. The most widely 
prototyped polymers are hydrophobic polyesters such as PCL,[257–261] 
PLLA,[262] or PLGA.[263] Rapid prototyped amphiphilic polymer scaffolds 
composed of polyethyleneoxide-terephthalate (PEOT) and polybutylene-
terephthelate (PBT) (PEOT/PBT) using a specialized printer have been explored 
for cartilage tissue engineering.[264–266] However, the PBT component is not 
biodegradable, resulting in crystalline, hard-to-resorb remnants upon degradation 
  
170 
in vivo.[267] Furthermore, rapid prototyping HA-PEOT/PBT composite scaffolds 
for bone tissue engineering was not explored. We hypothesize that rapid 
prototyping HA-PELA scaffolds offers a unique opportunity to combine the 
outstanding biological properties (osteoconductivity and osteoinductivity) of HA-
PELA with a well-defined 3-D macroporous architecture. Furthermore, we expect 
that the 3-D HA-PELA scaffold would exhibit novel self-fixation behavior derived 
from the unique hydration-induced swelling and stiffening behavior of the 
amphiphilic composite.  
Here we report the rapid prototyping of interconnected macroporous PELA 
and HA-PELA scaffolds using an unmodified consumer-grade 3-D printer. We 
examined the swelling behavior and mechanical properties of the scaffolds. We 
also quantitatively evaluated the hydration-induced self-fixation (as a result of 
hydration-induced swelling and stiffening) of the scaffolds using a custom-
designed in vitro pull-out test employing a sample holder simulating a confined 
tissue defect. To demonstrate the utility of the 3-D HA-PELA and PELA scaffolds 
for applications where opposing cell adhesive properties are desired (e.g. guided 
bone regeneration),[268] we examined their respective ability to support the 
attachment and proliferation of NIH3T3 fibroblasts. For potential bone tissue 
engineering applications, we examined the attachment and osteogenic 
differentiation of rMSCs on HA-PELA. Finally, we demonstrated the feasibility of 
fabricating biphasic HA-PELA/PELA scaffolds by rapid prototyping using this 
consumer-grade 3-D printer. 
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2. Materials and Methods 
2.1 Materials 
3,6-Dimethyl-1,4-dioxane-2,5-dione (D,L-lactide) was purchased from 
Sigma-Aldrich (St. Louis, MO), purified by recrystallization twice in anhydrous 
toluene, and dried under vacuum prior to use. PEG (20,000 Dalton, BioUltra) was 
purchased from Fluka (Switzerland). Polycrystalline hydroxyapatite powder 
(consisting of loose aggregates of ~100-nm crystallites) was purchased from Alfa 
Aesar (Ward Hill, MA). All other solvents and reagents were purchased from 
Sigma-Aldrich (St. Louis, MO) and used as received.  
2.2 Polymer synthesis  
PELA tri-block copolymer was synthesized and characterized as 
previously described.[209] Briefly, melt ring opening polymerization of D,L-lactide 
(0.12 mol) was initiated by poly(ethylene glycol) (20,000 Dalton, 0.2 mmol) with 
Sn(II) 2-ethylhexanoate (~95%, 0.06 mmol) catalysis. The reaction proceeded at 
130 ºC for 5 hours under argon. The crude PELA was dissolved in chloroform, 
purified by precipitation in methanol, and dried under vacuum before being 
subjected to GPC characterizations (described in 2.4). 
2.3 Scaffold fabrication 
The manufacturing process for 3-D PELA, HA-PELA, and PELA/HA-PELA 
biphasic scaffolds is depicted in Figure 4.1. Briefly, PELA/HA blends were 
solvent cast into films, extruded into filaments through a capillary rheometer, and 
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then rapid prototyped into 3-D scaffolds by FDM in a sub-ambient printing 
environment. 
2.3.1 Preparation of PELA and HA-PELA films 
PELA and HA-PELA dense films (~1.6 mm thick) were produced by 
solvent casting and sectioned into ~0.5 × 0.5 cm2 pellets for filament extrusion. 
For the fabrication of HA-PELA composite films, HA (3.3 g, 25% w/w PELA) was 
bath-sonicated in 20 mL chloroform for 30 min. PELA (10 g) was added and the 
mixture was stirred overnight. The HA-PELA mixture was subsequently poured 
into Teflon molds. The chloroform was evaporated in a fume hood at room 
temperature overnight and subsequently in a vacuum oven at 60 ºC for 24 h. 
PELA films were prepared by evaporating a chloroform solution of PELA without 
HA in the same mold followed by vacuum drying under identical conditions.  
 2.3.2 Filament extrusion 
The PELA and HA-PELA filaments were extruded using a LCR7000 
capillary rheometer (Dynisco Instruments, Franklin, MA) through a 2.81-mm 
diameter die. The barrel was preheated at 130 °C (for PELA) or 140 °C (for HA-
PELA) for ~90 sec before the PELA or HA-PELA pellets were loaded, followed by 
continued heating at the respective temperatures for 120 s. The filaments were 
extruded through the die with a 120 s run time and a barrel piston speed of 
32.84-mm min-1 and collected manually.  
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2.3.3 3-D Scaffold fabrication 
A 3-D CAD model of a 16 mm × 16 mm square prism (Fig. 4.2a, 2.4 mm 
or 4 mm in height) was designed in 3-Matics (Materialise, Belgium) and 
converted into g-code instructions by MakerWare (MakerBot Industries, Brooklyn, 
New York). A MakerBot® Replicator™ 2X 3-D printer (MakerBot Industries, 
Brooklyn, New York) cooled in a deli refrigerator at 4 ºC was used to print the 
scaffolds using the PELA or HA-PELA filaments. The sub-ambient printing 
environment was required to cool PELA below its Tg (~19 ºC) so that the filament 
could be continuously fed into the printer without undesired softening before 
reaching the heated printing nozzle. Nozzle temperatures of 130 ºC and 160 ºC 
were applied to print the PELA and HA-PELA, respectively. The build platform 
was maintained at 30 ºC to ensure stable adhesion of the bottom printed layer to 
the platform. Scaffolds were printed with a platform feed rate of 90 mm sec-1. 
Biphasic PELA/HA-PELA scaffolds were fabricated by extruding 3 layers 
of HA-PELA followed by 3 layers of PELA. PELA and HA-PELA filaments were 
loaded into separate nozzles of the Replicator™ 2X. The same printing 
conditions described above for printing PELA and HA-PELA were applied 
accordingly. 
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Figure 4.1. Depiction of the preparation of PELA and HA-PELA 3-D scaffolds by 
rapid prototyping. 
 
  
  
175 
Figure 4.1 
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2.4 Gel permeation chromatography  
PELA and HA-PELA composites were dissolved in tetrahydrofuran, 
centrifuged (720x g, 5 min) to pellet the HA, before the supernatant was collected 
and filtered with a 0.4-µm Teflon filter for gel permeation chromatography (GPC) 
analyses. Molecular weights and polydispersity of PELA was determined by GPC 
on a Varian Prostar HPLC system equipped with two 5-mm PLGel MiniMIX-D 
columns (Agilent, Santa Clara, CA) and a PL-ELS2100 evaporative light 
scattering detector (Polymer Laboratories, UK). Tetrahydrofuran was used as an 
eluent at 0.3 mL h-1 at room temperature. Molecular weight and polydispersity 
calculations were calibrated with EasiVial polystyrene standards (Agilent, Santa 
Clara, CA).  
2.5 Scaffold characterization 
2.5.1 Optical imaging 
Macroscopic optical images of the HA-PELA, PELA, and the biphasic 
scaffolds were taken on a Leica M50 stereomicroscope equipped with a Leica 
DFC295 digital camera (Leica Microsystems, Germany).  
2.5.2 Scanning electron microscopy and associated energy-dispersive x-ray 
spectroscopy (EDX) 
HA-PELA, PELA, and PELA/HA-PELA biphasic scaffolds were coated with 
3 nm of carbon and imaged on a Quanta 200 FEG MKII scanning electron 
microscope (FEI Inc., Hillsboro, OR) under high vacuum at 10 kV. EDX was 
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carried out to map the elemental compositions (Ca and P) of the biphasic 
scaffold at 15 kV with an Oxford-Link INCA 350 x-ray spectrometer (Oxford 
Instruments, United Kingdom).  
2.5.3 Porosity calculation 
The theoretical porosity (P) of the scaffolds was calculated by determining 
the percentage (%) of scaffold volume that is occupied by the polymer rods, as 
described by Zein et al.[110] and shown in equation (1): 𝑃 = !"!!"!" ×100%  (1) 
where Va (mm3) is the apparent scaffold volume and Vt is the scaffold true 
volume taken up by polymer. Assuming that the FDM polymer rods are cylindrical 
in shape with a uniform diameter, the true volume taken up by polymer (Vt) in a 
square prism can be calculated as 𝑉𝑡 = 𝐿×𝑁×𝑉𝑟𝑤 (2) 
where L is the number of rods per layer, N is the number of layers, and Vrw is the 
volume of each cylindrical rod which is determined by the printed line width and 
length. 
2.6 Swelling behavior 
The height and diameter (averaged from 3 measurements) of dry PELA 
and HA-PELA scaffolds (n=3), cored from the square prism FDM blocks using a 
biopsy punch, was measured with a digital caliper. Line width was averaged from 
5 measured lines per scaffold using a light microscope (Axioscop 2 MAT; Carl 
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Zeiss, Germany) and ImageJ (National Institutes of Health, Bethesda, MD). 
Scaffold mass was weighed using an analytical balance (ML104; Mettler-Toledo, 
Columbus, OH).  Hydrated scaffold dimensions and mass were measured at 
various time intervals following incubation in de-ionized water at 37 ºC. Residual 
water was removed prior to weighing by briefly blotting the scaffolds on 
KimWipes. Change in mass (M/M0) was calculated by dividing the mass following 
water equilibration (M) by the initial mass of a scaffold briefly submerged in water 
(M0). Change in volume (V/V0) was calculated in the same manner. Hydrated line 
width was measured following 24-h incubation in 37 ºC deionized water. 
2.7 Mechanical testing 
The compressive modulus of PELA and HA-PELA scaffolds (n=3) was 
determined on a Q800 DMA equipped with a liquid nitrogen gas cooling 
accessory (TA Instruments, New Castle, DE). Cylindrical specimens 6 mm in 
diameter and 4 mm in height, the dimensions used by Moroni et al. for 
characterizing mechanical properties of macroporous scaffolds,[256] were cored 
from the square prism FDM blocks. Unconfined compressive testing (N=3) was 
performed at 37 ºC for both dry (as-printed) and hydrated (24 h in deionized 
water) scaffolds. The height and diameter of each specimen was measured with 
a digital caliper prior to testing. Each specimen was held isothermal at 37 ºC for 
30 min before being pre-loaded with a force of 0.001N and ramped at a rate of 
1.0 N/min to 10 N. The compressive modulus was recorded as the slope of the 
linear region (0 to 0.5% strain) of the stress/strain curve. 
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2.8 Pull-out test 
A custom sample holder (Fig. 4.5A) simulating a confined circular tissue 
defect was developed to enable quantitative measurement of the hydration-
induced swelling/stiffening effect of the scaffolds via a pull-out test. A CAD model 
of the sample holder was designed in 3-Matics and fabricated on a MakerBot 
Thing-O-Matic™ 3-D printer using acrylonitrile butadiene styrene (ABS). In order 
to ensure consistent specimen placement, the specimen holder portion of the 
ABS prototype was tight-fitted with a standard cylindrical aluminum spacer (12.7 
mm OD x 6.35 mm ID x 4.76 mm H, W.W. Grainger Inc., Chicago, IL). Cylindrical 
PELA or HA-PELA scaffolds 6 mm in diameter and 4 mm in height, cored from 
square prism FDM blocks using a biopsy punch, were each drilled with a center 
axial hole 1.6 mm in diameter to enable the insertion of a drywall nail (1.6 mm 
diameter, 32 mm long, 3.8 mm diameter head, Fig. 4.5B). The specimen was 
inserted into the aluminum spacer, and either tested dry or equilibrated in 
deionized water within the holder for 2 h at 37 °C prior to test. The bottom stem 
of the custom ABS holder and the sharp end of the inserted nail were secured 
between the grips of a MTS Bionix 370 mechanical testing system (MTS 
Systems Corporation, Minneapolis, MN), respectively (Fig. 4.5C). Specimens 
were ramped at a rate of 50 mm min-1 until they were completely pulled out of the 
ABS/aluminum holder to determine the peak force as recorded by a 250N load 
cell (Interface, Scottsdale, AZ). 
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2.9 NIH3T3 cell attachment and proliferation 
HA-PELA and PELA scaffolds (6.3 mm in diameter, 2.4 mm in height) 
were washed 3 times in deionized water (5 min per wash), sterilized in 70% 
ethanol, and allowed to air dry in a laminar flow hood. Residual ethanol was 
removed with a wash in PBS followed by equilibration overnight in Dulbecco’s 
Modified Eagle Medium (DMEM, high glucose; Life Technologies, Grand Island, 
NY) supplemented with 10% bovine calf serum and 1% penicillin/streptomycin. 
Immediately prior to cell seeding, media were removed from the scaffolds by 
vacuum and the scaffolds were transferred to ultra low-attachment 24-well plates 
(Corning Inc., Corning, NY). NIH3T3 fibroblasts were trypsinized from adherent 
culture and seeded on the scaffolds (200,000 cells in 50 µL of medium), and 
allowed to attach in an incubator (37 ºC, 5% CO2) for 1 h.  
A Cell Counting Kit-8 assay (CCK-8; Dojindo Molecular Technologies Inc., 
Japan) was performed to assess the viability of cells attached on the scaffolds. At 
each time point, cell-laden scaffolds were transferred to a fresh well containing 
0.7 mL of medium and 9% (v/v) CCK-8 reagent. After 4-h incubation, 100 µL of 
medium was removed for measurement of absorbance at 450 nm with 650 nm 
background correction on a Multiskan FC microplate photometer (Thermo 
Scientific, Billerica, MA). The remainder of the medium was aspirated, the 
scaffolds were washed with PBS, and replaced with fresh medium for continued 
culture up to 14 days. The CCK-8 assay was carried out at day 1, 3, 5, 7 and 14. 
  
181 
NIH3T3 attachment on the HA-PELA and PELA scaffolds was also 
visualized by staining the viable cells with formazan dye using a MTT kit (Cell 
Proliferation Kit I; Roche, Indianapolis, IN). At 24 h post seeding, scaffolds were 
transferred to a fresh well containing medium with 9% (v/v) MTT labeling reagent. 
After 3 h of incubation, the scaffolds were imaged on a Leica M50 
stereomicroscope equipped with a Leica DFC295 digital camera (Leica 
Microsystems, Germany).  
2.10 rMSC attachment and osteogenic differentiation  
rMSCs were isolated from 289-300g male Charles River SD rats 
according to the procedure approved by the University of Massachusetts Medical 
School Institutional Animal Care and Use Committee, and enriched by adherent 
culture as previously described.[153] The cells were cultured in MSC expansion 
medium (αMEM without ascorbic acid, containing 20% FBS, 1% penicillin–
streptomycin and 2% L-glutamine). Passage 3 MSCs were seeded onto the 
scaffolds (200,00 cells in 50 µL of medium), and a CCK-8 assay was performed 
after 24 h as described in the previous section. 
In a separate set of experiments, rMSCs were seeded onto the HA-PELA 
scaffolds (400,000 cells in 50 µL medium) and allowed to attach in a humidified 
incubator (37 ºC, 5% CO2) for 1 h. Following attachment, 0.7 mL of fresh 
expansion medium was added and the scaffolds were cultured for 24 h. To 
induce osteogenic differentiation, the medium then was replaced with MSC 
expansion medium supplemented with 10 nM of dexamethasone, 20 mM of β-
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glycerol phosphate, and 50 µM of L-ascorbic acid 2-phosphate. The scaffolds 
were cultured in either expansion or osteogenic medium for 14 days with medium 
changes twice a week. Alkaline phosphatase staining was performed with an 
Alkaline Phosphatase Leukocyte kit according to manufacturer’s instructions 
(Sigma Aldrich). The protocol was modified to fix the scaffolds in 4% neutral 
buffered formalin for 15 min rather than in the Citrate-Acetone-Formaldehyde 
fixative because the scaffolds are soluble in acetone. Alkaline phosphatase 
stained scaffolds were imaged on a stereomicroscope.  
For observation of the microscopic morphology of the adherent cells and 
the deposited extracellular matrices by scanning electron microscopy (SEM), the 
scaffolds were air dried, sputter coated with Au (~ 12nm), and imaged on a 
Quanta 200 FEG MKII scanning electron microscope under high vacuum at 5 kV. 
2.11 Statistical analysis 
 All data are presented as mean ± standard deviation. Statistical 
analysis was performed using ANOVA with Tukey post-hoc. 
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3. Results 
3.1 Fabrication and characterization of PELA and HA-PELA scaffolds 
CAD software was used to design 16 mm × 16 mm square prism scaffolds 
with a staggered arrangement of lines (Fig. 4.2A). The line width and height was 
set to 0.4 mm, the same as the printing nozzle diameter. The perpendicular and 
staggered line arrangements between neighboring and alternating layers, 
respectively, were designed to maximize the retention of cells during initial cell 
seeding. Line spacing of 0.4 mm, which was shown to be advantageous over 
large spacing (e.g. 0.8 mm) in achieving sufficient seeding efficiency, was used 
to give a theoretical scaffold porosity of 61.7%. Six-layer (2.4 mm high) scaffolds 
were designed for all cell culture studies and 10-layer (4.0 mm high) scaffolds 
were designed for all physical characterizations. The scaffolds were rapid 
prototyped based on the CAD models by FDM on an unmodified consumer-grade 
3-D printer. Macroscopic images of the scaffolds (Fig. 4.2B) revealed that their 
line width was consistent with the CAD model (0.4 mm). Scanning electron 
micrographs showed a roughened fiber appearance for the HA-PELA composite 
scaffolds (Fig. 4.2C) and a smooth fiber appearance for the un-mineralized PELA 
scaffold (Fig. 4.2D). Cross-sections of both scaffolds revealed circular fibers with 
open pores between fibers (Fig. 4.2C & D). 
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Figure 4.2. Images of the CAD model and the rapid prototyped scaffolds. (A) 
Top, isometric, and side views of scaffold CAD model. (B) Stereomicroscopy 
images of rapid prototyped HA-PELA and PELA scaffolds. Scale bars = 5 mm. 
(C) Scanning electron micrographs of the HA-PELA scaffold. Scale bars = 1 mm. 
(D) Scanning electron micrographs of the PELA scaffold. Scale bars = 1 mm. 
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Figure 4.2 
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GPC was used to determine the effect of filament extrusion and rapid 
prototyping on the molecular weight and polydispersity of PELA (Table 4.1). 
PELA underwent a slight decrease in molecular weight, while the molecular 
weight of HA-PELA was minimally affected by the fiber extrusion at elevated 
temperatures (130 °C for PELA and 140 °C for HA-PELA). The rapid prototyping 
of PELA at the same nozzle temperature of 130 °C, however, did not lead to 
further decreases in the molecular weight of the printed PELA scaffold. No 
significant changes in the molecular weight distributions of PELA and HA-PELA 
were detected throughout the extrusion and rapid prototyping. 
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Table 4.1. Molecular weight distribution during the processing of PELA and HA-
PELA. 
 
  
  
188 
Table 4.1 
 
 
 
 
 
a referring to the filament extrusion temperature or the nozzle temperature applied 
to the prototyping of the scaffolds. 
  
PELA sample Proc. Temp.a Mn Mw Mn/Mw 
As synthesized 
PELA  85,873 134,077 1.56 
HA-PELA filament 140 ºC 84,615 129,902 1.53 
HA-PELA scaffold 160 ºC 82,537 130,945 1.58 
PELA filament 130 ºC 75,553 116,465 1.54 
PELA scaffold 130 ºC 76,415 117,039 1.53 
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3.2 Swelling behavior of HA-PELA and PELA  
The swelling and water absorption behavior of the HA-PELA and PELA 
scaffolds (n=3) in deionized water at 37 ºC was monitored over time (Fig. 4.3). 
The mass and volume of HA-PELA scaffolds increased more rapidly than PELA, 
resulting in a higher total swelling after 24 h (Fig. 4.3A & B).  The mass and 
volume of both scaffolds increased more rapidly within the first 2-4 h, followed by 
slower but continued increases, reaching 75% (mass) and 66% (volume) for HA-
PELA, and 34% (mass) and 43.8% (volume) for PELA by 24 h, respectively. The 
line width of the scaffolds also increased over the 24 h swelling period for both 
scaffolds (Fig. 4.3C), with the fully hydrated HA-PELA scaffold exhibiting 
significantly higher line width than that of PELA.  
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Figure 4.3 Swelling behavior of HA-PELA and PELA scaffolds (n=3). (A) Change 
in scaffold mass (swelled mass (M) / initial mass (M0)) over time in deionized 
water at 37 ºC. (B) Change in scaffold volume (swelled volume (V) / initial volume 
(V0)) over time in deionized water at 37 ºC. (C) Change in line width after 24 h 
hydration in deionized water at 37 ºC. *P < 0.05. 
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Figure 4.3 
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3.3 Hydration-induced stiffening of the scaffolds 
The effect of hydration on the compressive modulus of HA-PELA and 
PELA scaffolds was determined by unconfined compressive testing at 37 ºC. In 
both dry and hydrated states, HA-PELA exhibited a significantly higher 
compressive modulus than PELA (Fig. 4.4). After hydration in 37 ºC deionized 
water for 24 h, the compressive moduli of both HA-PELA and PELA significantly 
increased. The magnitude of hydration-induced stiffening was higher for PELA 
than HA-PELA, with an increase in compressive modulus of 395% compared to 
37.5%. 
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Figure 4.4. Compressive moduli of dry and hydrated PELA and HA-PELA 
scaffolds (n=3) at 37 ºC. *P < 0.05. 
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Figure 4.4 
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3.4 Hydration-induced self-fixation of scaffolds in a simulated confined 
defect 
A device was designed to assess how the hydration-induced swelling and 
stiffening of the HA-PELA and PELA scaffolds may be exploited to facilitate their 
stable self-fixation into skeletal tissue defects as synthetic bone grafts. The CAD 
model and rapid prototyped ABS holder (Fig. 4.5A) incorporated a cylindrical 
aluminum spacer to hold a cylindrical test specimen with a bottom stem and a 
drywall nail penetrating through the center axis of the specimen (Fig. 4.5B) to fit 
in the grips of a MTS mechanical testing system. This design allows convenient 
placement of a test specimen in a precisely configured confined cylinder to allow 
for a pull-out test to be reproducibly carried out on any standard mechanical 
testing machine (Fig. 4.5C). The peak force required to pull the scaffold out of the 
specimen holder via the nail grip was determined. This force was measured for 
dry HA-PELA and PELA scaffolds and for scaffolds pre-swelled in the fixation 
device in deionized water at 37 ºC for 2 h. The peak force increased by 15-fold 
and 6.3-fold following hydration of HA-PELA and PELA scaffolds in the fixation 
device, respectively (Fig. 4.5D). The peak fixation force of the hydrated HA-PELA 
scaffolds was significantly higher than that of the hydrated PELA scaffolds. The 
observed increase in peak force upon hydration, positively correlated with the 
difficulty of pulling out the specimen, is a potential indicator of how the specimens 
may swell/stiffen and become stably fixated within a tissue defect. 
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Figure 4.5. Hydration-induced self-fixation test. (A) CAD image of the self-fixation 
testing device with aluminum spacer. (B) Image of the rapid prototyped self-
fixation testing device with HA-PELA scaffold inserted. (C) Image of the testing 
device secured to the grips of the MTS mechanical testing system. (D) Peak 
forces required to pull HA-PELA and PELA scaffolds (n=4) out of the self-fixation 
device before and after hydration. *P < 0.05.  
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Figure 4.5 
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3.5 NIH3T3 attachment and proliferation on the rapid prototyped scaffolds 
A CCK-8 assay was used to quantify the viability of NIH3T3 fibroblasts 
cultured on HA-PELA, PELA, and biphasic scaffolds (Fig. 4.6A). The CCK-8 
reagent has low toxicity and the colored formazan product is soluble in medium, 
allowing the cellular viability on the same scaffolds to be longitudinally monitored 
in a non-destructive manner. Initial cell attachment was significantly higher on 
HA-PELA than PELA or the biphasic scaffolds, and the much higher cellular 
viability was maintained on HA-PELA for 14 days. The extremely poor cellular 
attachment on PELA left few viable cells on PELA by day 3. Differences in cell 
attachment between HA-PELA and PELA were further confirmed by staining 
viable cells with formazan dye (Fig. 4.6B). The HA-PELA scaffolds supported the 
attachment of viable cells evenly distributed across different layers of the 
composite scaffold.  The PELA scaffold, however, only contained a small number 
of viable cells trapped within the pores, with few cells directly adhered to the low-
fouling fibers. 
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Figure 4.6. CCK-8 cell viability assay of NIH3T3 attachment and proliferation on 
HA-PELA and PELA scaffolds (n=3). *P < 0.05. (B) Stereomicroscopy images of 
MTT stained scaffolds 24 h post NIH3T3 seeding. Dark purple stains denote 
viable cells adhered on the scaffolds. Scale bars = 1 mm. 
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Figure 4.6 
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3.6 MSC attachment and osteogenic differentiation on the rapid prototyped 
scaffolds 
The MSC attachment on HA-PELA was assessed in order to determine 
the suitability of HA-PELA for supporting potential stem/progenitor cell 
attachment and bone in-growth in vivo. CCK-8 assay revealed significantly higher 
(e.g. 16-fold increase in viable cells at 24 h) seeding efficiency of MSCs on the 3-
D HA-PELA scaffolds than on the PELA scaffolds (Fig. 4.7A), further supporting 
the cell-adhesive nature/osteoconductivity of the former and the low-fouling 
nature of the latter. The ability of the HA-PELA scaffold to support osteogenic 
differentiation of rMSCs was examined by culturing the cells on the scaffolds in 
expansion or osteogenic medium for 14 days. Extensive positive (red) alkaline 
phosphatase staining detected throughout the 3-D macroporous scaffold (e.g. as 
revealed by surface, side and cross-section views) confirmed the osteogenic 
differentiation of the adherent rMSCs cultured in osteogenic medium (Fig. 4.7B). 
No non-specific staining was detected in the expansion medium control. SEM 
micrographs revealed the deposition of extracellular matrices including mineral 
nodules surrounding the rMSCs adhered to the scaffold after 14-day culture in 
osteogenic differentiation medium (Fig. 4.7C), further confirming that these 
rMSCs underwent osteogenic differentiation upon culture induction.  
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Figure 4.7. rMSC attachment and osteogenic differentiation on HA-PELA 
scaffolds. (A) CCK-8 cell viability assay of rMSCs attached to HA-PELA and 
PELA scaffolds at 24 h after initial seeding (n=3). *P < 0.05. (B) Alkaline 
phosphatase staining of rMSCs cultured on HA-PELA in expansion medium (left) 
or osteogenic medium (right) for 14 days. Side and cross section views of the 
stained scaffold cultured in osteogenic medium are shown below. (C) SEM 
micrographs of rMSCs cultured on HA-PELA in osteogenic medium for 14 days. 
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Figure 4.7 
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3.7 Rapid prototyping biphasic PELA/HA-PELA scaffolds 
Biphasic scaffolds composed of 3 PELA layers and 3 HA-PELA layers 
were designed using CAD (Fig. 4.8A) and fabricated by FDM. Stereomicroscopy 
images showed distinct yet well-connected PELA and HA-PELA phases (Fig. 
4.8B). Scanning electron microscopy and EDX mapping of the cross-section of 
the biphasic scaffold confirmed the distinct mineral composition in the HA-PELA 
fibers (Fig. 4.8C). The calcium (Ca) and phosphate (P) signals were clearly 
localized within and on the surface of the HA-PELA fibers while only minor 
background noise was detected in the adjacent PELA phase.  
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Figure 4.8. PELA/HA-PELA biphasic scaffold. (A) CAD model of the PELA/HA-
PELA biphasic scaffold. (B) Stereomicroscopy images of a 6-mm core punched 
out from the biphasic scaffold. Scale markings = 1.0 mm (C) Scanning electron 
micrograph of a biphasic scaffold (top). Elemental mapping overlay (bottom) of 
calcium (green) and phosphate (red). Scale bars = 1 mm. 
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Figure 4.8 
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4. Discussion 
Recent work from our group has demonstrated the potential of electrospun 
HA-PELA scaffolds for bone tissue engineering applications.[209] Compared to 
hydrophobic PLA, amphiphilic PELA exhibited significantly improved mechanical 
properties (10-fold increase in ultimate tensile strain), hydrophilicity, and 
bioactivity (osteoconductivity and highly sensitized response to the induction of 
osteogenesis of bone marrow stromal cells) when combined with HA.[209] 
Furthermore, the amphiphilic nature of PELA resulted in hydration-induced 
structural rearrangement (supported by DSC) and stiffening of the polymers,[209] 
a property that we hypothesize could be exploited to create scaffolds that can 
secure themselves within a confined bony defect (self-fixation). Stable graft 
fixation is important for preventing bone resorption,[269] and the fitting and 
fixation of bone grafts is a significant clinical problem, particularly in complex 
cranio-maxillofacial defects.[6,7]  
Here we demonstrated facile fabrication of 3-D PELA, HA-PELA, and 
biphasic scaffolds with controlled macroporosity and architecture by FDM using a 
consumer-grade 3-D printer. We evaluated their swelling and mechanical 
properties under physiological conditions and designed a fixation test to examine 
the ability of the scaffolds to self-fixate within a confined cylindrical defect upon 
hydration in vitro. Furthermore, we evaluated these scaffolds’ abilities to support 
cell adhesion/growth, thereby determining the suitability of the biphasic scaffold 
for applications such as guided bone regeneration.  
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The FDM process consists of feeding a thermoplastic polymer filament 
through a heated nozzle, guided by software instructions converted from the 
CAD model, and depositing thin rods of polymer layer by layer that fuse with one 
another at their contact points. We used an unmodified consumer-grade 3-D 
printer, MakerBot® Replicator™ 2X to fabricate the scaffolds.  The only 
“customization” required for printing PELA and HA-PELA polymers are (1) the 
preparation of PELA and HA-PELA filaments to feed the 3-D printer, and (2) the 
identification of appropriate environmental and printing nozzle temperatures to 
support the smooth feeding (without premature softening) and printing (without 
degradation) of PELA/HA-PELA rather than ABS, the default polymer used for 
MakerBot® Replicator™ 2X.  
In order to produce the filaments for FDM, a capillary rheometer was used 
to extrude the PELA and HA-PELA. The capillary rheometer or melt flow indexer 
allowed for smaller quantities of polymer (gram-scale vs. kilogram-scale required 
by conventional extruder) to be used. The melt flow indexer is also more cost-
effective (<$5,000) compared to micro-extruders (>$100,000). We extruded pre-
fabricated dense films obtained from solvent casting where loose aggregates of 
HA nanocrystals[153] were homogeneously blended with PELA in the composite. 
To ensure that the filament was smoothly fed into the heated printing nozzle 
without premature softening, we carried out the FDM in a deli refrigerator at 4 °C, 
well below the glass transition temperature of PELA (~19 ºC). This temperature 
prevented the filament from softening/melting and sticking in the drive gear 
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before reaching the printing nozzle, the temperature of which was set at 130 ºC 
for PELA and 160 ºC for HA-PELA. With this approach, we were able to fabricate 
PELA and HA-PELA scaffolds with fiber dimensions precisely matching the CAD 
model (Fig. 4.2) without undesired line width widening/thinning due to 
inconsistent extrusion through the heated nozzle. GPC confirmed that the 
printing nozzle temperature chosen largely maintained the integrity of PELA and 
HA-PELA composite (Table 4.1). It is worth noting that the molecular weight of 
the HA-PELA composite decreased less than the molecular weight of PELA 
during the filament extrusion and subsequent processing, even though the 
processing temperatures for HA-PELA were higher, suggesting an insulating and 
protective effect of HA on the degradable polymer. This result is consistent with 
our prior observation that the electrospun HA-PELA meshes exhibited an 
increased thermal decomposition temperature compared to the PELA meshes as 
determined by TGA.[209] 
PEG/PLA co-polymers are known to exhibit significant water absorption 
due to the hydrophilic PEG segment.[270,271] Additionally, we showed 
previously that electrospun PELA and HA-PELA scaffolds significantly stiffened 
upon hydration.[209] Here, we examined the swelling behavior and hydration-
dependent mechanical properties of the rapid prototyped porous 3-D PELA and 
HA-PELA scaffolds at 37 ºC. Both HA-PELA and PELA 3-D scaffolds were 
readily wetted by water and exhibited significant swelling in water within 2 h, with 
the prototyped line width increasing by 25% in 24 h (Fig. 4.3). The incorporation 
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of HA significantly increased the swelling of the scaffolds. This result may be 
attributed to the further increased hydrophilicity upon HA incorporation and the 
more roughened HA-PELA fiber morphologies that promoted better water 
penetration within HA-PELA. These observations support that the 3-D PELA-
based scaffolds are highly hydrophilic, in agreement with prior water contact 
angle and swelling experiments carried out on electrospun PELA meshes and 
dense solvent-cast PELA films.[60,209] 
Polymers typically soften upon hydration due to the plasticizing effect of 
water.[189] However, hydration-induced stiffening has been described previously 
for electrospun PELA[209] and other amphiphilic polymers.[189,272] This 
phenomenon is likely caused by hydration-induced phase separation of the 
hydrophilic PEG blocks from the hydrophobic segments,[189,209,273] which was 
confirmed by modulated differential scanning colorimetry with our electrospun 
PELA or HA-PELA fibrous meshes[209] and by small-angle x-ray scattering of 
other related amphiphilic systems.[189] We showed here that the compressive 
moduli of 3-D HA-PELA were higher than those of the PELA scaffolds in both dry 
and hydrated states (Fig. 4.4). The hydration-induced increase in compressive 
modulus was observed with both scaffolds, but the effect was more pronounced 
in PELA (~4-fold increase) than in HA-PELA (1.38-fold increase). However, the 
fully hydrated HA-PELA scaffold was more than twice as stiff as the hydrated 
PELA scaffold. The higher (by 6.7-fold) modulus of the dry HA-PELA scaffold 
compared to the dry PELA supported good structural integration of HA with the 
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amphiphilic polymer. The increase in modulus of the hydrated HA-PELA 
suggests that HA did not disrupt the hydration-induced phase separation of 
PELA. 
The swelling behavior and hydration-induced stiffening of the rapid 
prototyped amphiphilic scaffolds led us to hypothesize that a dry HA-PELA or 
PELA scaffold readily placed within a confined tissue defect (with minimal 
resistance) could gradually conform to the defect upon swelling under 
physiological conditions and remain securely fixed within the defect as it stiffens. 
Such a gradual self-fixation would allow both convenient placement and better 
integration of an implant within the often-complex defect geometries. Inspired by 
push-out tests evaluating the fixation of osseous implants to surrounding native 
bone tissue,[274,275] we developed an in vitro pull-out test to quantify the 
hydration-induced self-fixation behavior. The test specimen was placed into a 
rapid prototyped testing device (Fig. 4.5B), allowed to swell in water, and the 
force required to pull it out of the testing device was measured. While this test 
does not fully recapitulate the environment of a tissue substrate, it provides a 
reproducible and facile method to quantitatively compare the self-fixation 
behavior of various scaffolds in vitro, thereby serving as a valuable, although 
imperfect, predictor. We observed significant fixation of both HA-PELA and PELA 
scaffolds after 2 h of hydration (Fig. 4.5D). The peak force required to remove the 
hydrated HA-PELA scaffold was 15-fold higher than that for the dry scaffold. The 
fixation force measured for the hydrated HA-PELA was also significantly higher 
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than that of hydrated PELA, likely due to a combination of the more pronounced 
swelling and the more substantial stiffening of the hydrated HA-PELA. To our 
knowledge, this is the first report of rapid prototyped biomaterial scaffold 
exhibiting well-characterized hydration-induced self-fixation behavior. 
The low-fouling PEG component in PEG-PLA di-block films[60,195,196] 
and electrospun PELA[62,176] was previously shown to translate into low cellular 
adhesion. In our prior work, we showed that the electrospun HA-PELA meshes, 
unlike the low-fouling PELA counterpart, readily supported cellular adhesion and 
proliferation of bone marrow-derived stromal cells.[209] The substantial 
difference between PELA and HA-PELA in supporting cell adhesion could 
potentially be exploited for applications where varying degrees of tissue ingrowth 
are required on opposing sides of a biomaterial scaffold. One such application is 
guided bone regeneration (GBR).[268] The principle behind GBR is to exclude 
fibroblasts and soft tissue from occupying the bony defect while encouraging the 
defect be populated with osteogenic cells and filled with new bone.[276,277] We 
hypothesized that the low-fouling PELA, when properly incorporated into the 
scaffolds, would inhibit this fibroblast adhesion. Using a CCK-8 assay, we 
showed that the PELA scaffold indeed restricted the adhesion of fibroblasts (Fig. 
4.6A). Only a small number of fibroblasts loosely adhered to the PELA scaffold, 
as visualized by MTT staining after 24 h (Fig. 4.6B), and they failed to proliferate 
over time (Fig. 4.6B). By contrast, nearly 5 times fibroblasts adhered to the HA-
PELA upon cell seeding and they remained viable and stably attached to the 
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scaffold during the 14-day culture period (Figs. 4.6A & B), agreeing with the 
general trend we previously observed with electrospun PELA vs. HA-PELA 
scaffolds.[209]  
We further confirmed that the osteoconductive HA-PELA readily supported 
the cellular adhesion and differentiation of MSCs. The incorporation of HA 
effectively offset the low-fouling effect of the PEG component of the amphiphilic 
composite, resulting in 10 times higher rMSC seeding efficiency on HA-PELA 
than on the PELA (Fig. 4.7A). The rMSCs remained adhered over long-term 
culture (14 days) and were able to differentiate and produce mineralized 
extracellular matrix in the presence of osteogenic medium (Fig. 4.7B &C). 
Combined with previously elucidated highly sensitized response of the MSCs 
adhered to HA-PELA (as opposed to PELA or HA-PLA) to osteogenic 
inductions,[209] these observations support 3-D HA-PELA as a promising 
scaffold for guiding bone regeneration upon surgical implantation to a bony 
defect. While the current study did not attempt to optimize of scaffold porosity 
and architecture, new computational modeling methods such as those based on 
triply periodic minimal surfaces could be employed to enable CAD of 
macroporous scaffolds with further improved cell seeding efficiency and 
mechanical properties.[102,278–280] Chemical modification of PELA with 
reactive groups to support techniques such as projection stereolithography would 
facilitate the fabrication of such next-generation scaffold designs.[101] 
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As a proof-of-concept, we fabricated a PELA/HA-PELA biphasic scaffold 
for potential GBR applications using the consumer-grade 3-D printing system 
(Fig. 4.8). The top low-fouling PELA phase was designed to prevent fibroblast 
adhesion/scar tissue encapsulation/soft tissue collapse into the defect in vivo 
while the bottom HA-PELA phase, upon insertion into a bony defect, was 
designed to support the attachment of osteoblasts or progenitors residing in the 
bony tissue environment to encourage bone ingrowth. Outstanding control in line 
width and clear separation of the distinct phases (Figs. 4.8B & C) was 
accomplished in the biphasic construct using the consumer-grade printer. 
A PubMed search for prototyping publications in the past decade 
combining keyword search results from “fused deposition modeling”, “three-
dimensional printing”, and “rapid prototyping” revealed an interesting trend 
indicative of the need for easier-to-use and more versatile rapid prototyping 
instrumentation in order to achieve broader and more sustained use of this 
technology (Fig. 4.9). The number of rapid prototyping-related publications 
appeared to have plateaued by 2010 with increasing numbers of publications in 
2013. By comparison, the electrospinning technique, garnered initial attention 
from the research community almost 4 years later than rapid prototyping yet 
showed a much more rapid and sustained growth in terms of related publications 
(e.g. resulting in twice as many publications in 2013). This discrepancy in the 
number of publications may be in part due to the substantially lower investment 
(e.g. a few thousand dollars) required for an electrospinning setup than for 
  
215 
custom-designed or research-grade printing systems (e.g. could be >$100,000). 
With the popularization of consumer-grade printers in the past few years, the use 
of rapid prototyping technology for fabricating novel biomaterial scaffolds by 
research laboratories as well as biotech industries could see a renewed upward 
trend.  
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Figure 4.9. Number of PubMed citations of rapid prototyping and electrospinning 
publications since 2001. Search results based on the key words “rapid 
prototyping”, “fused deposition modeling”, and “three-dimensional printing” were 
combined for the total rapid prototyping publications in each calendar year. 
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Figure 4.9 
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5. Conclusions 
To the best of our knowledge, this study is the first to rapid prototype 
PELA or HA-PELA, a class of amphiphilic degradable biomaterials recently 
shown to exhibit exciting physical (e.g. hydrophilicity, mechanical integrity, and 
hydration-induced structural rearrangement and mechanical strengthening) and 
biological properties (e.g. osteoconductivity & up-regulated osteogenic gene 
expression),[209] into 3-D macroporous tissue engineering scaffolds. We 
describe the use of an unmodified, consumer-grade 3-D printer for the scaffold 
fabrication, facilitating the translation of this promising biomaterial to tissue 
engineering applications and promoting its wider use by the research community. 
Of note, the rapid prototyped PELA and HA-PELA composite scaffolds 
demonstrated unique swelling and mechanical properties that translated into 
hydration-induced self-fixation behavior. A customized specimen holder and a 
novel yet straightforward in vitro pull-out test was designed to quantify the self-
fixation property resulting from hydration-induced swelling and stiffening of the 
amphiphilic scaffolds. The unique self-fixation behavior is attractive for scaffold-
assisted tissue engineering applications where the ability of a scaffold to conform 
and secure itself within a tissue defect is desired for its stable implantation. We 
demonstrated differential abilities of rapid prototyped PELA and HA-PELA 
scaffolds to suppress or support the adhesion and proliferation of NIH3T3 
fibroblasts and MSCs. Furthermore, MSCs adhered to HA-PELA were able to 
undergo potent osteogenic differentiation under in vitro culture induction. These 
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cell-adhesion properties can potentially be exploited in biphasic constructs with 
spatially controlled cell adhesion. Future work will explore the rapid prototyped 
biphasic constructs for guided bone regeneration where self-fixation and discrete 
cell adhesive properties may be exploited for facile scaffold implantation/stable 
fixation and promoting bone defect repair while preventing scar tissue 
encapsulation/soft tissue collapse. 
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CHAPTER V: Shape-Memory Performance of Thermoplastic Amphiphilic 
Triblock Copolymer Poly(D,L-lactic acid-co-ethylene glycol-co-D,L-lactic 
acid) (PELA)/Hydroxyapatite Composites 
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Abstract 
Biodegradable amphiphilic polymers and polymer/HA composites are 
promising materials for skeletal tissue engineering. When such materials 
possess thermal-responsive shape memory properties, they may be delivered in 
a minimally invasive temporary shape to a tissue defect and subsequently 
triggered to conform to the defect. Here we report the shape memory properties 
of high molecular weight (120 kDa) thermoplastic amphiphilic PELA and HA-
PELA composites. The tensile and storage moduli of HA-PELA positively 
correlate with the HA content, supporting good structural integration of HA with 
PELA. Physical entanglements of the polymer chains enable their cold-
deformation and stable fixation into temporary shapes at room temperature and 
rapid recovery (< 3 s) to their original shapes at 50 ºC. Stable fixation of large 
deformations can be achieved at -20 ºC. Strain-controlled cyclic thermal 
mechanical testing reveals that while the rate of shape recovery from tensile 
deformations decreased with the higher HA content, all HA-PELA composites (up 
to 20 wt% HA) are able to achieve near complete shape recovery (>90%) upon 
10-min equilibration at 50 ºC. Finally, the permanent shapes of HA-PELA 
composites can be reprogramed at 50 ºC and rapid prototyped macroporous 
scaffolds can be fabricated with retained shape memory properties. 
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1. Introduction 
Shape memory polymers (SMPs) can be programed with a permanent 
shape, subsequently deformed into a stable temporary shape, and triggered to 
recover back to their permanent shape. In the case of thermal-responsive SMPs, 
the recovery trigger is a temperature above the transition temperature (Ttrans), 
either glass transition temperature (Tg) or melting temperature (Tm), of the 
polymer. Programming the permanent shape is accomplished by casting the 
polymer into a mold for thermoset SMPs, or by deforming the polymer at a 
temperature above the Tm for thermoplastic SMPs. For both thermoset and 
thermoplastic SMPs, deforming the polymer above the Tg may program the 
temporary shape. The net-points (physical entanglement or chemical crosslinks) 
of a SMP network are responsible for setting the SMPs permanent shape while 
temperature sensitive switching domains fix the temporary shape.[281] 
Engineering synthetic biomaterials with shape memory properties has the 
potential to enable more effective in vivo delivery of “smart” implants or tissue 
engineering scaffolds. The SMP implant could be delivered in a minimally 
invasive temporary shape to a tissue defect and subsequently thermally triggered 
to recover to its pre-programmed permanent shape precisely fitting the defect. 
In order for thermal responsive SMPs to be safely applied for biomedical 
applications, two basic requirements of the SMPs must be met: 1) 
biocompatibility, and 2) reasonably narrow Ttrans within a safe temperature range 
(<60ºC).[282,283] In a bone environment, for example, exposure to temperatures 
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above 45 ºC for one minute or short exposure to temperatures above 70 ºC 
induce necrosis.[283] Therefore, the Ttrans and rate of shape recovery are 
particularly important to reduce thermal damage to surrounding tissue. In 
addition, to facilitate clinical translation, versatile and scalable fabrication 
methods (e.g. a thermoplastic polymer would be more desired than thermoset in 
terms of the cost and ease of processing), bioactivity tailored for the specific 
application, physical properties enabling facile surgical handling (hydrophilicity, 
elasticity), and biodegradability are desired. Biodegradable SMPs have 
captivated the biomedical research community since they were exploited by 
Lendlein and Langer in 2001/2002 as resorbable self-tightening 
sutures.[284,285] A wide variety of SMPs have since been developed with 
varying mechanical properties, shape memory performance, and 
bioactivity.[281,286] We have previously shown that a degradable urethane-
crosslinked SMP with GPa-glassy state storage modulus at body temperature 
can achieve stable temporary shape fixing at room or body temperature and full 
and rapid (<3 s) permanent shape recovery at ~50 ºC.[287] This network was 
composed of polyhedral oligomeric silsesquioxane (POSS)-centered macromers 
grafted with 8 identical poly(D,L-lactic acid) (PLA) arms. However, while the 
POSS-PLA SMP is biocompatible, its degradation was shown to result in acute 
inflammation locally, which could be of a concern if it is used in large quantity in 
vivo.[48] This immune response is likely elicited by the acidic degradation 
byproducts of PLA.[235]  
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Calcium phosphates such as HA, the main mineral component in bone, 
have been blended with biodegradable polyesters to improve their bioactivity and 
buffer acidic degradation byproducts.[137,236,288,289] This HA/polymer 
composite strategy can be applied to improve the biological performance of 
biodegradable SMPs. The shape memory performance of HA-PLA composites 
has been studied extensively.[290–292] While such composites have shape 
memory behavior, they tend to exhibit slow permanent shape recovery (e.g. 100 
s) even at relatively high triggering temperatures (e.g. 70 ºC). Overall, 
biodegradable polymer/HA composites exhibiting an optimal combination of 
shape memory properties and biological performance are lacking. In our prior 
work, we blended high molecular weight (>100,000 Da) PELA amphiphilic triblock 
co-polymer with HA and electrospun the stable suspension into nano/micro 
fibrous scaffolds.[209] The HA-PELA scaffolds exhibited significantly improved 
handling characteristics (elasticity, hydrophilicity) and bioactivity (e.g. ability to 
support potent osteogenic differentiation of stem cells) than electrospun HA-PLA 
counterparts. Both the amphiphilic PELA and the incorporation of HA were critical 
for achieving the ultimate performance of the electrospun scaffolds, with the 
hydrophilic PEG block of PELA responsible for binding and dispersing the HA 
while the HA enhancing the osteoconductivity and osteoinductivity of the 
composite. The shape memory performance of PELA and its HA composites, 
however, has not been evaluated. 
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The shape memory behavior of amphiphilic polymers is a result of the 
phase separation between the hydrophilic and hydrophobic blocks.[293] By 
design, the phase exhibiting a higher thermal transition may act as the physical 
crosslinks or hard segments, while the other phase exhibiting the lower thermal 
transition could act as the switching phase or soft segments.[294] Amphiphilic 
polymer networks are often crosslinked to achieve sufficient mechanical integrity 
for shape memory and stability in aqueous solutions. For example, thiol-ene 
cross-linked PEG-PCL foams have been shown to exhibit shape memory 
properties at biologically relevant temperatures (40-50 ºC).[295] The shape 
memory performance of photo-crosslinked amphiphilic gels composed of PEG 
and PCL or PEG and PLGA have also been reported.[296,297] In general, photo-
polymerized networks are not as amenable to polymer processing approaches 
such as extrusion or rapid prototyping as thermoplastics. When the amphiphilic 
polymers are of sufficiently high molecular weight to facilitate physical 
entanglement and achieve aqueous stability, tough and flexible thermoplastics 
can be fabricated.[192,270,271,298,299] Gu & Mather reported the shape 
memory behavior of high molecular weight (Mn>200,000 Da) PCL-PEG 
thermoplastic polyurethanes.[293] Such materials can be cold-deformed to high 
strains (e.g. ~1240% strain) by a combination of elastic and plastic deformations 
at room temperature, which is above the Tg but below the Tm of both PCL and 
PEG blocks. Upon the release of the external stress, the material immediately 
recovered its elastic strain (from ~1240% loaded to 800% strain unloaded) while 
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the plastic deformations were fully recovered after 1 min at 70 ºC, a temperature 
above the Tm for both blocks. The shape memory behavior of this system was a 
result of the physical crosslinks between the high molecular weight polymer 
chains (entanglements), acting as stable net points even above the Tm, and the 
recoverable stretching and recoiling of the PCL and PEG phases.  
Here we hypothesized that a thermoplastic SMP can be generated with 
high molecular weight amphiphilic PELA and that HA can be incorporated with 
PELA while preserving shape memory properties. To test these hypotheses, we 
fabricated uniform composites of HA and PELA and examined their thermal 
mechanical properties and reprogrammable shape memory behavior around a 
physiologically relevant temperature, as a function of the HA content. To further 
assess their suitability for minimally invasive biomedical uses, the shape memory 
performance of rapid prototyped HA-PELA scaffolds was also examined.  
2. Materials and Methods 
2.1. Materials  
3,6-Dimethyl-1,4-dioxane-2,5-dione (D,L-lactide) was purchased from 
Sigma–Aldrich (St. Louis, MO), purified by recrystallization twice in anhydrous 
toluene, and dried under vacuum prior to use. PEG (BioUltra, 20,000 Dalton) was 
purchased from Fluka (Switzerland). Polycrystalline HA powder was purchased 
from Alfa Aesar (Ward Hill, MA). All other solvents and reagents were purchased 
from Sigma–Aldrich (St. Louis, MO) and used as received.  
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2.2. PELA synthesis and characterization 
2.2.1. Synthesis 
PELA tri-block copolymer was synthesized by melt ring-opening 
polymerization as previously described.[209] Briefly, PEG (20,000 Dalton, 4 g, 
0.2 mmol) was heated to 100 ºC in a Schlenk flask and stirred under vacuum for 
1 h to remove residual water. The melt was cooled to room temperature before 
Sn(II) 2-ethylhexanoate (~95%, 24.18 mg, 0.06 mmol) in anhydrous toluene was 
introduced by syringe. The toluene was removed by heating the mixture under 
vacuum at 100 ºC for 15 min. The mixture was cooled to room temperature 
before D,L-lactide (17.295 g, 0.12 mol) was added under argon purge. The melt 
polymerization proceeded at 130 ºC for 5 h under argon. The crude PELA was 
dissolved in chloroform, purified by precipitation in methanol, and dried under 
vacuum.  
2.2.2. Characterization 
The molecular weight and polydispersity of PELA was determined by gel-
permeation chromatography on a Varian Prostar HPLC system equipped with 
two 5mm PLGel MiniMIX-D columns and a PL-ELS2100 evaporative light 
scattering detector (Polymer Laboratories). THF was used as an eluent at 0.3 
ml/h at room temperature. Molecular weight and polydispersity calculations were 
calibrated with EasiVial polystyrene standards (Agilent, Santa Clara, CA). 1H 
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NMR spectra were recorded on a Varian Mercury 400 MHz spectrometer at 298 
K using CDCl3 containing tetramethylsilane as the solvent.  
2.3. PELA and HA-PELA films 
2.3.1. Fabrication 
Dense PELA and HA-PELA films were prepared by solvent casting. HA (0 
to 20% w/w relative to PELA) was bath-sonicated in 4 mL chloroform for 30 min. 
PELA (1.25 g) was added and the mixture was stirred overnight. The HA-PELA 
mixture was subsequently poured into Teflon molds. The chloroform was 
evaporated in a fume hood at room temperature overnight and subsequently in a 
vacuum oven at 60 ºC for 24 h. PELA films were prepared by evaporating a 
chloroform solution of PELA without HA in the same mold followed by vacuum 
drying under identical conditions. Films were stored at -20 ºC prior to use. 
2.3.2. Scanning electron microscopy (SEM) 
The bottom surface of the solvent-cast films and their cross-sections were 
sputter coated with Au (~4 nm thick) and imaged on a Quanta 200 FEG MKII 
scanning electron microscope (FEI Inc., Hillsboro, OR) under high vacuum at 10 
kV. 
  
230 
2.4. Mechanical testing 
2.4.1. Tensile modulus / strength 
The tensile modulus of PELA and HA-PELA films at room temperature 
was determined on a MTS Bionix 370 mechanical testing system (MTS Systems 
Corporation, Minneapolis, MN). ASTM D882-97 guidelines were followed with the 
exception of the initial grip displacement due to sample size constraints.[300] 
Specimens (5.3 mm × 35 mm × ~0.2 mm, n=3) were loaded into the MTS 
machine with an initial grip separation of 10 mm and subjected to a grip 
separation of 100 mm/min. The resulting force was recorded with a 250 N load 
cell (Interface, Scottsdale, AZ). The elastic modulus was calculated from the 
initial linear region of the stress-strain curve (1-5% strain). The initial toe region, if 
present, was excluded from the modulus calculation. 
The tensile modulus at 37 ºC was measured with a Q800 Dynamic 
Mechanical Analyzer (DMA) equipped with a gas cooling accessory (TA 
Instruments, New Castle, DE). Specimens (5.3 mm × 35 mm × ~0.2 mm) were 
loaded into a film tension fixture with a grip separation of 10 mm (n=3), 
equilibrated at 37 ºC, held isothermally 10 min, then subjected to a 1-mN pre-
load force. Tensile modulus was measured by ramping the specimens at a strain 
rate of 1 N /min. The modulus was calculated from the initial linear region of the 
stress strain curve (1-5% strain). The initial toe region, if present, was excluded 
from the modulus calculation. 
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2.4.2. Temperature-dependent storage modulus  
The tensile storage moduli of PELA and HA-PELA were measured on a 
Q800 DMA equipped with a gas cooling accessory. Specimens (5.3 mm × 35 mm 
× ~0.2 mm) were loaded into a film tension fixture and equilibrated at -40 ºC for 
10 minutes before the temperature was ramped from –40 ºC to 70 ºC at a 
heating rate of 2 ºC/min. The storage modulus was recorded at a strain amplitude 
of 0.02% and a frequency of 1 Hz.  
2.4.3. Strain-controlled cyclic thermal mechanical testing 
Shape memory characterization was performed under tension on a DMA 
Q800 equipped with a gas cooling accessory. Specimens (5.3 mm × 35 mm × 
~0.2 mm) were equilibrated at 50 ºC for 5 min and cooled to 25 ºC and 
equilibrated for another 5 min prior to testing. The specimens were subjected to a 
50% strain, and cooled at 2 ºC/min to -20 ºC while the constant strain of 50% 
was maintained. This yielded the elongated temporary shape εl. After being held 
at -20 ºC for 5 min, the force on the sample was released to 0.01N and the 
resulting strain was recorded as the unloaded temporary shape εu. Shape 
recovery was triggered by heating the specimens at a rate of 2 ºC/min to 50 ºC 
and holding at 50 ºC for 10 min. The recovered sample strain was recorded as εp. 
Each specimen was subjected to 3 consecutive cycles of testing. The second 
cycle was used to calculate the strain fixing ratio (Rf ) and the strain recovery 
ratio (Rr) reported in Table 1. The Rf and Rr in a given cycle N were determined 
by using the following formulas: 
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𝑅! 𝑁 = ℰ! ! !ℰ! !!!ℰ! ! !ℰ! !!!        (1) 
 𝑅! 𝑁 = ℰ! ! !ℰ! !ℰ! ! !ℰ! !!!        (2) 
2.4.4. Stress-controlled cyclic thermal mechanical testing 
Specimens (5.3 mm × 35 mm × ~0.2 mm) were equilibrated at 50 ºC for 5 
min and cooled to 25 ºC prior to testing. After being equilibrated at 25 ºC for 5 
min, the specimens were subjected to a 0.8 MPa tensile stress, and cooled at 2 
ºC/min to -20 ºC while the constant stress was maintained. This yielded the 
elongated temporary shape under stress εl. After being held at -20 ºC for 5 min, 
the stress was released to a 1-mN pre-load force. The resulting strain was 
recorded as the unloaded temporary shape εu. Shape recovery was triggered by 
heating the specimens at a rate of 2 ºC/min to 50 ºC and holding at 50 ºC for 5 
min. The recovered sample strain was recorded as εp. Each specimen was 
subjected to 4 consecutive cycles of testing. The Rf and Rr in a given cycle N 
were determined using formulas (1) and (2). 
2.5. Demonstration of reprogrammable shape memory 
A flat bar (5.3 mm × 35 mm × 0.2 mm) of HA-PELA (20 wt% HA) was 
deformed into a temporary spiral shape at room temperature. Shape recovery (to 
permanent flat bar) was initiated by submerging the specimen in 50 ºC deionized 
water. In order to reprogram the permanent shape into a spiral, the specimen 
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was submerged in 50 ºC deionized water and deformed into a spiral shape. The 
specimen was then allowed to cool to room temperature while the spiral shape 
was fixed. Subsequently, the specimen was deformed into a temporary flat bar 
shape at room temperature. Shape recovery (to reprogrammed permanent spiral) 
was initiated by submerging the specimen in 50 ºC deionized water. 
2.6. Demonstration of three-dimensional (3-D) rapid prototyped scaffold 
with shape memory behavior 
2.6.1. Scaffold fabrication 
A 3-D CAD model of a 16 mm × 16 mm x 2.4 mm square prism composed 
of a staggered arrangement of 0.4 mm lines was designed in 3-Matics 
(Materialise, Belgium, Fig. 6A) and converted into g-code instructions by 
MakerWare (MakerBot Industries, Brooklyn, New York). A MakerBot® 
Replicator™ 2X 3-D printer (MakerBot Industries, Brooklyn, New York) was used 
to fabricate the 3-D macroporous HA-PELA scaffolds (25 wt% HA) based on the 
CAD design, as we previously described.[225] A biopsy punch was used to core 
a 5-mm diameter specimen from the rapid prototyped prism. 
2.6.2. Shape memory demonstration 
The rapid prototyped HA-PELA scaffold was deformed at room 
temperature by manual compression into a collapsed cylinder shape. Recovery 
of the permanent expanded shape was triggered by submerging the scaffold in 
50 ºC deionized water. 
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3. Results and Discussion 
3.1. Characterization of PELA and HA-PELA composites  
GPC and NMR characterizations confirmed the synthesis of high 
molecular weight PELA (Mn = 120,000 Da; Mw = 190,000 Da; Mw/Mn = 1.56; 1H 
NMR (400 MHz, CDCl3) δ 5.19 (m, 1126H), 3.65 (m, 1816H), 1.5 (m, 3921H) 
ppm.) We blended the PELA with various concentrations of HA (0 to 20 wt%), 
and solvent cast the composites into films. The favorable interaction between the 
hydrophilic PEG domain and hydrophilic HA mineral helped maintain the stable 
and uniform HA dispersion during the solvent casting procedure.[138] This was 
evidenced by the minimal settling of HA to the bottom face of the films (Fig. 
5.1A), and the uniformly distributed HA across the thickness of the films (Fig 
5.1B) as revealed by SEM micrographs of the cross-sections.  
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Figure 5.1. Scanning electron micrographs of the bottom surface (left) and cross-
sections (right) of solvent-cast PELA films with 0-20 wt% of HA. Scale bars = 50 
µm. 
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Figure 5.1 
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We examined the mechanical properties of the PELA and HA-PELA films 
by tensile testing. We aimed to test the films to failure under tension by following 
the ASTM D882-97 guidelines for thin plastic sheeting.[300] However, all films 
were highly elastic and either could not break within the limits of the MTS testing 
machine (~1000% strain) or broke at the grips. There was no significant 
difference in the elastic modulus of the films with lower HA contents (<10 wt% 
HA), however, the elastic modulus of the 20 wt% HA composite was significantly 
higher than all other groups (Figure 5.2A). We also examined the elastic modulus 
of the films at 37 ºC to estimate their mechanical properties in vivo (Figure 5.2B). 
These films could not be strained to failure on the DMA (> 100% strain) at 37 ºC, 
and their moduli were approximately an order of magnitude lower at 37 ºC than 
those at 25 ºC. The reinforcing effect of the structurally incorporated HA on the 
elastic modulus of the amphiphilic composites persisted at 37 ºC, with the 20 
wt% HA composite exhibiting significantly higher modulus. 
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Figure 5.2. Elastic moduli (n=3) of PELA films with 0-20 wt% of HA at (A) 25 ºC 
or (B) 37 ºC. Specimens (5.3 mm × 35 mm × ~0.2 mm) were ramped at 100 
mm/min (25 ºC) on an MTS mechanical testing system or at 1 N/min (37 ºC) on a 
Q800 dynamic mechanical analyzer.  * p < 0.05 (One way ANOVA with Tukey 
post-hoc). 
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3.2. Thermal mechanical properties of PELA and HA-PELA composites 
We examined the storage moduli of PELA and HA-PELA composites as a 
function of temperature to determine the suitable temperature range for 
programming shape memory. The storage modulus of PELA was expected to 
drop around its Tg (~ 19 ºC, as we previously determined by DSC).[209] In 
agreement with the tensile strength results, the initial glassy state GPa-storage 
moduli (-40 ºC) of the HA-PELA composites increased with increasing HA 
content (Figure 5.3). The storage moduli dropped by an order of magnitude 
around 19 ºC, making it possible to deform the composites into temporary 
shapes at room temperature. This feature could allow the surgeon to deform the 
PELA or HA-PELA implant into a temporary shape desired for minimally invasive 
implantation at the surgical table without heating. Above 40 ºC, the storage 
moduli descended into an elastic state plateau, supporting the feasibility of 
triggering shape recovery at this temperature. The storage modulus at 50 ºC 
increased with the addition of HA (10 and 20 wt%), indicating that the reinforcing 
effect of HA was maintained at elevated temperatures. This reinforcement is 
likely a result of the HA particles limiting polymer chain motion.[301,302] 
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Figure 5.3. Temperature-dependent storage moduli of PELA films with 0-20 wt% 
of HA. Specimens (5.3 mm × 35 mm × ~0.2 mm) were subjected to 0.02% strain 
at a frequency of 1 Hz while temperature was ramped at 2 ºC/min on a Q800 
dynamic mechanical analyzer. 
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3.3. Shape memory performance of PELA and HA-PELA composites 
Cyclic thermal mechanical testing was used to quantitatively assess the 
shape memory properties of PELA and HA-PELA composites. Prior to testing, we 
heated the films to 50 ºC, and cooled them back to 25 ºC to remove any potential 
thermal memory. Cyclic testing was performed under both strain-controlled 
(Figure 5.4A) and stress-controlled conditions (Figure 5.4B). The strain-controlled 
testing allows for a fair comparison of the shape memory behaviors among the 
samples with varying HA compositions by subjecting them to the same tensile 
strain. All calculations of shape fixation ratios and shape recovery ratios were 
based on the second cycle of strain-controlled testing (Table 5.1). The temporary 
shape of the films was programed by deforming the specimens at 25 ºC followed 
by cooling to -20 ºC to fix the shape. Under these programing conditions, all films 
exhibited a shape fixation ratio (Rf) of >99% regardless of the HA content (Table 
5.1). Stable fixation of a substantially strained (50% stain) temporary shape could 
not be accomplished at room temperature, possibly due to the elastic recovery of 
the strained polymer chains above their Tg (~19 ºC). Shape recovery was initiated 
by heating the films to 50 ºC. While incorporation of 20% HA reduced the 
recovery ratio of PELA by ~5%, all films recovered to >90% of their initial strain 
within 10 min at 50 ºC. The incorporation of 5% and 10% HA had a negligible 
effect on the recovery ratio (~1-2%). However, HA incorporation reduced the rate 
of shape recovery as evident by the lower recovery ratio prior to the 10-min hold 
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at 50 ºC. This is likely due to the HA particles slowing the movements of the 
polymer chains, as previously observed for HA/PLA composites.[290]  
The cyclic testing under the stress-controlled mode takes into account the 
stiffening effect of the incorporated HA. The decreasing tensile strains achieved 
under the constant stress as a function of increasing HA content (Figure 5.4B) 
suggest that the polymer chain movement was restricted in the presence of HA. 
The shape fixation and recovery ratios of 20 wt% HA-PELA determined from 
strain-controlled (50% strain) and stress-controlled (~18% strain) testing were 
similar. The shape recovery ratio determined by the latter prior to and after a 5-
min hold at 50 ºC was 61.8% and 90.6%, respectively. This observation supports 
that good shape memory properties of PELA were largely retained despite the 
incorporation of HA content as high as 20%. Taken together, these cyclic thermal 
mechanical tests show that both PELA and HA-PELA films exhibited high shape 
fixation (>99%) and recovery ratios (>90%). For applications such as bone tissue 
engineering where the incorporation of osteoconductive HA is desired, up to 20 
wt% HA can be blended with PELA while maintaining the shape memory 
behavior. However, to achieve optimal shape memory properties, the 
incorporation of < 10 wt% HA should be considered. 
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Figure 5.4. Shape memory behavior determined by (A) strain-controlled and (B) 
stress-controlled cyclic thermal mechanical testing of PELA films with 0-20 wt% 
of HA. Three consecutive cycles for each specimen (5.3 mm × 35 mm × ~0.2 
mm) are shown. 
 
  

  
247 
Table 5.1. Shape memory properties of HA-PELA films with varying HA contents 
determined from strain-controlled cyclic thermal mechanical testing. 
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Table 5.1 
HA content 
(wt%) 
Shape 
fixing ratio (Rf) 
Recovery 
ratio at 50 ºC (Rr) 
(no hold) 
Recovery ratio (Rr) 
after 10 min hold at 50 ºC 
0 99.3% 85.3% 95.6% 
5 99.4% 74.2% 94.2% 
10 99.4% 75.8% 94.0% 
20 99.4% 72.4% 90.6% 
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3.4. Demonstration of reprogrammable shape memory  
The high molecular weight of PELA enables the formation of physical net-
points within the polymer network, obviating the need for chemical crosslinking 
and permitting thermoplastic shape memory properties. The permanent shape of 
thermoplastic SMPs can be reprogrammed at elevated temperatures 
(>Tm).[285,303] This is advantageous because the permanent shape can be 
programed after polymer processing/formation rather than being limited to the 
shape of the mold, as the case for thermoset SMPs. This can enable 
reuse/recycling of the SMP and fine-tuning of the shapes based on end-users’ 
requirements. We demonstrated the ability to reprogram the permanent shape of 
HA-PELA (20 wt% HA) (Figure 5.5). The HA-PELA was first solvent cast into a 
flat bar shape, which defined its initial permanent shape. Cold-deforming the film 
into a spiral and fixing at room temperature programmed the temporary shape. 
Submerging the HA-PELA in 50 ºC water triggered rapid recovery (< 3 s) back to 
the permanent flat bar shape (Figure 5.5A). To reprogram the permanent shape, 
the flat bar of HA-PELA was submerged in 50 ºC water and deformed into a 
spiral (Figure 5.5B). The reprogrammed spiral shape was fixed upon cooling to 
room temperature. A stable temporary flat bar shape was programed by simply 
un-rolling the spiral at room temperature. Submerging the flat bar in 50 ºC water 
triggered rapid recovery (<3 s) to the reprogramed permanent spiral shape. Of 
note, while we needed to cool the samples in order to maintain the strained 
temporary shape during cyclic stress-controlled testing, the spiral or flat bar 
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temporary shapes, without extensive tensile deformations, could be stably fixed 
at room temperature for over 24 h. This difference in shape fixation may be due 
to the varying amounts of plastic/elastic deformation between stretching the 
specimen under high strains vs. the spiral-wrapping. When wrapping the PELA or 
HA-PELA specimen into a spiral or unwrapping a spiral into a flat bar, the 
polymer chains were only exposed to relatively low strains, thus allowing for the 
lower energy deformations be adequately fixed at room temperature. When 
straining the samples under tension, the low content of PEG (~ 15 wt%) in PELA 
was insufficient to introduce enough crystallinity to prevent the release of stored 
energy within the polymer network and the spontaneous shape recovery at room 
temperature. In previously reported PCL-PEG composites, the semi-crystalline 
PCL combined with the higher content of crystalline PEG (>30 wt%) was 
sufficient to prevent complete elastic recovery at room temperature.[293]  
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Figure 5.5. Reprogrammable shape memory of HA-PELA films (20 wt% HA). (A) 
Cold-deformation and fixation into a temporary spiral at room temperature (r.t.) 
and rapid shape recovery to permanent flat bar shape (as cast) at 50 °C. (B) 
Reprogramming the flat bar into a permanent spiral shape at 50 °C, cold-
deformation and fixation into a temporary flat bar at r.t., and subsequent rapid 
recovery back to reprogrammed permanent spiral.  
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Figure 5.5 
 
  
  
253 
3.5. Shape memory rapid-prototyped macroporous HA-PELA scaffolds 
Taking advantage of the thermoplastic nature of HA-PELA, we also 
prepared 3-D macroporous scaffolds by rapid prototyping. Tissue engineering 
scaffolds composed of a biodegradable SMP, delivered in a minimally invasive 
fashion to the defect site, could potentially minimize surgical morbidity.  Here we 
show that the shape memory properties observed with the dense HA-PELA film 
are retained with the rapid prototyped 3-D scaffold (Figure 5.6). The 
macroporous HA-PELA cylindrical scaffolds were readily manually deformed into 
a compressed cylindrical shape at room temperature, and could rapidly (~ 3 s) 
recover to their original shape at 50 ºC. Techniques such as solvent-
casting/particulate leaching,[295,304] thermal induced phase separation,[305]  
and gas foaming[306] have been used to fabricate macroporous shape memory 
materials for tissue engineering applications. Compared to these techniques, 
rapid prototyping offers more precise control over pore size, pore 
interconnectivity, and scaffold shape. To our knowledge, this is the first report of 
a rapid prototyped biodegradable polymer-mineral composite scaffold exhibiting 
thermal responsive shape memory behavior.   
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Figure 5.6. Shape memory properties of a rapid prototyped macroporous 
cylindrical HA-PELA (25 wt% HA) scaffold. (A) CAD image (left) and 
stereomicroscopy image (right) of the rapid prototyped HA-PELA scaffold. (B) 
Cold-pressing and fixation of the HA-PELA scaffold into a collapsed disc at room 
temperature. (C) Rapid shape recovery of the collapsed disc into the original 
cylindrical shape in a 50 °C water bath. Scale bars = 3 mm. 
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Figure 5.6 
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4. Conclusions 
We demonstrated the shape memory behavior of uncross-linked 
amphiphilic biodegradable thermoplastic polymer PELA and HA-PELA 
composites around physiologically relevant temperatures. Both PELA and HA-
PELA composites were highly elastic and could be readily deformed at room 
temperature. Temporary shapes with small strain deformations could be stably 
fixed at room temperature while extensive tensile deformations required lower 
temperatures to fix. Both PELA and HA-PELA were able to rapidly recover their 
permanent shapes at a safe triggering temperature of 50 ºC, around the Tm of the 
PEG component. Furthermore, the permanent shape of these thermoplastic 
materials could be readily reprogrammed at 50 ºC, owing to the physical 
crosslinks within the high molecular weight PELA network. We demonstrated that 
the incorporation of HA (up to 10 wt% HA) had a minimal impact on the shape 
memory performance of PELA (e.g. no change in the nearly quantitative shape 
fixing ration; a slight decrease in recovery ratio from 95.6% to 94.0-94.2%). 
Higher HA content (20 wt%) increased the tensile modulus of the composites 
while preserving good shape memory properties (99.4% shape fixation, 90.6% 
shape recovery). Finally, we showed that the attractive shape memory behavior 
of HA-PELA was retained with macroporous scaffolds fabricated by rapid 
prototyping. The shape memory properties demonstrated with the HA-PELA 
composites, combined with their previously established osteoconductivity and 
osteoinductivity, make them uniquely suited for guided skeletal tissue 
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regeneration where the safe delivery and precise fitting of the scaffold within a 
complex defect is desired.  
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CHAPTER V: DISCUSSION AND PERSPECTIVES 
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1. Summary of thesis work 
The design of the biomaterial described in this thesis was guided by three 
basic objectives: 1) dispersion and binding of HA with hydrophilic polymer blocks, 
2) biodegradation, 3) sufficient molecular weight and hydrophobic block length for 
uncross-linked aqueous stability and thermoplastic polymer processing. 
Importantly, in order to increase the likelihood of clinical translation, the 
biomaterial should be as simple and easy to produce as possible and be 
composed of materials that have been previously used in FDA-approved devices. 
In fulfilling these objectives, HA-PELA-based bone tissue engineering scaffolds 
highlight how the rational selection of biocompatible building blocks with 
synergistic interactions can result in smart (i.e. self-fitting / shape memory, 
guiding stem cell differentiation) tissue engineering scaffolds bearing a 
combination of unique handling properties and robust biological performance.  
Chapters II and III described the in vitro and in vivo performance of 
electrospun HA-PELA scaffolds, respectively. Electrospinning was chosen as the 
scaffold fabrication strategy because it produces materials with ECM-mimetic 
microstructures and high surface areas for growth factor binding/release. The 
thin electrospun membranes can be used for guided bone regeneration,[175,307] 
to wrap around bone defects as synthetic periosteum,[308] or spiral-wrapped to 
fill long bone defects as described in this thesis. Unlike HA-PLA, the favorable 
dispersion of HA in PELA enabled the fabrication of HA-PELA scaffolds with 
uniform morphologies and HA content. The improved adhesion and dispersion of 
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HA with PELA and the amphiphilic nature of PELA resulted in improved handling 
properties (hydrophilicity, elasticity, aqueous stability) and bioactivity (more 
potent MSC differentiation) of HA-PELA compared to HA-PLA. While calcium 
phosphate bearing materials are known to guide the osteogenic differentiation of 
MSCs [126], the osteogenic gene induction from cells cultured on HA-PELA is 
markedly more robust than from other HA-containing synthetic biomaterials. For 
example, little or no differences in RUNX2 or osteocalcin mRNA expression were 
observed when adding calcium-deficient HA to electrospun PLLA scaffolds.[131] 
Similarly, little change in gene expression was observed when culturing human 
embryonic stem cell-derived MSCs on PLLA/PLGA scaffolds with varying HA 
contents.[309] HA-PELA’s combination of enhanced bioactivity and handling 
properties is unmatched by other synthetic bone scaffold materials. 
Indeed, the unique characteristics of HA-PELA translated into the ability of 
HA-PELA to serve as an effective scaffold for guiding bone regeneration in vivo. 
The elasticity of HA-PELA enabled it to be wrapped into spirals and stably press-
fit into 5-mm critical size femoral defects in rats. The hydrophilicity of HA-PELA 
facilitated seeding of the electrospun scaffolds with MSCs or rhBMP-2 prior to 
implantation. The bioactivity of HA-PELA resulted in templated bone formation by 
MSCs along the bone defects and robust bone formation with a single low dose 
of rhBMP-2. There was a mild foreign body reaction to the degrading scaffolds at 
12 weeks post-op but no evidence of systemic side effects or allergic reactions to 
the scaffold. Incomplete bridging of the defects by the MSC loaded scaffolds may 
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have been a result of the relatively low cell viability after implantation, as 
evidenced by tracking GFP-labeled MSCs. Taken together, chapters II and III of 
this thesis work demonstrate that electrospun HA-PELA is a promising scaffold 
for bone tissue engineering applications. 
While electrospun scaffolds have distinct advantages, as previously 
described, they also suffer from dimensional constraints and limited 
macroporosity that impeded more timely restoration of the mechanical integrity of 
the long bone defect. Therefore, chapter IV described an alternative scaffold 
fabrication strategy, the rapid prototyping of PELA and HA-PELA into 3-D 
macroporous scaffolds. A method was developed to generate filaments of PELA 
and HA-PELA and fabricate 3-D scaffolds by FDM using a consumer-grade 3-D 
printer (MakerBot® Replicator2XTM). The printing conditions were optimized such 
that uniform scaffolds with line widths matching the CAD model were generated. 
Both PELA and HA-PELA scaffolds swelled and stiffened in water, with greater 
swelling and compressive modulus for HA-PELA. Other amphiphilic polymers 
including PEG/PBT swell in water, a property that has been shown to improve 
bone apposition and bone ingrowth in vivo.[310] Hydration-induced modulus 
increases have been observed in a few amphiphilic non-degradable networks 
[189], and while PEG-PLA copolymers have been studied for decades, this 
hydration-induced stiffening behavior has only been observed for the molecular 
weight and composition of PELA designed in this dissertation. One reason that 
this novel PELA behavior has not been discovered until now is that most studies 
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used low molecular weight (<100 kDa) copolymers that do not have sufficient 
molecular entanglements and PLA weight ratios to stiffen upon hydration. This 
combination of swelling and increased modulus in a biodegradable amphiphilic 
polymer has not been previously reported. 
The unique hydration-induced physical changes in 3-D HA-PELA were 
exploited for hydration-induced self-fixation, whereby the scaffolds could swell, 
stiffen and secure themselves in a simulated confined defect. This novel self-
fixation behavior coupled with the compressibility of HA-PELA could facilitate its 
secure fitting in bone defects. The addition of HA effectively offset the low-fouling 
property of the PEG component and facilitated the attachment of fibroblasts or 
MSCs. Biphasic PELA/HA-PELA scaffolds were successfully prepared by rapid 
prototyping for potential applications where differential cell attachment is 
required, such as for preventing fibrous tissue ingrowth in guided bone 
regeneration. The PELA surface is designed to prevent fibroblast attachment and 
oppose soft tissue collapse, while the HA-PELA face exposed towards the bone 
space could support the adhesion and osteogenic differentiation of progenitor 
cells. Chapter IV of this thesis exemplifies how a simple and translatable polymer 
design can yield smart (self-securing / tailored cell attachment) tissue 
engineering scaffolds. Furthermore, the ability to rapid prototype PELA and HA-
PELA on an unmodified consumer-grade printer enables the translation of this 
approach to the greater research community.  
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Chapter V examined the thermal responsive shape memory properties of 
PELA and HA-PELA. Shape memory scaffolds could be delivered in a minimally 
invasive (e.g. collapsed) temporary shape to the defect and then be triggered to 
recover to a preprogrammed permanent shape under a safe thermal trigger. 
However, SMPs are often thermoset materials that cannot be readily fabricated 
into porous scaffolds and/or are hydrophobic polyesters that have limited 
bioactivity and mix poorly with HA. Themoplastic SMPs can be molded into 
diverse architectures above their transition temperature, enabling reprograming 
of their permanent shape if needed. In a clinical setting, this could allow the 
surgeon to fine-tune the permanent shape prior to implantation. Due to the high 
molecular weight of PELA (>100,000 Da), physical entanglements in the polymer 
network act as net-points for the SMP. The addition of up to 10 wt.% HA had no 
impact on the shape memory efficiency of PELA, whereas the incorporation of 20 
wt.% HA slowed the shape recovery rate, likely due to the HA particles restricting 
the movement of the polymer chains during recovery. The shape memory 
properties of HA-PELA were retained in rapid-prototyped macroporous 3-D 
scaffolds. Overall, chapter V demonstrates how the unique shape memory 
behavior of HA-PELA can be employed for potential minimally invasive delivery 
and stable fixation of the “smart” HA-PELA scaffolds for tissue engineering 
applications.  
A search on PubMed for the term “bone tissue engineering” yields over 
20,000 results but only ~8 bone biomaterials are in clinical use. This dichotomy is 
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due in part to either the failure to consider the multiple requirements for 
successful clinical translation and/or the overly complex and expensive 
biomaterials designs that are impractical for commercialization.[25] This thesis 
work changes the state of the field of bone tissue engineering by demonstrating 
how simple and scalable biomaterials can be engineered with smart delivery 
modalities and robust biological performance. Incorporating simplicity as a key 
element of biomaterial design has the potential to catalyze the translation of 
biomaterials from the bench to the bedside. 
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2. Future directions 
2.2.1 Limitations of HA-PELA 
The design and characterization of HA-PELA presented in this dissertation 
provides a framework for the design of high-performance bone tissue 
engineering biomaterials by using amphiphilic degradable polymers. However, 
there are a number of limitations to the current design of HA-PELA that should be 
acknowledged and overcome in future work.  
Structural bone grafts are intended to provide mechanical support 
immediately following implantation. Typically composed of allogenic bone, they 
are indicated for large load-bearing defects or to supplement bone for revision 
total hip arthroplasty procedures.[311–313] HA-PELA’s low elastic modulus 
(~200 kPa for HA-PELA versus ~17 GPa for human cortical bone [314]) makes it 
unsuitable for use as a weight-bearing structural bone grafting material. 
Therefore, HA-PELA alone would be indicated as a non-structural graft for 
maxillofacial or cranial sites. Alternatively, electrospun HA-PELA scaffolds pre-
seeded with cells or growth factors could be used as a synthetic periosteum to 
wrap around structural allografts and improve their osteointegration. 
PELA alone is relatively low-fouling and supports limited cell adhesion due 
to the presence of PEG. Whereas the addition of HA significantly increased cell 
adhesion onto PELA, cell adhesion could be further improved to facilitate the 
delivery of high densities of cells. This could be accomplished by strategies such 
as increasing the weight percentage of HA, decreasing the weight percentage or 
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molecular weight of PEG in PELA, or coating the scaffolds will cell-adhesive 
polydopamine [315]. 
Finally, while HA-PELA was designed as a biodegradable scaffold, the 
current degradation rate of HA-PELA (~ 1yr for complete degradation) is slower 
than the rate of normal new bone formation (3-4 months for healing [121]). 
Replacing the PLA block in PELA with PLGA could accelerate the scaffold 
degradation rate. By varying the ratio of the lactide and glycolide blocks, the 
degradation rate of PLGA can be varied from 1-4 months.[44] Incorporating PEG 
can further tune the degradation rate of PLGA.[316] An additional concern is the 
acidic pH surrounding degrading PLA implants which leads to secondary immune 
responses and potential bone resorption.[48] Indeed, immune cell infiltration was 
visible in the degrading electrospun HA-PELA scaffolds at 12 weeks post-op. 
This secondary immune response could potentially be mitigated by buffering the 
acidic degradation products with faster dissolving calcium phosphates such as 
tricalcium phosphate.[236] 
2.2.2 Electrospun HA-PELA 
The spiral-wrapped electrospun scaffold approach described in Chapter III 
is a promising strategy for healing long bone defects, however, functional 
restoration of the bone defect was not achieved by 12 weeks. In future studies, 
the spiral-wrapped scaffolds could be modified with macropores to increase bone 
fusion between layers, similar to a design used by Jiang et al.[93] Alternatively, 
the incorporation of sacrificial PEG fibers could increase the porosity of the 
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electrospun scaffolds. Another strategy to increase bone bridging could be to 
electrospin HA-PELA into aligned fibers that are oriented with the femoral defect. 
Lee et al. found that aligned fibers resulted in greater bone formation in mouse 
calvarial defects than randomly oriented fibers.[315] Regardless of scaffold 
design, future work should also explore how healing progresses at later time 
points, once the scaffolds are fully degraded. A recent in vitro degradation study 
(PBS @ 37 ºC) of HA-PELA found a 30% mass loss at 24 weeks and ~96% at 46 
weeks. Therefore, a one-year time point is appropriate for assessing the long-
term responses to HA-PELA degradation in vivo. 
By design, the spiral-wrapped HA-PELA scaffolds are readily amenable to 
testing combinations of growth factors and/or cells. One approach for improving 
bone healing is to increase angiogenesis in the defect by adding exogenous 
endothelial cells or pro-angiongeic growth factors. Bone is highly vascularized, 
with the blood flow supplying nutrients to the osteoblasts, osteocytes, and 
osteoclasts critical for bone maintenance and remodeling.[317] For a cell-based 
strategy to accelerate defect bridging, endothelial cells could be seeded with 
rMSCs or combined with rhBMP-2 in the spiral-wrapped HA-PELA scaffolds. Co-
cultures of endothelial cells and MSCs have been shown to induce enhanced 
osteogenesis in vitro than MSCs alone.[318] In vivo, incorporating endothelial 
progenitor cells has been shown to increase early vascularization and bone 
formation in critical-size rat femoral defects.[319]  
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The addition of growth factor combinations or other therapeutics to HA-
PELA could further accelerate bone healing. Patel et al. showed that the delivery 
of rhBMP-2 combined with vascular endothelial growth factor (VEGF) may 
accelerate bone defect bridging.[320] However, there was no difference in bone 
formation between the BMP-2 and BMP-2+VEGF groups at 12 weeks post-op. 
One potential reason for a limited beneficial effect at later stages is that VEGF 
promotes early vessel formation but may inhibit vessel maturation and 
stabilization.[317,321] Sphingosine 1-phosphate (S1P) is a phospholipid that has 
been shown to promote both the early and late stages of blood vessel 
formation,[322] and enhance healing in models of diabetes[323] and ischemic 
limb injury.[324] Our group recently used electrospun membranes of PELA and 
alkylated PELA block copolymers to improve the controlled release of S1P.[322] 
We found that unmodified PELA and PELA modified with 14-carbon bearing 
lactide units resulted in sustained release of bioactive S1P over 7 days. Based 
on the release characteristics of S1P from amphiphilic polymers such as PELA, 
future work will explore the synergistic effects of S1P and rhBMP-2 delivery from 
spiral-wrapped HA-PELA for healing critical size femoral defects in rats. Other 
potential additives to HA-PELA include bone anabolic factors such as 
prostaglandin E2. Prostaglandin E2 has been shown to stimulate bone formation 
and increase overall bone mass in both adolescent and aged rats.[325] However, 
the sustained release of Prostaglandin E2 from bone tissue engineering scaffolds 
has not yet been explored. 
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2.2.3 Rapid prototyped PELA/HA-PELA 
The promising preliminary results shown in Appendix I demonstrate the 
feasibility of healing mandibular defects with rapid prototyped HA-PELA and 
rhBMP-2, but warrant further study with an increased sample size to enable 
quantitative conclusions. It would be beneficial to monitor the healing at longer 
time points, for example 6 and 12 months, when the scaffold is expected to 
degrade. If 25 wt.% HA is insufficient to buffer the acidic degradation byproducts 
of PLA, there may be some inflammation and/or bone resorption at these later 
time points. If polymer degradation does result in poorer healing outcomes, future 
work should be to minimize the amount of foreign material required to provide a 
sufficient template for bone ingrowth. This may be accomplished through 
optimization of the HA-PELA scaffold morphology using CAD by adjusting the 
line spacing of the scaffolds. For example, Figure 6.1 shows CAD models of rat 
femoral defect sized (5 mm height, 3 mm diameter) scaffolds with increasing line 
spacing which correlates to increasing porosity and decreasing the mass of 
polymer. Further optimization of the scaffold morphology could be to explore 
different line arrangements, such as a staggered design, as shown in Figure 6.1, 
versus a straight-line arrangement. 
While the FDM line size and spacing of 3-D HA-PELA scaffolds closely 
matches the CAD design, the dimensional accuracy and reproducibility of FDM 
fabricated HA-PELA implants based on patient-specific CT data will need to be 
validated. Rapid prototyped bone implants based on patient-specific CT data 
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have been FDA approved (i.e. OsteoFabTM by Oxford Performance Materials). 
Therefore, the resolution of CT scanning and reconstruction is sufficient for the 
fabrication of custom bone grafts. However, the OsteoFabTM implants are 
fabricated by the selective laser sintering of a non-degradable polymer. This 
fabrication process is very different from the 3-D HA-PELA process. FDM 
fabricated degradable bone implants have not yet been approved for clinical use. 
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Figure 6.1. CAD models of rat femoral defect sized scaffolds with increasing line 
spacing. 
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Figure 6.1 
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3. Concluding remarks 
The hype surrounding tissue engineering has waxed and waned since the 
“Vacanti mouse” with an ear-shape tissue grown on its’ back garnered 
widespread media attention in 1997.[40] Cell sourcing, vascularization/nutrient 
transport, immune response, and scaffold degradation are just a few of the 
issues that need to be resolved to fully realize the promise of regenerating 
complex tissues and organs. Furthermore, while some tissue engineered 
products have entered clinical use (Carticel®, Apligraf®, Dermagraft®), the 
regulatory approval process and business constraints for such cell-based or cell-
biomaterial combination therapies remain as significant hurdles.[118,326] The 
tissue engineering research in our laboratory has taken two paths: (1) the 
synthesis of novel biomaterials with unique functionalities to enable the design of 
next generation of tissue engineering scaffolds, (2) the strategic combination of 
building blocks previously used in FDA-approved devices with synergistic 
interactions to facilitate clinical translation. Both approaches will lead to better 
outcomes for patients; however, the second approach uses clinical translation as 
an essential design component and has the potential to make a more rapid 
impact. Designing biomaterials / tissue engineered therapies with translation in 
mind is important to realize the hope of tissue engineering. 
The body of work presented in this thesis exemplifies how this strategic 
integration of simple components can produce smart tissue engineering 
scaffolds. Electrospun and rapid prototyped HA-PELA scaffolds are simple to 
  
274 
produce in large quantities, available off-the-shelf, easy to use (hydrophilic, 
moldable/press-fit), feature unique delivery modalities (self-fitting / shape-
memory), and are bioactive. PLA, PEG, and HA are all used in FDA-approved 
implants, resulting in a potential 510(k) FDA-approval pathway for HA-PELA. 
This reduces the approximate cost of approval to $1-50 million and 3-6 years, 
versus $45-150 million and 5-8 years for a premarket approval (PMA) 
pathway.[118] The incorporation of exogenous cells or growth factors into HA-
PELA would likely require PMA or regulation of it as a combination product and 
extend the approval time and cost. The clinical niche for HA-PELA, whether 
guided bone regeneration, cranio-maxillofacial bone grafting, synthetic 
periosteum, or other, should be worked out based on scientific evidence and 
clinical need/market analysis. Future studies should involve further collaboration 
with clinicians to define the clinical niche and validate the performance of HA-
PELA in a large animal model.  
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APPENDIX I: Ongoing work with 3-D HA-PELA scaffolds 
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This thesis work describes the development and characterization of HA-
PELA-based bone tissue engineering scaffolds, however, significant work 
remains to achieve the ultimate goal of translating these smart materials to the 
clinic. Ongoing work includes improving the cell seeding efficiency on 3-D 
macroporous HA-PELA scaffolds and testing the performance of 3-D 
macroporous HA-PELA scaffolds in augmenting the repair of critical-size 
mandibular defects in vivo.  
1.1 Optimizing cell seeding into rapid prototyped macroporous scaffolds 
Chapter IV describes how 3-D HA-PELA scaffolds support the attachment 
and differentiation of MSCs. However, the large pore size of rapid prototyped 
scaffolds (~400 µm) compared to the size of a cell (~10-20 µm) results in sub-
optimal entrapment of seeded cells within the scaffold. Therefore, cell seeding 
techniques, cell densities, and media volumes needed to be optimized in order to 
achieve optimal cell attachment and proliferation. Prior studies have explored the 
use of agarose treated plates,[1] dynamic culture,[1] cell sheets,[2] or fibrin 
glues[3,4] to improve seeding efficiency. We are currently developing a simple 
and reproducible protocol to improve seeding efficiency of rMSCs onto rapid 
prototyped macroporous scaffolds. We compared the efficiency of a direct 
seeding technique to that facilitated by fibrin glue by measuring cell viability 
(CCK-8), DNA content, and staining to visualize cell distribution (MTT) (Fig. 1).  
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Figure 1. Experimental scheme for optimizing cell seeding onto HA-PELA 
scaffolds. 
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Figure 1 
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We previously showed by the CCK-8 cell viability assay that seeding cells 
on the macroporous scaffolds in pHEMA-coated low-attachment plates vs. in 
standard tissue culture polystyrene (TCPS) followed by immediate transfer of the 
cell-seeded scaffold to a new TCPS well results in no difference in cell seeding 
efficiency. Furthermore, allowing the cells to attach for varying period of time (1-3 
h) prior to submerging in culture medium results in no difference in cell seeding 
efficiency (Fig. 2). We also found that increasing the cell suspension 
concentration from 2 X 106 cells/mL to 6 X 106 cells/mL in a 30-µL volume 
improved the viability of the adherent cells on the macroporous scaffold, while 
further increasing the cell suspension concentration to 12 X 106 cells/mL did not 
provide further benefit. Thus, for all subsequent cell seeding experiments, 
pHEMA-coated low-attachment plates were used and 30 µL of 6 X 106 cells/mL 
cell suspension and 1 h seeding time prior to the addition of culture medium were 
applied.  
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Figure 2. Optimizing direct seeding of a cell suspension onto HA-PELA. 
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Figure 2 
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Our choice of fibrin as an auxiliary vehicle to improve cell seeding 
efficiency on HA-PELA scaffolds is inspired by the unique biological function of 
fibrin. During blood clotting, the serine protease thrombin cleaves soluble 
fibrinogen that polymerizes into a fibrin clot. This fibrin clot provides a scaffold for 
the initial stages of wound healing.[5] Fibrin glues are clinically used as 
hemostatic agents and tissue sealants. The intrinsic biocompatibility and cell-
adhesiveness of fibrin has also led to applications as cell-delivery vehicles [6] 
and tissue engineering scaffolds.[7,8] Fibrin glues have also been widely used to 
improve the cell seeding efficiency and retention in synthetic polymer-based 
scaffolds.[4,9–11] We hypothesize that fibrin could also improve cell seeding 
efficiency on 3-D HA-PELA scaffolds. We compared the fibrin gel integrity when 
polymerizing 2 mg/mL to 10 mg/mL fibrinogen, in cell culture medium, with 0.83 
U/mL thrombin in cell culture medium. Based on a tube inversion test, the 2 
mg/mL fibrinogen solution did not form a solid gel even after 3 h at 37 ºC but the 
5 mg/mL and 10 mg/mL fibrinogen gelled rapidly (<2 min). Therefore, the 5 
mg/mL fibrinogen concentration was chosen for cell seeding experiments. When 
comparing directly seeding cells in medium to seeding the cells in fibrin, the latter 
resulted in a significantly higher cell viability (CCK-8) and DNA content after 24 h 
(Fig. 3 A & B). These results were confirmed by visualizing viable cells with MTT 
reagent (Fig. 3 C).  
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Figure 3. Comparing (A) cell viability, (B) DNA content, and (C) MTT staining of 
cells seeded directly or with a fibrin gel. 
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Figure 3 
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An alternative strategy being explored is to use bio-orthogonally cross-
linked fast-degrading synthetic hydrogels to improve the cell seeding efficiency. A 
PEG-based hydrogel platform developed in our laboratory can be cross-linked 
without the use of toxic initiators or UV light and has highly tunable and 
predictable degradation rates ensuring its timely disintegration.[12] We are 
comparing the efficacy of fibrin to these synthetic gels in enabling more effective 
cell seeding on macroporous scaffolds and their temporal effect on cellular 
behavior as they degrade. 
1.2 Healing rat mandibular defects with 3-D HA-PELA 
Cranio-maxillofacial sites are the most frequent sites of bone grafting due 
to tumor metastasis and subsequent tumor resection as well as developmental 
defects such as cleft palate [13] or trauma.[14] The difficulty of shaping and 
securing autografts and allografts into the often-complex cranio-maxillofacial 
defect geometries results in a significant clinical need for custom rapid 
prototyped or easily moldable synthetic bone grafts.[15–18] The ability to rapid 
prototype self-fitting shape memory HA-PELA scaffolds may make them uniquely 
suited for such cranio-maxillofacial grafting procedures.  
The bones of the skull and mandible are formed through an 
intramembranous ossification process, as opposed to endochondral ossification 
for long bones, and may have a different healing capacity from long bones.[19] 
Therefore, the femoral defect model described in this dissertation may be 
inappropriate for testing bone-grafting materials for cranio-maxillofacial 
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applications. A critical-size mandibular defect in rats was chosen as the in vivo 
model to test the efficacy of the 3-D rapid-prototyped macroporous HA-PELA 
scaffolds. Mandibular defects in rats have been used by other groups to test the 
healing potential of membranes and porous scaffolds with or without pre-loaded 
progenitor cells or therapeutics.[20–28] This defect model involves creating a 5-
mm diameter through-and-through defect in the mandibular ramus using a 
trephine burr. Mandibular defects of this size do not heal without intervention and 
are typically filled with soft fibrous scar tissue. The critical-size mandibular defect 
model in rats can reasonably emulate relevant cranio-maxillofacial defects 
encountered clinically. 
In a pilot study, 3-D HA-PELA scaffolds (5 mm diameter, 1.6 mm thick), 
with or without pre-loaded 1 µg of rhBMP-2 or 100 ng of rhBMP-2/7, were 
implanted into 5-mm mandibular defects in male rats (~350 g weight) and 
monitored for up to 12 weeks by µ-CT. Bone ingrowth was compared to an empty 
defect control. End point histology was performed to further assess bone 
formation and immune response. An overview of the study procedure is shown in 
Figure 4. 
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Figure 4. Testing 3-D HA-PELA scaffolds in rat mandibular defects. (A) Study 
overview. (B) Surgical procedure. 
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Figure 4
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µ-CT results show that the empty control was not filled with new bone by 
12 weeks, confirming the critical size nature of the 5-mm mandibular defect (Fig. 
5A). Defects treated with HA-PELA alone and HA-PELA + 100-ng rhBMP-2/7 
resulted in some bone ingrowth, primarily in the periphery of the defects, but was 
not completely filled by 12 weeks (Fig. 5A). rhBMP-2/7 has been shown to be 
more potent (up to 10-fold) than rhBMP-2 in terms of in vitro osteoinductivity.[29] 
rhBMP-2/7 may contribute to both the early and later stages of bone healing and 
has been successfully used by our lab to heal 5-mm rat femoral segmental 
defects in combination with HA-pHEMA in 400-ng loading dose. [30] Here, the 
limited healing observed with 100 ng of rhBMP-2/7 could be due to differences in 
healing between the mandibular defects and the femoral defects or due to 
inadequate loading dose of the protein. Defects treated with HA-PELA + 1-µg 
rhBMP-2 where filled with bone by 12 weeks (Fig. 5A). Quantitative µ-CT 
analysis confirmed this result, with higher bone volume in the rhBMP-2 treated 
group than HA-PELA alone or HA-PELA + rhBMP-2/7 (Fig. 5B). There appeared 
to be no difference in bone density between groups, although the sample size is 
insufficient to draw statistical conclusions. This pilot study suggests that 3-D HA-
PELA with 1 µg of rhBMP-2 may be sufficient to heal critical size mandibular 
defects in rats. By comparison, Kowalczewski et al. used 5 µg of rhBMP-2 in 
combination with a keratin-based scaffold to heal similar mandibular defects.[31] 
Similarly, DeConde et al. used rhBMP-2 doses ranging from 0.5 µg to 15 µg in a 
PLGA-based scaffold and found 5 µg rhBMP-2 resulted in the highest percentage 
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(~70%) of defect fill, albeit in a different defect geometry (5 mm x 5 mm marginal 
defect).[32] Our preliminary healing results with a lower dose of rhBMP-2 provide 
further validation of the efficacy of HA-PELA in healing bone defects.   
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Figure 5. µ-CT analysis of HA-PELA treated mandibular defects. (A) 3-D 
reconstructions. (B) Quantitative analysis of bone volume and bone mineral 
density. 
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Figure 5 
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Histology shows bone ingrowth from the defect margins into the HA-PELA 
scaffolds. Robust and mature bone ingrowth was observed throughout the 
scaffold in the rhBMP-2 group (Fig. 6) as evidenced by the H&E staining showing 
dense and recanalized bone with strong birefringence under polarized light. Less 
mature bone formation was seen in the HA-PELA alone and the rhBMP-2/7 
groups, but immature bone ingrowth could still be detected in the scaffold pores. 
Purple toluidine blue staining at areas of new bone formation indicates an 
endochondral ossification mechanism. Positive staining for alkaline phosphatase 
and tartrate resistant acid phosphate (TRAP) at the interface of new bone and 
HA-PELA scaffold indicates active bone remodeling and scaffold resorption. 
Minimal immune cell infiltration could be detected by H&E for all treatment 
groups, indicating minimal adverse local immune response to the HA-PELA 
scaffold or its degradation byproducts at 12 weeks. Overall, histology confirms 
the osteoconductivity and biocompatibility of 3-D HA-PELA scaffolds.  
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Figure 6. Histology of mandibular defects treated with 3-D HA-PELA scaffolds 
alone or loaded with rhBMP-2/7 or rhBMP-2. Bright field and polarized light (PL) 
micrographs of hematoxlyn & eosin (H&E), toluidine blue (Tol Blue), and Alkaline 
Phosphatase (ALP) / tartrate-resistant acid phosphatase (TRAP) stained 
sections. S = scaffold; NB = new bone; BM = bone marrow. Scale bars = 500 µm 
 
  
  
346 
Figure 6 
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APPENDIX II: Stem cell labeling using polyethylenimine conjugated (α-
NaYbF4:Tm3+)/CaF2 upconversion nanoparticles 
 
This appendix has been adapted from: 
Zhao L*, Kutikov A*, Shen J, Duan C, Song J, Han G. “Stem Cell Labeling using 
Polyethylenimine Conjugated (α-NaYbF4:Tm3+)/CaF2 Upconversion 
Nanoparticles” Theranostics 2013; 3(4):249-257. (*Equal contribution) 
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Preface 
Tracking the fate of delivered cells is important for determining the 
mechanisms of cell-guided tissue repair and improving tissue engineering 
therapies. While GFP-labeling was used in this dissertation to track the MSCs, 
this approach has distinct disadvantages. These include strong tissue auto-
fluorescence, down regulation of GFP expression, and poor tissue penetration 
requiring ex vivo imaging. This appendix describes some of our work on 
developing improved labeling approaches for MSCs, in collaboration with the 
laboratory of Dr. Gang Han.  
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Abstract 
We report on a polyethylenimine (PEI) covalently conjugated (α-
NaYbF4:Tm3+)/CaF2 upconversion nanoparticle (PEI-UCNP) and its use for 
labeling rat mesenchymal stem cells (rMSCs). The PEI-UCNPs absorb and emit 
near-infrared light, allowing for improved in vivo imaging depth over conventional 
probes. We found that such covalent surface conjugation by PEI results in a 
much more stable PEI-UCNP suspension in PBS compared to conventional 
electrostatic layer by layer (LbL) self-assembling coating approach. We 
systematically examined the effects of nanoparticle dose and exposure duration 
on rat mesenchymal stem cell (rMSC) cytotoxicity. The exocytosis of PEI-UCNPs 
from labeled rMSCs and the impact of PEI-UCNP uptake on rMSC differentiation 
was also investigated. Our data show that incubation of 100-µg/mL PEI-UCNPs 
with rMSCs for 4 h led to efficient labeling of the MSCs, and such a level of PEI-
UCNP exposure imposed little cytotoxicity to rMSCs (95% viability). However, 
extended incubation of PEI-UCNPs at the 100 µg/mL dose for 24 hour resulted in 
some cytotoxicity to rMSCs (60% viability). PEI-UCNP labeled rMSCs also 
exhibited normal early proliferation, and the internalized PEI-UCNPs did not leak 
out to cause unintended labeling of adjacent cells during a 14-day transwell 
culture experiment. Finally, PEI-UCNP labeled rMSCs were able to undergo 
osteogenic and adipogenic differentiation upon in vitro induction, although the 
osteogenesis of labeled rMSCs appeared to be less potent than that of the 
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unlabeled rMSCs.  Taken together, PEI-UCNPs are promising agents for stem 
cell labeling and tracking. 
1. Introduction 
Mesenchymal stem cells (MSCs) are multipotent cells that can 
differentiate into a number cell types. This technology holds great promise in a 
variety of life-threatening disease treatments such as diabetes,1 cardiovascular 
disease,2 spinal-cord injuries3 and cancers4. In order to facilitate their therapeutic 
use, the migration and differentiation of transplanted stem cells must be 
monitored over time with high spatial resolution. Optical imaging has emerged as 
a promising method for cell labeling due to its high sensitivity, cost-effectiveness, 
and rapid processing time. However, typical labeling agents such as organic 
dyes and fluorescent nanoparticles emit visible light with limited tissue 
penetration depth. To this end, many near infrared (NIR) emitting probes have 
been developed that take advantage of the elevated light penetration depth of 
NIR light.  However, current NIR probes have drawbacks for in vivo tracking of 
stem cells. For example, synthetic NIR dyes are rapidly photobleached, making 
them ill suited for longitudinal study of stem cell fate. Common NIR quantum dots 
(e.g., CdTe, InAs, PbS) are composed of highly toxic elements, limiting their 
clinical applications.  
Lanthanide-doped upconversion nanoparticles (UCNPs) are promising 
materials for stem cell tracking due to their unique optical properties. Unlike 
traditional organic- 5-7 and protein-based materials 8, metal complexes9-12 or 
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semiconductor quantum dots 13, 14, these UCNPs generally have converse 
excitation and emission profiles: they are excited at NIR (980 nm), which is 
converted to a higher energy for emission at a visible or a shorter NIR 
wavelength. We have recently developed a novel biocompatible (α-
NaYbF4:Tm3+)/CaF2 UCNP with enhanced NIR emission.15 We demonstrated 
that such core/shell UCNPs are ideal for high contrast and deep tissue 
bioimaging. For example, they are completely free of autofluorescence for in vitro 
cell imaging and exhibit an exceptionally high signal-to-noise-ratio in vivo 
(i.e.,310 for Balb-c mice). The combination of NIR excitation and emission of this 
UCNP allows for outstanding tissue penetration depth (>3.2 cm), and it is 6-8 
orders of magnitude brighter than conventional fluorescence based imaging 
probes in two-photon processes 16-20, with minimal light scattering and 
background from the surrounding tissue21-23. In addition, this nanoparticle is less 
toxic than quantum dots since they do not contain class I and class II toxic 
elements. The constituent ions of the shell of this UCNP, calcium and fluoride, 
are essentially endogenous elements in the living systems.  
Proper surface modification of UCNPs is necessary to facilitate cellular 
uptake and subsequent applications for stem cell labeling. The intrinsic dynamic 
nature of cell surface antigen presentations on MSCs and the lack of unique cell 
surface markers or marker combinations for some animal MSCs (particularly 
mouse MSCs) have made an antibody-based UCNP surface modification and 
MSC targeting approach elusive.  Surface modification of UCNPs with 
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polycationic macromolecules enabling non-specific endocytosis are facile and 
practical, and have been the most commonly used strategy for shuttling 
nanoparticles across cell membranes for drug delivery or cell-labeling 
applications. Herein, we report on the development of a polyethylenimine (PEI)-
conjugated (α-NaYbF4:Tm3+)/CaF2 UCNP. We evaluated its stability, cytotoxicity, 
cell uptake, exocytosis, and impact on cell proliferation and differentiation in 
regard to the labeling of rat mesenchymal stem cells (rMSCs).  
2. Materials and methods 
2.1. Materials 
Yb2O3 (99.9%), Tm2O3 (99.9%), CF3COONa (99.9%), CF3COOH, CaCO3, 
1-octadecene (90%), oleic acid (90%), diethylene glycol (99%), 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (EDC⋅HCl), poly(acrylic acid) 
(PAA), N-hydroxysulfosuccinimide sodium salt (sulfo-NHS), NOBF4 (97%) and 
branched polyethylenimine (PEI, Mw 25,000) were all purchased from Sigma-
Aldrich and used without further purification. The trifluoroacetates of Yb and Tm 
were prepared as described 24.  
2.2. Instrumentation 
The size and the morphology of the core and core/shell nanocrystals were 
characterized by transmission electron microscopy (TEM) using a JEM-2010 
microscope at an acceleration voltage of 200 KV. The powder x-ray diffraction 
(XRD) patterns were recorded by a Siemens D500 diffractometer using Cu Kα 
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radiation (λ = 0.15418 nm). The 2θ angle of the XRD spectra was recorded at a 
scanning rate of 5 °/minute. Upconvertion photoluminescence (PL) spectra were 
recorded using a Fluorolog-3.11 Jobin Yvon spectrofluorimeter with a slit width 
defining a spectral resolution of 2 nm. The PL was excited at 975 nm using a 
fiber-coupled laser diode (Sheaumann, MA, USA) introduced to the sample 
chamber of the spectrofluorimeter. All upconversion PL spectra have been 
corrected for the spectral sensitivity of the system. Photographic images of 
upconverting nanocrystal colloids were taken with a digital camera (Canon 
Powershot SD800IS, Japan) without any filters. 
2.3. Synthesis of PEI-Coated Core/Shell α-(NaYbF4:0.5% Tm3+)/CaF2 UCNPs  
The hydrophobic oleic acid coated α-(NaYbF4:0.5% Tm3+)/CaF2 UCNPs 
were fabricated based on our previously reported approach 15.The PEI 
modification on the UCNPs was carried out in a 3-step reaction (Scheme 1). In 
the first step, oleic acid ligands on the UCNP surface were removed using a 
nitrosonium tetrafluoroborate approach (NOBF4). 25 During this reaction, 5 mL of 
oleic acid coated UCNP dispersion in hexane (∼5 mg/mL) was mixed with a 5 mL 
dichloromethane solution of NOBF4 (0.01 M) at room temperature. The resulting 
mixture was shaken gently, typically for 10 hours, until the precipitation of the 
UCNPs was observed. After centrifugation to remove the supernatant, the 
precipitated UCNPs were re-dispersed in dimethylformamide (DMF). In order to 
purify the UCNPs, toluene and hexane (1:1 v/v) were added to flocculate the 
UCNP dispersion. After centrifugation, DMF was added to re-disperse the 
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UCNPs, forming a stable colloidal dispersion. In the second step, 150 mg of PAA 
was added into a DMF dispersion of NOBF4-treated UCNPs (5 mL, ∼5 mg/mL) 
followed by vigorous stirring at 80 °C. After 30 minutes, the nanoparticles were 
precipitated by the addition of acetone and re-dispersed in water to form a stable 
dispersion. In the third step, the PAA-capped UCNPs were covalently grafted 
with branched PEI. 30 mg of PAA-capped UCNPs in 5 mL of DI water were 
activated by 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC⋅HCl, 50 mg) and sulfo-NHS (5 mg) in order to form the succinimidyl ester. 
PEI (20 mg) in PBS buffer (2 mL) was then added to the reaction. After 2 hours 
of incubation at room temperature, the PEI-conjugated UCNPs (PEI-UCNPs) 
were purified by centrifugation and re-dispersion in DI water (5 mL).  The 
electrostatic layer-by-layer (LbL) self-assembled PEI coated UCNPs were 
synthesized as follows. PAA-capped UCNPs (30 mg) in 5 mL of DI water were 
mixed with PEI (20 mg) in a PBS buffer (2 mL). After 2 hours of incubation at 
room temperature, the PEI LbL assembled UCNPs were purified by 
centrifugation and re-dispersion in DI water (5 mL). 
2.4. Isolation and culture of rat bone marrow stromal cells 
All animal procedures were conducted in accordance with the principles 
and procedures approved by the University of Massachusetts Medical School 
Animal Care and Use Committee. Rat bone marrow cells were isolated from the 
long bones of a 4-week old male Charles River SASCO SD rat as previously 
described 26, and cultured in expansion medium (ascorbic acid-free αMEM 
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containing 20% FBS, 2% L-Glutamine, and 1% Penicillin-Streptomycin) at 37 ºC 
and 5% CO2. After removing non-adherent cells on day 4 of the culture, adherent 
rat bone marrow stromal cells enriched for MSCs (rMSCs) were cultured to reach 
80% confluence before being passaged. 
2.5. Cytotoxicity of PEI-UCNPs 
Passage 1 rMSCs were seeded onto 96-well tissue culture plates 
(15,625/cm2 or 5,000/well) and cultured for 24-h prior to the addition of PEI-
UCNPs (0, 20, 50 and 100 µg/mL). Following 4 h or 24 h of incubation with PEI-
UCNPs, the cells were washed 3 times with PBS to remove un-internalized PEI-
UCNPs and fresh expansion medium was added. Cytotoxicity of 4 h or 24 h 
treatment with PEI-UCNPs was quantified by MTT assay (Roche) 24 h after the 
initial UCNP treatment. The effect of the 24 h UCNP exposure on rMSC 
proliferation was further examined by MTT 48 h after the removal of un-
internalized UCNPs. Three replicates were used for each experimental condition. 
Absorbance of the MTT product was read on a Multiskan FC microplate 
photometer (Thermo Scientific) at 570 nm with a 690nm background correction. 
2.6. Imaging of UCNP-labeled rMSCs 
Passage 1 rMSCs were seeded onto glass-bottom dishes (MatTek Corp., 
12,500/cm2) and cultured for 24 h prior to the addition of PEI-UCNPs (0, 50 or 
100 µg/mL final concentration in medium). The rMSCs were exposed to the 
particles for 4 or 24 h before the un-internalized PEI-UCNPs were removed by 
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washing the cells 3 times with PBS.  The cells were fixed by 3.7 v/v% methanol-
free formaldehyde in PBS for 10 min and washed 3 times in PBS. Fixed cells 
were permeabilized with Triton X-100 (0.1% in PBS) for 5 min, washed with PBS, 
and then incubated in PBS containing 1% BSA for 30 min. Actin was stained with 
2 units of Alexa Fluor 488-phalloidin (Invitrogen) in PBS containing 1% BSA for 
20 min. Cell nuclei were stained with 300 nM of DAPI (Invitrogen) for 5 min. 
Cytoskeletal actin, UCNP uptake, and cell nuclei were visualized under a 2-
photon microscope (Zeiss LSM 7 MP with W Plan-Apochromatic 20X objective) 
with 870-nm excitation for Alexa Fluor 488 phalloidin, 980-nm excitation for the 
UCNPs, and 690-nm excitation for DAPI, respectively. 
2.7. PEI-UCNP exocytosis from rMSCs 
A transwell system was used to study whether the internalized PEI-
UCNPs were released from the rMSCs. The PEI-UCNP labeled rMSCs (4-h 
incubation with 100 µg/mL particles) were cultured on the transwell insert (the 
upper compartment; 3.0µm pore size, polyester membrane). Unlabeled rMSCs 
were cultured in the underlying plate well (the lower compartment). The same cell 
seeding density of 10,000 rMSCs/cm2 was applied for both top and bottom 
compartments. The labeled and unlabeled cells were co-cultured for up to 14 
days prior to fixation, DAPI staining, and imaging as described above. To confirm 
that PEI-UCNPs can pass through the transwell membrane, PEI-UCNPs (100 
µg/mL) were added to a cell-free control upper compartment and the rMSCs on 
the bottom compartment were imaged after 24 h. 
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2.8. Induced differentiations of PEI-UCNP labeled rMSCs 
Passage 1 rMSCs (10,500 cells/cm2) were seeded onto a 12-well plate and 
cultured until they reached 70% confluence. rMSCs were labeled by 4-h 
incubation with PEI-UCNPs (100 µg/mL) followed by 3 washes with PBS. 
Osteogenic differentiation was induced by supplementing the expansion medium 
with 10-nM dexamethasone, 20-mM ß-glycerol phosphate, and 50-µM L-ascorbic 
acid 2-phosphate. Adipogenic differentiation was induced by supplementing the 
expansion medium with 0.5-µM dexamethasone, 0.5-µM isobutylmethylxanthine, 
and 50-µM indomethacin. The rMSCs were differentiated for 14 days, with 
changes of differentiation medium twice a week, and fixed. Osteogenic 
differentiation was visualized by Alizarin Red S staining for mineral deposition. 
Adipogenic differentiation was visualized by staining lipid deposits with Oil Red O. 
MSCs without UCNP labels were cultured, induced to differentiate, and stained in 
the same manner. Staining specificity was validated by negative Alizarin Red S 
staining of cells following adipogenic induction and negative Oil Red O staining of 
cells following osteogenic induction. 
3. Results 
3.1. Synthesis and characterization of PEI-UCNPs  
PEI was coupled to the surface of the UCNPs by covalent conjugation with 
the PAA. The nanoparticles formed a clear, aggregate free solution in the PBS 
buffer. The PEI coating preserved the upconversion emissions in regard to both 
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visible and near infrared regions (Figure 1A). When excited with a 980nm NIR 
laser diode, we observed strong upconversion luminescence emitted from the 
nanoparticles in the PBS buffer with the naked eye (Figure 1B). TEM imaging 
showed that the PEI-UCNPs are monodispersed in size (Figure 1C). In contrast 
to the electrostatic LbL self-assembly approach, we found that covalently bound 
PEI resulted in significantly enhanced stability of the PEI-UCNPs. Dynamic light 
scattering measurement showed that the hydrodynamic nanoparticle size of this 
covalently bonded PEI-UCNP was almost identical before and after 24-h 
incubation in PBS (~ 91nm), while the size of LbL self-assembled PEI-UCNPs 
increased from ~100nm to ~1um in 5 hours (Figure 2A). Zeta potential 
measurement of the PEI-UCNPs confirmed the presence of a PEI surface 
coating with a positive potential of approximately +17.8 mV, which would be 
suitable for binding with negatively charged cell surfaces (Figure 2B).  
3.2. PEI-UCNP cellular uptake and cytotoxicity  
In order to determine the optimal time and nanoparticle concentration for 
stem cell labeling, rMSCs were treated with different concentrations of PEI-
UCNPs (0, 20, 50, or 100 µg/ml) for 4 h and 24 h. After incubation, the cells were 
washed and imaged using a 2-photon microscope. The upconversion 
luminescence was observed in nearly all of the rMSCs, demonstrating that the 
stem cells were successfully labeled with the PEI-UCNPs. The level of PEI-
UCNP uptake in individual cells was proportional to the nanoparticle treatment 
concentration and exposure time (Figure 3A). Co-staining for cytoskeletal actin 
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and nuclei further validated the localization of PEI-UCNP signal within the 
cytoplasm of rMSCs (Figure 3B).  
We next examined the cytotoxicity of the nanoparticles at the 
aforementioned concentrations and time points. The MTT assay showed that 
nearly 95% of rMSCs were viable following a 4 h nanoparticle exposure at 
concentrations up to 100 µg/mL. There was no significant difference in cell 
viability between the PEI-UCNP labeled groups and unlabeled control (p > 0.05). 
When the exposure time was increased to 24 h, the cell viability significantly 
decreased compared to the unlabeled control at each concentration examined, 
with a 63% reduction at the treatment concentration of 100 µg/mL (Figure 3C). 
There was no significant difference in toxicity between 50 µg/ml and 100 µg/mL 
doses at this exposure time. To investigate the impact of PEI-UCNP labeling on 
the proliferation capability of rMSCs, rMSCs were incubated with PEI-UCNPs at 
various concentrations for 24 h. After removal of un-internalized UCNPs, the cells 
were cultured for another 48 h before being subjected to MTT assay. The short-
term proliferation of rMSCs was minimally impacted by the PEI-UCNP labeling. 
All groups exhibited significant increases in the number of viable cells, with 1.84-
fold increase in viable cells for rMSCs treated with 100 µg/mL of PEI-UCNPs 
after 48 h culture as compared to 1.79-fold increase for unlabeled rMSCs (Figure 
3D). 
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3.3. Exocytosis of PEI-UCNPs from labeled rMSCs 
One potential challenge for in vivo tracking of UCNP-labeled stem cells is 
the possibility that the uptaken nanoparticles could be exocytosed over time, 
leading to the unintended labeling of other surrounding cells. We investigated this 
issue using a transwell culture system27 where rMSCs labeled with PEI-UCNPs 
(100 µg/mL, 4h) were cultured on the porous membrane in the upper 
compartment while the unlabeled rMSCs were cultured in the lower compartment 
(Figure 4A). PEI-UCNPs added to a cell-free upper compartment were able to 
quickly pass through the membrane and cause the labeling of rMSCs seeded in 
the lower compartment in 1 day (Figure 4B, control). The labeled and unlabeled 
cells were co-cultured for 14 days and the cells in the bottom compartment 
remained free of any PEI-UCNP signal throughout this culture period, supporting 
that there were no particles excytosed from the labeled cells in the upper 
compartment (Figure 4D).  
3.4. Differentiation of PEI-UCNP labeled rMSCs 
 The effect of PEI-UCNP labeling on the osteogenic and adipogenic 
differentiations of rMSCs were assessed. Passage 1 rMSCs labeled with PEI-
UCNPs (100 µg/mL, 4 h) were cultured in osteogenic or adipogenic medium for 
14 days and their differentiation potency was compared with that of unlabeled 
MSCs. Light microscopy shows that the PEI-UCNP labeled rMSCs were able to 
undergo osteogeneic and adipogenic differentiation as supported by the positive 
Alizarin Red S (Figure 5A) and Oil Red O (Figure 5B) staining, respectively. The 
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intensity of Alizarin red S staining, however, was reduced for the PEI-UCNP 
labeled rMSCs compared to the unlabeled control  (Figure 5A).  
4. Discussion 
 The ability to label and track stem cells has far reaching applications in 
tissue engineering and regenerative medicine, where the fate of implanted stem 
cells remains unclear. Stem cell labeling with NIR probes has the potential to 
allow for the in vivo study of stem cell fate with greater tissue penetration depth 
and spatial resolution than conventional cell labeling methods. Herein, we report 
the application of a recently developed UCNP with NIR-excitation and NIR-
emission to the labeling of rMSCs. 
We compared two approaches of modifying the surface of the UCNPs with 
PEI, facilitating non-specific cellular uptake. In one approach, we used an LbL 
method that deposits PEI by electrostatic interactions around the nanoparticle 
surface. In a second approach, we covalently coupled the PEI to the UCNP 
surface through a PAA intermediate. The presence of a PEI coating was 
confirmed by zeta potential measurements that indicated a positive charge on the 
particle surface. We found that the covalently linked PEI resulted in increased 
particle stability, with no increase in hydrodynamic size over the course of a 24 h 
incubation in PBS. In contrast, the LbL assembled PEI resulted in rapid particle 
aggregation in PBS. Due to their increased stability, we chose the UCNPs with 
the covalently coupled PEI coating (PEI-UCNPs) for further cell-based analysis. 
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We used rMSCs as a model to determine the efficacy of PEI-UCNPs for 
stem cell labeling. MSCs are a multipotent cell that can differentiate into 
osteoblasts, chondrocytes, myocytes and adipocytes. They have been studied 
widely for musculoskeletal tissue engineering and have been used clinically. 
Tracking labeled MSCs in vivo is important for the validation and development of 
MSC-based therapeutic strategies. We show that the PEI-UCNP concentration 
and incubation-time can be optimized to achieve efficient rMSCs labeling with 
negligible cytotoxicity. Specifically, we showed that a 4 h incubation with 100 
µg/mL PEI-UCNPs effectively labeled rMSCs while maintaining ~95% cell 
viability. Although a longer exposure of 24 h did lead to increased cytotoxicity in a 
dose dependent manner, the cytotoxicity did appear to level off beyond a particle 
concentration of 50 µg/mL. Further, UCNP signals were localized to the rMSC 
cytoplasm and did not negatively impact the short-term (48 h) proliferation of 
MSCs.  
Transwell coculture experiments showed that PEI-UCNP internalized in 
the rMSCs did not leak out via exocytosis during a 14-day period to cause 
unintended labeling of surrounding cells. This supports the feasibility of in vivo 
cell tracking over a couple of weeks without causing non-specific secondary 
labeling of other cells. Finally, we showed that PEI-UCNP labeled rMSCs were 
able to differentiate along the osteogenic and adipogenic lineages upon in vitro 
induction, suggesting that the PEI-UCNP labeling did not abolish these key 
functions of MSCs. Although the PEI-UCNP labeled rMSCs exhibited less potent 
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osteogenic differentiation than the unlabeled control, the potency of adipogenic 
differentiation was largely unaffected by PEI-UCNP labeling. It remains to be 
seen whether other lineage commitments and in vivo differentiation of MSCs is 
affected by the PEI-UCNP labeling. Finally, exploring even more cytocompatible 
surface coating strategies may further minimize the observed impact on the 
osteogenic differentiation potency of PEI-UCNP labeled rMSCs.  
5. Conclusions 
The NIR-excitation and NIR-emission of α-NaYF4:Yb3+,Tm3+/CaF2 UCNPs 
allows for increased tissue penetration depth, facilitating in vivo imaging. We 
report the development of core/shell α-NaYbF4:Yb3+,Tm3+/CaF2 UCNPs with a 
covalently coupled PEI coating (PEI-UCNPs) and their validation for stem cell 
labeling applications. We show that the covalently coupled PEI coating results in 
greater particle stability in PBS than UCNPs coated with PEI using a layer-by-
layer approach. The PEI-UCNPs show reasonable cytocompatibility at a 
concentration and exposure time adequate for efficient labeling of rMSCs. The 
cell viability remained above 95% after a 4 h PEI-UCNP exposure at 100 µg/mL. 
Further, the PEI-UCNP labeling did not impair short-term cell proliferation. 
Exocytosis of internalized PEI-UCNP from labeled cells was not observed during 
a 14-day culture period. Finally, PEI-UCNPs labeled rMSCs were able to 
undergo osteogenic and adipogenic differentiations upon in vitro induction, 
although the potency of the former was reduced compared to unlabeled control. 
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Taken together, PEI-UCNPs have promising applications in cell labeling and in 
vivo tracking. 
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Scheme 1. A surface modification scheme for PEI coated α-(NaYbF4:0.5% 
Tm3+)@CaF2 UCNPs. 
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Figure 1. (A) The upconversion photoluminescence spectrum under laser 
excitation at 980 nm. (B) A photograph of PEI-UCNPs when excited by a NIR 
laser at 980 nm. (C) A TEM image of the NaYF4:Yb3+,Tm3+/CaF2 nanoparticles 
coated with 25kD PEI. (inset: High resolution TEM) (D) X-ray diffraction (XRD) 
patterns of α-NaYbF4:Tm core and α-NaYF4:Yb,Tm /CaF2 core/shell UCNPs. 
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Figure 2. (A) The hydrodynamic (HD) size distributions of covalently conjugated 
and LbL self assembled PEI-UCNPs. (B) Plot of the zeta potential of covalently 
conjugated PEI-UCNPs  
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Figure 3. The uptake efficiency of PEI-UCNPs by rMSCs and the viability and 
proliferation of labeled rMSCs. (A) Two-photon microscopy images of rMSCs 
following 4-h and 24-h incubation with various concentrations of PEI-UCNPs. 
Scale bar = 50 µm (B) Co-localization of UCNP signal with rMSC actin and nuclei 
following incubation with 50 µg/mL UCNPs for 24 h. Scale bar = 50 µm (C) rMSC 
viability following 4 h and 24 h incubation with various concentrations of PEI-
UCNPs. Percent viability is calculated relative to the MTT absorbance of 
unlabeled rMSCs. (D) The impact of PEI-UCNP labeling on rMSC proliferation as 
determined by MTT assay. Significance of statistical comparisons were 
determined by one-way ANOVA with Tukey post-hoc. All pairwise comparisons 
are significant ( p < 0.05) unless denoted as n.s. (p > 0.05, (not significant). 
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Figure 4. Exocytosis of PEI-UCNPs by labeled rMSCs. (A) Schematic of a 
control transwell setup containing PEI-UCNPs on the top well membrane and 
rMSCs on the bottom well, and the two-photon imaging of the bottom dish rMSCs. 
(B) Schematic of a transwell co-culture setup containing PEI-UCNP labeled 
rMSCs on top well membrane and unlabeled rMSCs on the bottom dish, and the 
two-photon imaging of the bottom dish rMSCs over a 14 day period. Cell nuclei 
were stained with DAPI. No UCNP fluorescence is visible in the bottom dish of 
the transwell plate. Scale bar = 50 µm. 
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Figure 5. Osteogenic and adipogenic differentiation of PEI-UCNP labeled 
rMSCs. (A) Alizarin red S staining of unlabeled rMSCs after 14-day culture in 
adipogenic (negative staining control) and osteogenic medium (positive control), 
and labeled rMSCs after 14-day culture in osteogenic medium. Scale bar = 100 
µm. (B) Oil red O staining of unlabeled rMSCs after 14-day culture in osteogenic 
(negative staining control) and adipogenic medium (positive control), and labeled 
rMSCs after 14-day culture in adipogenic medium. Scale bar = 100 µm. 
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